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Colorectal cancer (CRC) is one of the most frequently occurring malignancies and 
leading causes of cancer mortality worldwide. Numerous challenges exist 
pertaining to the detection and treatment of this prevalent disease. Existing 
screening modalities such as fecal occult blood test and colonoscopy either lack 
sensitivity and specificity or are too invasive and costly. Despite advances in the 
therapeutic management of CRC, resistance to fundamental therapies such as 5-
fluorouracil (5FU) and cetuximab remains a relevant problem, calling for 
effective strategies for a priori prediction of clinical response. To address these 
challenges, the overall goal of this thesis was to evaluate new approaches and 
identify molecular markers that can facilitate the non-invasive fecal-based 
screening of CRC and enhance the clinical prediction of treatment response. 
 
This project takes on a translational front by starting with the acquisition of 
clinical samples and data derived from a locally relevant population of a defined 
CRC anatomical subtype and grade. A gas chromatography/time-of-flight mass 
spectrometry (GC/TOFMS) method was developed for the metabotyping of 
lyophilized human feces and subsequently adopted to characterize the fecal 
metabonomic profiles of CRC patients and healthy subjects. The work established 
proof-of-principle that GC/TOFMS-guided fecal metabonomics could 
differentiate CRC patients from healthy subjects (Q
2
=0.215) and be a viable 
approach for the non-invasive detection of CRC. Marker metabolites (e.g. 
fructose, linoleic acid and nicotinic acid) were further revealed and provided 
novel insights into the tumorigenesis of CRC.  
 
Following metabonomic characterization, microRNAs (miRNAs) were profiled in 
the fecal samples of CRC patients as a mean to further identify biomarkers that 
can aid in the non-invasive detection of the cancer. Microarray analysis uncovered 
17 fecal markers (p<0.05) differentially regulated in CRC. Fecal miR-223 and 
miR-451 represented robust markers in distinguishing CRC patients from healthy 
x 
 
subjects, as evident from areas under the receiver operator characteristic curves of 
0.939 and 0.971, respectively.  
 
To mitigate challenges in CRC treatment, the role of nucleoside transporters in 
the clinical resistance to the cornerstone therapy, 5FU, was investigated. The 
intra-tumoral mRNA expression of a panel of nucleoside transporters, including 
hENT1, was measured in CRC patients prior to 5FU-based chemotherapy. These 
transporters showed promise as predictive markers of clinical response to 5FU; 
particularly, high hENT1 levels correlated with poor 5FU efficacy. Additionally, 
in vitro chemical inhibition of hENT1 resulted in an augmentation of 5FU-
mediated cytotoxicity, substantiating the role of hENT1 in 5FU resistance. 
 
The prevalence of key genetic alterations along the EGFR pathway (KRAS, 
BRAF, PI3K, EGFR mutations) relevant to the resistance to the newer targeted 
agent, cetuximab, was also determined. KRAS mutation was revealed as a 
prominent phenomenon that occurred in 33.3% of the Singapore metastatic CRC 
population. The study laid an important groundwork for future local studies 
concerning KRAS mutation status as a predictive marker of cetuximab response.  
  
Collectively, our work highlighted promising molecular biomarkers and 
approaches for the non-invasive detection of CRC and prediction of treatment 
response. These efforts constituted part of the continuous endeavor towards better 
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CHAPTER 1 Introduction  
 
1.1 Incidence and mortality of colorectal cancer (CRC) 
 
Colorectal cancer (CRC) is the third most frequent malignancy in men and the 
second in women worldwide, according to the latest GLOBOCAN statistics in 
2008 [1]. The incidence of CRC varies widely across the globe, with the highest 
rates documented in more developed regions including Europe, Australia and 
North America and lower rates in Africa and Asia [1]. Nevertheless, in Asian 
countries such as China, Singapore, South Korea and Japan, CRC displayed a 
rapidly rising trend [2]. A two- to four-fold upsurge in the incidence of CRC was 
encountered over the past few decades [3]. Among Southeast Asian countries, 
Singapore has the highest age-standardized incidence rates [4], with 39.6 per 
100,000 per year  in males and 27.6 in females [5]. Within Singapore, CRC is the 
most commonly diagnosed cancer, accounting for 17.6 and 13.9%, respectively, 
of all cancers [5].  
 
Coupled with the high incidence is an astounding mortality rate of CRC. 
Approximately 608 000 deaths from CRC are estimated worldwide, comprising 
8% of all cancer mortality, making it the fourth leading cause of cancer-related 
death [1]. In Singapore, deaths from CRC constituted 14.7% of all cancer 
mortalities in men and 15.2% in women, representing the second and third highest 
cause of cancer mortality in the two genders, respectively [5]. The age-
standardized rate for mortality from CRC was as high as 16.5 per 100,000 per 
year in males and 10.8 in females [5]. Strikingly, CRC mortality has doubled in 
both men and women over the past three decades in Singapore [6]. In light of the 
high incidence and mortality rate of the disease, constant efforts by clinicians and 





1.2 Clinical challenges 
 
Broadly, the management of CRC can be improved in two areas namely 
enhancing detection and optimizing treatment. Timely detection of the cancer 
halts its progression to more advanced stages, effectively averting much of the 
deaths from CRC. In the treatment of diagnosed cancer, patients typically undergo 
surgical tumor resection followed by chemotherapy. At this stage, effective 
management of systemic chemotherapy is paramount in dictating patients’ 
survival outcome. Both approaches of timely detection and optimal chemotherapy 
are therefore instrumental in reducing the mortality rate from CRC. Nevertheless, 
numerous perennial challenges are faced by clinicians pertaining to these two 
aspects of disease management. Specifically, the first part of this chapter outlines 
the limitations of established screening modalities and provides an overview of 
emerging fecal-based screening techniques. The second part of the chapter 
highlights the conundrum of drug resistance involving several important therapies 
of CRC, followed by the existing and potential predictive markers of treatment 
response. 
 
1.3 CRC screening 
 
1.3.1 Importance of timely detection  
 
The importance of timely detection is underscored by the deteriorating prognosis 
of CRC with disease progression. While the 5-year survival rate of patients 
remains as high as 90% in the early stages of the cancer, patients’ survival rate 
diminishes to 12% in the advanced or metastatic stage [7]. Yet a considerable 
percentage (56%) of CRC cases are only diagnosed at late stages where regional 
lymph node spread or distant metastasis has occurred [8]. Timely detection of 
CRC at its early stages by population screening hence becomes a strategic 




1.3.2 Current screening methods and their limitations 
 
1.3.2.1 Fecal occult blood test (FOBT) 
 
As an inexpensive and non-invasive method, fecal occult blood test (FOBT) has 
been a mainstay of CRC screening. Clear evidence from a number of clinical 
trials has credited FOBT with a significant role in reducing CRC-related mortality 
[10-13]. Traditionally, guaiac FOBTs (available as Hemoccult II and Hemoccult 
SENSA), based upon the detection of peroxidase-like activity of the heme moiety 
in the feces, are commonly used. However, the test is highly susceptible to 
interferences from dietary heme in red meat as well as plant peroxidases in certain 
fruits and vegetables, necessitating dietary restriction 3 days prior to fecal 
sampling. Moreover, it does not distinguish between bleeding from the upper and 
lower gastrointestinal tract (GIT). The advent of immunochemical FOBT (e.g. 
HemeSelect, Hemoccult ICT, OC-Sensa micro) circumvents the non-selectivity 
by capitalizing on the specific binding of antibodies to hemoglobin of human 
origin [14]. In addition, as globin is digested rapidly in the stomach and small 
intestine, immunochemical FOBT is unaffected by bleeding in the upper GIT 
[14]. Nonetheless both forms of FOBTs remained inadequate in their clinical 
sensitivity and specificity in detecting CRC [15]. Particularly, many colorectal 
tumors may not bleed at the time of fecal sampling and would inadvertently evade 
detection by FOBTs. Laborious repeats in sampling from consecutive bowel 
movements become essential at times to enhance the sensitivity. This may have a 
negative impact on the compliance and adoption rate amongst the general 
population. Conversely, high false-positive rates as a result of trivial yet frequent 
occult bleeding unrelated to malignancies (e.g. hemorrhoids, fissures) may entail 
unnecessary follow-up investigations. Representative trials elucidating the 
performance characteristics of both forms of FOBTs in a screening setting are 
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et al [16] 




51.6%  94.4%  
a
 Target population consisted of asymptomatic persons at average risk of CRC. 
b
 Total number of subjects screened 
c
 Sensitivity is defined as the percentage of CRC patients who are tested positive; 
Specificity is defined as the percentage of healthy subjects who are tested 
negative. 
 
1.3.2.2 Colonoscopy and other procedures 
 
In contrast to FOBT, the excellent diagnostic accuracy of colonoscopy and the 
ability to remove pre-cancerous polyps for histological analysis renders it the gold 
standard for detecting and preventing CRC [15]. However, the procedure cost, 
need for specialized personnel and facilities, cumbersome bowel preparation, 
invasive nature of the procedure and risks of complications such as bowel 
perforation limit its widespread application as a population screening modality. 
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The challenge of implementing it as a screening procedure is further exemplified 
by the low uptake rate of merely 1.7% in Germany [19]. Other modalities for 
direct examination of the colorectum include sigmoidoscopy, double contrast 
barium enema and CT colonography but these procedures similarly demand a 
high cost and uncomfortable bowel preparation. These limitations have spawned 
efforts to develop alternative methods that are accurate yet cost-effective and 
easily administered as population screening tools for CRC.  
 
1.3.3 Emerging fecal-based screening techniques 
 
In the characterization of CRC, the feces represents a valuable biological matrix 
[19-22]. Its direct contact with and transient stay in the colon and rectum enriches 
important molecular information that provides insights into the health/disease 
status of the lower GIT and unique metabolic interaction between the host, 
symbiotic microbes and xenobiotics [23]. Furthermore, non-invasive fecal-based 
tests engender good patient receptivity, as evidenced by the reasonable uptake rate 
of 60-78% for FOBT [13]. These perspectives have provided the impetus to 
explore additional fecal-based tools that would facilitate population screening for 
CRC.  
 
As CRC is a heterogeneous disease characterized by varying conglomeration of 
cellular alterations, the exploration of multiple molecular markers and approaches 
may be fundamental to the effectiveness of detection. To this end, numerous 
molecular changes spanning from DNA, RNA to protein levels have been 
investigated in the feces of CRC patients. 
 
1.3.3.1 Fecal DNA 
 
A large body of research focuses on the profiling of the hallmark genetic and 
epigenetic abnormalities of CRC in neoplastic cells shed into the feces [16, 24-
27]. These fecal DNA markers consist of gene mutations that arise in the adenoma 
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to carcinoma sequence (typically APC, p53 and KRAS, Figure 1.1) as well as 
DNA alterations reflecting the microsatellite instability pathway (Bat-26) and 
abnormal apoptosis (L-DNA). Unlike the intermittent nature of occult bleeding, 
DNA markers are released continuously into the feces following the constant 
exfoliation of tumor cells [28]. Fecal DNA therefore facilitates a more robust 
screening strategy compared to guaiac FOBT. A superior sensitivity was 
demonstrated by the multitargeted genetic assay in detecting CRC, in a seminal 
trial of 2507 asymptomatic average-risk patients (51.6% versus 12.9%, 
respectively, Table 1.1) [16]. With further technical refinements and the inclusion 
of new markers such as the hypermethylated vimentin gene, an assay sensitivity 
of 83% was attained [29, 30]. More recently, Ahlquist and co-workers developed 
a next-generation stool DNA test that yielded an exemplary sensitivity of 85% 
and specificity of 90% in a case-control study of 678 subjects [31]. With 
unremitting efforts to optimize the assay performance, fecal DNA is currently the 





Figure 1.1 Vogelstein’s model of CRC pathogenesis depicting the sequential 
accumulation of key oncogenic mutations leading to CRC  
(adapted from [32] and [33])  
APC, adenomatous polyposis coli; EGFR, epidermal growth factor receptor; DCC, deleted in 






1.3.3.2 Fecal mRNA 
 
Besides DNA, another emerging technology involves the use of an mRNA-based 
fecal assay to detect genetic lesions of CRC at the transcriptional level. In 
particular, the overexpression of COX-2 was reported in 80% to 90% of 
adenocarcinoma and 50% to 60% of adenomas [34, 35]. Currently, fecal tests 
using COX-2, MMP-7, TP53 and MYBL-2 mRNAs achieved a sensitivity of 58% 
to 90% in detecting CRC [36, 37]. Other potential mRNA markers include CD44 
variant exons [38] and protein kinase C [39]. While promising as screening 
markers, the challenge of  fecal mRNAs lies in their inordinately poor stability in 
the feces, which has hindered their detection in approximately 25% of fecal 
samples [37]. This research area hence remains at its infancy and further 
optimization are required before fecal mRNAs can assume a role in CRC 
screening.  
 
1.3.3.3 Fecal protein 
 
Downstream of mRNA,  aberrant protein expression has also surfaced as potential 
fecal biomarkers for screening, including tumor pyruvate kinase type M2, 
calprotectin,  S100 calcium binding protein A12 and metallopeptidase inhibitor 1 
[40]. These markers exhibited a wide-ranging sensitivity of 63 – 93% and 
specificity of 47 – 98%. Like mRNA, the study of fecal protein markers is 
relatively nascent against the background of other rapidly emerging markers and 
has yet to be actualized in the screening setting.   
 
1.3.3.4 Post-transcriptional fecal markers – novel screening tools 
 
While prevailing studies focused predominantly on DNA and mRNA aberrations 
as potential fecal markers, a knowledge gap exists regarding the role of post-
transcriptional changes. Without the need to be transcribed and translated into 
proteins prior to exerting their biological effect, these downstream alterations are 
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perceived to be more directly associated with tumor phenotype than DNA or 
mRNA. Such critical yet underappreciated perturbations include metabolic and 
microRNA (miRNA) changes as illustrated in Figure 1.2. Their role in CRC and 
potential as novel fecal screening markers are delineated in the following sections. 
 
 
Figure 1.2 Genetic, transcriptional and post-transcriptional events in the tumor 
cell 
 
1.3.3.4.1 Fecal metabonomic approach 
 
As a result of the dysregulated cellular metabolism and transport that supports 
their untethered cell growth, cancer cells often carry unique metabolic fingerprints 
[41-44]. Metabonomics is an emerging systems biology approach that measures 
the dynamic multiparametric metabolic responses of living systems to 
pathophysiologic stimuli or genetic modification [45]. Through the simultaneous 
and non-targeted analysis of a plethora of endogenous metabolites, this 
“hypothesis-free” strategy enables a fingerprint of the disease-related biochemical 
perturbations caused by the host tumor cell and its environment (e.g. symbiotic 




Clinical metabonomic studies comparing matched tumor and healthy tissue from 
CRC patients have consistently revealed alterations in the levels of amino acids, 
nucleosides and carbohydrates, as summarized in Table 1.2 [47-55]. For example, 
there exists an upregulation of uridine which may be associated with the higher 
propagation rate of tumor cells. Reduced glucose and elevated lactate are also 
common, recapitulating a cancer phenomenon of altered glycolysis, also known as 
the Warburg effect [56]. Besides host-related factors, dysbiosis of gut symbiotic 
microbiota is another key feature of CRC [57-59]. For instance, a lower 
abundance of Eubacterium rectale and an increased population of Enterococcus 
faecalis have been observed in the feces of CRC patients. Collectively, the 
repertoire of metabolic derangements derived from both cancer cells and gut 
microbes may culminate in a distinct metabolic phenotype (metabotype) that 
characterizes the pathology of CRC. During its direct transit through the gut 
lumen, it is likely that the feces assimilate this unique metabotype. It was hence 
hypothesized that fecal metabonomics could distinguish CRC patients from 





Table 1.2 Metabonomic analyses of CRC tumor and adjacent normal mucosae 
Study No. of 
CRC 
patients 






















Ong et al [48] 26 GC/MS 
Mal et al [49] 6 GC/MS 
Denkert et al [50] 27 GC/MS 











Lipids Mirnezami et al 
[52] 
44 HR-MAS NMR 
b
 
Jiménez et al [53] 26 HR-MAS NMR 
b
 
Piotto et al [54] 44 NMR 
Lean et al [55] 15 NMR 
a
 Marker metabolites present in more than 2 tissue metabonomic studies. 
Metabolites with controversial directions of change were excluded. 
b
 HR-MAS NMR: High resolution magic angle spinning NMR 
 
Previous studies have demonstrated the potential utility of nuclear magnetic 
resonance (NMR) spectroscopy in the metabolic profiling of fecal water in CRC 
patients [60, 61]. Notably, low fecal levels of acetate and butyrate, both products 
of gut bacteria, were found in these patients. While promising, the inherently low 
sensitivity of NMR precludes the detection of low-abundance metabolites. This 
limitation has spurred a growing interest in developing more sensitive techniques 
for fecal or fecal water metabotyping such as liquid chromatography/mass 
spectrometry (LC/MS) [62, 63] and gas chromatography/mass spectrometry 
(GC/MS) [64-68]. In particular, GC/MS also offers advantages in terms of 
reproducibility, robustness and reliable structural identification of metabolites 
[69]. Recently, gas chromatography/time-of-flight mass spectrometry 
(GC/TOFMS)-based analyses of plasma, serum, urine and exhaled breath have 
shown promise in the non-invasive characterization of diabetes [70, 71], 
hepatocellular carcinoma [72], bladder cancer [73] and asthma [74]. These studies 
showcased the feasibility of GC/TOFMS-based metabonomics in discovering 
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diagnostic biomarkers of various diseases. Given the promise of GC/TOFMS 
technology and the abundant metabolic information contained within the feces, 
GC/MS-based fecal metabonomics could represent a new frontier in the non-
invasive detection of CRC.  
 
1.3.3.4.2 Fecal microRNAs (miRNAs) 
 
Besides metabolic perturbations, accumulating evidence suggests an important 
role of miRNAs in tumorigenesis. MiRNAs are 19-24 nucleotide non-coding 
RNAs which negatively regulate gene expression post-transcriptionally by 
suppressing translation and facilitating degradation of target mRNAs (Figure 1.2) 
[75]. Due to their ability to modulate the expression of oncogenes and tumor 
suppressors, miRNAs have increasingly been implicated in tumorigenesis [76-79]. 
A growing number of clinical studies have congruently shown deregulated 
miRNA expression in surgically excised colorectal tumor compared to matched 
normal mucosae (Table 1.3). For instance, an upregulation of oncogenic miR-
135b that inhibits the tumor suppressor APC gene has been characteristic of 
colorectal tumors [80-88]. By virtue of its direct contact with the colorectum, 
feces represents a valuable resource of this unique miRNA signature for the 
detection of CRC. Of note, recent reports have highlighted the exceptional 
stability of miRNAs in a variety of biological matrices including formalin-fixed 
tissues [89], serum [90] and even feces [91, 92], making them reliable biomarkers. 
Notably, while mRNA underwent significant degradation in the feces, a 
substantial portion of miRNA remained intact for up to 72 hours [91]. Taken 
together, these positive attributes render fecal miRNA suitable markers for the 




Table 1.3 Differential expression of miRNAs in CRC tumor compared with 
adjacent normal mucosae  
miRNAs increased in 
CRC 



















 Table adapted from [93] 
 
To date, targeted fecal profiling has been undertaken by few groups on selected 
miRNAs known to be dysregulated at the tumor level [91, 94-98]. These efforts 
have led to the identification of promising markers such as fecal miR-135b, miR-
92a and miR-21. In recent years, non-targeted fecal miRNA profiling has been 
explored concurrently by our research group and two other groups [92, 99]. The 
comprehensive profiling culminated in the discovery of novel screening markers 
such as fecal miR-144* [92]. Collectively, the study of fecal miRNAs is gaining 
increasing interest and heralds a new and exciting approach to CRC screening.  
 
1.4 CRC treatment  
 
The preceding discussion illuminates the importance of CRC screening and offers 
insights into existing and emerging screening strategies. Alongside timely 





1.4.1 Current treatment strategies 
 
Current treatment modalities for CRC include surgery, radiotherapy, 
chemotherapy and other targeted molecular therapies. Surgery remains the 
definitive treatment for all stages of resectable CRC [100]. Post-operatively, 
adjuvant chemotherapy, comprising largely 5-fluorouracil (5FU), has been the 
standard of care for stage III cancer patients. Notably, an approximate 30% 
relative reduction in the risk of disease recurrence and a 22 – 32% decrease in 
mortality were evident among this group of patients receiving adjuvant 
chemotherapy [101]. 
 
In the metastatic setting, treatment consists mainly of systemic chemotherapy. As 
in the earlier stages, 5FU has been the mainstay of therapeutic regimens and 
yields a response rate of 40-50% when used in combination with oxaliplatin and 
irinotecan [102, 103]. In recent years, the emergence of novel targeted therapies 
such as cetuximab and bevacizumab augment the median overall survival of 
patients with advanced cancer significantly [104]. Two new FDA-approved drugs, 
regorafenib and aflibercept, further expand the treatment options for metastatic 
CRC (mCRC) patients [105]. 
 
1.4.2 Problem of treatment resistance to 5-fluorouracil (5FU) and cetuximab  
 
Despite advances in treatment regimens, numerous challenges persist in the 
therapeutic management of CRC. For instance, treatment failures are prominent in 
a considerable percentage (e.g. as high as 50% of mCRC) of patients on 5FU-
based therapies [102, 103]. In addition to not receiving the most effective 
treatment, this non-responding group of patients are subjected to unnecessary 
toxic side effects such as nausea, diarrhea, hand and foot syndrome and 
neutropenia. Besides 5FU, the rate of resistance to the newer agent cetuximab is 
also noteworthy. Approximately 80% of the patients treated with cetuximab 
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incurred additional treatment costs and skin toxicity without deriving response 
benefit from the treatment [106-108]. Taken together, there exists an urgent need 
to identify panels of molecular markers that can predict patients’ response to 
traditional and targeted therapies. Such a priori prediction of clinical response 
would contribute towards an individualized treatment plan tailored to the 
phenotype of each patient. 
 
1.4.3 Predicting outcome of treatment with 5FU  
 
With an unequivocal role that spanned over four decades, 5FU has been the 
cornerstone drug for the treatment of both early and advanced stages of CRC. 
[109]. 5FU is converted intracellularly to several metabolites as summarized in 
Figure 1.3 [109, 110]. The key active metabolite, 5-fluoro-2’-deoxyuridine-5’-
monophosphate (5-FdUMP), exerts cytotoxicity through the inhibition of 
thymidylate synthase (TS) [111]. An inactive ternary complex is formed between 
TS, FdUMP and 5,10-methylenetetrahydrofolate (5,10-CH2FH4), preventing the 
conversion of dUMP to dTMP. Depletion of dTMP induces imbalances in the 
deoxynucleotide pool, severely disrupts DNA synthesis and repair and 
cumulatively leads to lethal DNA damage. In addition, mis-incorporation of 5-
fluoro-2’-deoxyuridine-5’-triphosphate (5-FdUTP) and 5-fluorouridine-5’-
triphosphate (5-FUTP) into DNA and RNA exacerbates the cellular damage. The 
level of 5FU is moderated by a metabolizing enzyme, dihydropyrimidine 
dehydrogenase (DPD), which catabolizes it to its inactive form [112]. 
Additionally, the level of 5,10-CH2FH4 is regulated by methylenetetrahydrofolate 





Figure 1.3 Intracellular metabolic pathway of 5FU 
5-FUrd, 5-fluorouridine; 5-FUMP, 5-fluorouridine-5′-monophosphate; 5-FUDP, 5-fluorouridine-
5′-diphosphate; 5-FUTP, 5-fluorouridine-5′-triphosphate; 5-FdUrd, 5-fluoro-2′-deoxyuridine; 5-
FdUMP, 5-fluoro-2′-deoxyuridine-5′-monophosphate; 5-FdUDP, 5-fluoro-2′-deoxyuridine-5′-
diphosphate; 5-FdUTP, 5-fluoro-2′-deoxyuridine-5′-triphosphate; dUMP, 2′-deoxyuridine-5′-
monophosphate; TMP, thymidine-5′-monophosphate; DHFU, dihydrofluorouracil; UP, uridine 
phosphorylase; TP, thymidine phosphorylase; TS, thymidylate synthase; DPD, dihydropyrimidine 
dehydrogenase; 5,10-CH2FH4, 5,10-methylenetetrahydrofolate; MTHFR, 
methylenetetrahydrofolate reductase; 5-CH3FH4, 5-methyltetrahydrofolate; FH2, Dihydrofolate; 
FH4, Tetrahydrofolate. 
 
1.4.3.1 Reported predictive markers of resistance to 5FU 
 
As resistance to 5FU poses a constant challenge to the management of the disease, 
efforts to identify effective predictive markers of patients’ response have been 
escalating. A review of literature found TS and several metabolizing enzymes to 
be implicated: 
i. The best studied predictive marker of response is TS, the main cellular 
target of the drug. Elevated mRNA and protein expression of TS in CRC 
correlated significantly with a poorer response to 5FU [113-115]. For 
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instance, considerably higher response rates were observed in tumors with 
low versus high TS staining by immunohistochemistry (67% versus 24%) 
[115]. On the contrary, a preliminary meta-analysis indicated a lack of 
correlation between TS expression status and survival outcome in patients 
receiving adjuvant 5FU [116].  
ii. Evidence suggests that a polymorphism within the TS gene promoter 
affects TS expression, with the triple repeat homozygotes (3R/3R) linked 
to higher tumor levels than double repeat homozygotes (2R/2R) or 
heterozygotes (2R/3R). Patients harboring the 3R/3R genotype hence did 
not benefit from adjuvant 5FU-based chemotherapy, while those with 
2R/2R homozygotes and 2R/3R heterozygotes experienced improved 
survival [117]. However, conflicting results [118, 119] limited the use of 
TS polymorphism as a predictive marker of 5FU response.  
iii. Thymidine phosphorylase (TP) converts 5FU to 5-FdUrd, which is in turn 
transformed to the active metabolite 5-FdUMP. On average, the mRNA 
level of TP in non-responders was 2.6-fold higher than that of the 
responding patients [120]. Low TP protein expression was also modestly 
associated with better survival [121]. However, these observations 
deviated from in vitro finding where the inhibition of TP negated 5FU 
activity [122]. 
iv. Patients with low mRNA or protein expression of DPD achieved longer 
disease-free and overall survival compared with those with high levels of 
DPD [114, 121, 123].  
v. A C677T polymorphism in MTHFR conferred better clinical response to 
5FU, presumably through a reduced enzyme activity and increased level 
of 5,10-CH2FH4 [124, 125], though a lack of association was also reported 
[126].  
 
To date, studies have focused primarily on relevant metabolic enzymes and drug 
target of 5FU as predictors of resistance. Nevertheless, these markers do not 
account for all cases of resistance due to the complex nature of CRC, mandating 
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the search for other biomarkers. Interestingly, the role of cellular transporters in 
5FU response among CRC patients has not been widely studied.  
 
1.4.3.2 Role of hENT1 in predicting outcome of treatment with 5FU 
 
Nucleoside transporters are present ubiquitously on cellular membranes and have 
been crucial in determining the intracellular bioavailabilty, disposition and 
effectiveness of various therapeutic nucleoside analogs such as gemcitabine and 
cytarabine [127]. Being a nucleoside-resembling pyrimidine analog (                      
Figure 1.4), it is postulated that the transport of 5FU or its metabolites may 
similarly be affected by these nucleoside transporters. Nucleoside transporter 
systems are generally divided into two classes: human equilibrative nucleoside 
transporters (hENTs) and concentrative nucleoside transporters (hCNTs) [127, 
128]. The former is responsible for the facilitated diffusion of physiologic 
nucleosides and comprises four isoforms, hENT1–4. The latter is a sodium-
dependent active transport system and comprises three isoforms, namely hCNT1–
3. Among the nucleoside transporters, hENT1 has been best characterized. Its 
associations with the transport of and resistance towards many drugs have also 
been well studied [129-132]. Notably, in pancreatic cell lines, high levels of 
hENT1 have been found to correlate significantly with resistance to 5FU [129]. 
Similarly in CRC, preliminary studies showed that colorectal tissue specimens 
that were resistant to 5FU in an in vitro cell viability assay tend to exhibit higher 
expression of hENT1 [130]. It is thus likely that hENT1 levels in CRC tissue may 
influence, and be a possible predictive marker of, the clinical response to 5FU.   
 
 




1.4.4 Predicting outcome of treatment with cetuximab 
 
Apart from traditional therapies like 5FU, molecular targeted therapies have 
begun to assume an important role in CRC, with cetuximab being the flagship 
agent. Cetuximab (Erbitux
®
) is a monoclonal antibody used widely in the targeted 
treatment of mCRC.  It binds to the epidermal growth factor receptor (EGFR) and 
attenuates its downstream oncogenic signalling along the RAS/RAF/MAPK and 
PI3K/AKT axes, thereby inhibiting tumor growth and progression (depicted in               
Figure 1.5) [133]. Yet, compared to 5FU, an even smaller subset of patients (8% 
to 23%) achieves an objective response and benefit from cetuximab [106-108]. 
The identification of predictive markers of cetuximab response hence becomes 
pertinent to guiding drug selection, thereby improving the cost-effectiveness of 
the treatment.  
 
 




1.4.4.1 Reported predictive markers of resistance to cetuximab 
 
In predicting patients’ response to anti-EGFR therapy, various genetic alterations 
along the EGFR pathway have emerged as promising markers. For instance, 
landmark trials, including the multicenter CRYSTAL and OPUS studies, have 
revealed that activating mutations in KRAS, a critical regulatory protein along the 
RAS/RAF/MAPK axis, abrogates the therapeutic effect of cetuximab and serves 
as a powerful negative predictor of its clinical efficacy [134-138]. Henceforth, 
major advisory bodies have promulgated the restricted administration of 
cetuximab to mCRC patients with wild type KRAS status [139, 140]. More 
recently, there is also persuasive evidence for cetuximab resistance conferred by 
mutations in BRAF and PI3K, regulators of the RAS/RAF/MAPK and PI3K/AKT 
pathways respectively [141, 142]. Additionally, EGFR gene mutation, a common 
feature in non-small cell lung cancer (NSCLC), has been linked to the efficacy of 
EGFR tyrosine kinase inhibitors such as gefitinib [143-146]. Given the similar 
mechanism of action of cetuximab and gefitinib, mutation at the EGFR tyrosine 
kinase domain could thereotically alter the sensitivity to cetuximab in mCRC 
patients. 
 
1.4.4.2 Importance of determining prevalence of reported predictive markers in 
specific populations 
 
While compelling data exists on the aforementioned mutations as potential 
predictive markers of cetuximab resistance in predominantly Caucasian mCRC 
patients, the relevance and importance of these findings within specific 
populations in Asia rests on the local prevalence of these genetic alterations. 
Despite widespread efforts to establish the prevalence of these mutations among 
Asian countries such as China and Japan [147-153], there is scarce data on their 
prevalence in Singapore. The latter knowledge is crucial in view of the unique 
ethnic composition and lifestyle profile that may influence mutation patterns, as 
postulated from the differential incidence of CRC across populations [3]. A 
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thorough review of literature to date found only one study that assessed KRAS 
mutations in eight mCRC tumors in Singapore [154]. In this study, the 
frequencies of other genetic mutations relevant to the chemoresistance of 
cetuximab (BRAF, PI3K and EGFR) have not been systematically analyzed. 
 
1.5 Chapter conclusion 
 
In this chapter, we reviewed existing screening strategies and explored emerging 
technologies that may hold promise for future population screening for CRC. In 
addition, current and potential predictive markers of response to treatment with 
two widely used drugs, cetuximab and 5FU, were discussed. With the current 
state of knowledge in the detection and personalized treatment of CRC, the 




CHAPTER 2  Rationale and Objectives 
 
2.1 Research gaps and hypotheses 
 
Based on the available literature evaluated in Chapter 1, several research gaps and 
hypotheses exist pertaining to the screening and treatment of CRC.  
 
2.1.1 CRC screening 
 
As discussed in Chapter 1, metabolic profiling of fecal water using NMR 
spectroscopy has unveiled promising markers for identifying CRC patients in 
previous studies [60, 61]. It is likely that complementary analytical platforms such 
as GC/TOFMS may broaden the metabolic coverage and further delineate the 
fecal metabonomic profile characterizing CRC patients. We hence hypothesized 
that GC/TOFMS-based fecal metabonomics may be a viable approach for the 
non-invasive detection of CRC.  
 
For reliable GC/MS-based fecal metabonomic analysis, development and 
validation of a suitable analytical method are prerequisites. However, 
fundamental efforts on method development and validation as well as metabolite 
identification in GC/MS-based fecal metabonomics have not been forthcoming. 
 
Additionally, while selected fecal miRNAs have emerged as potential screening 
markers [91, 94-98], a holistic understanding of the global fecal miRNA profile in 
CRC patients is lacking, particularly in Asian patients. Non-targeted fecal miRNA 
profiling enables the discovery of novel markers but has hitherto been conducted 
predominantly in Caucasian CRC patients [92, 99] who may possess different 
genetic predispositions [3, 155] and hence dissimilar fecal miRNA signature from 
their Asian counterparts. Global profiling is therefore warranted in the Asian 
context and is hypothesized to uncover valuable fecal markers for detecting CRC 




2.1.2 CRC treatment 
 
As preliminary evidence indicated that in vitro manifestations of 5FU resistance 
correlated with higher hENT1 expression [130], we hypothesized that 
intratumoral levels of hENT1, as well as other related nucleoside transporters, 
may influence the clinical response to 5FU. Thus far, no clinical outcome data has 
been reported. 
 
Mutations in oncogenes along the EGFR signaling pathway, namely KRAS, 
BRAF, PI3K and EGFR, have been implicated in the resistance to cetuximab in 
mCRC patients. However, the relative significance of these mutations based on 




The overarching aim of the thesis is to evaluate new approaches and identify 
molecular markers that can facilitate the non-invasive fecal-based screening of 
CRC and enhance the clinical prediction of treatment response. The specific 
objectives are to: 
1) Develop and validate a GC/TOFMS method for the metabonomic 
profiling of human feces. 
2) Evaluate the ability of a GC/TOFMS-based fecal metabonomic approach 
in accurately classifying CRC patients and healthy subjects. 
3) Characterize the global human fecal miRNA profiles in CRC patients and 
healthy subjects to elucidate fecal markers for non-invasive detection of 
the disease. 
4) Investigate the role of hENT1 and related nucleoside transporters in 
predicting clinical treatment outcome with 5FU-based therapy. 
5) Determine the prevalence of KRAS, BRAF, PI3K and EGFR somatic 





The management of CRC is multi-disciplinary, ranging from prevention, 
detection by population screening, diagnosis, staging and prognosis, treatment to 
post-treatment surveillance. While each pillar of disease management merits 
dedicated research attention, this study is focused on improving CRC 
management by addressing challenges in the detection and treatment of the 
disease, by building on the tools and skill sets being developed in the group.  
 
CRC can either be inherited (familial adenomatous polyposis, hereditary 
nonpolyposis colorectal cancer) or sporadic. This thesis is limited to the 
investigation of sporadic adenocarcinoma, which forms the majority of CRC.  
 
In facilitating the non-invasive screening of CRC, our role is not to develop 
biomarkers that supersede existing fecal markers. Rather, we focus on exploring 
alternative molecular modalities that may complement current screening tools to 
increase confidence and granularity of information during screening. A direct 
comparison of their performance with FOBT or fecal DNA is therefore not within 
the scope of this thesis. In addition, this report is confined to utilizing the least 
invasive fecal matrix for the detection of CRC. Similar studies on other matrices 
such as serum or plasma have been reviewed by Menendez et al and Wang et al 
[156, 157]. 
 
Drug resistance may be intrinsic or acquired during treatment. Acquired 
resistance yields a scenario where patients who are initially responsive to a 
treatment become rapidly resistant subsequently. While the latter is also an 
important clinical issue, this report is designed to address the pre-treatment 





The major challenge in the conduct of this study is a slow recruitment rate 
underlied by various logistical factors. With a small sample size, this thesis 
comprises a number of pilot studies that serves to urgently address several 
important research questions faced in the management of CRC, and to provide 
novel directions to project subsequent research efforts. 
 
2.4 Thesis outline  
 
To achieve the specific objectives of this thesis (section 2.2), five sub-studies are 
designed systematically, as summarized in Figure 2.1.  
 
 
Figure 2.1 Evaluation of new approaches and identification of molecular markers 
relevant to the management of CRC 
 
In Chapter 3, we set out to develop and validate a GC/TOFMS method for the 
global metabonomic profiling of human feces. An important analytical 
confounding effect of blood in stool will also be assessed. Using the developed 
method, the metabolic composition of feces from CRC patients and healthy 
subjects will be investigated in Chapter 4. The study determines if GC/TOFMS-
25 
 
based metabonomics could be a viable approach for the non-invasive detection of 
the disease.  
 
Using microarray analysis, Chapter 5 examines the global human fecal miRNAs 
in a cohort of CRC patients and healthy subjects in Singapore to elucidate novel 
fecal screening markers. Potential fecal miRNA markers will be further confirmed 
using real time polymerase chain reaction (PCR). An overview of the 
characteristics of the patients recruited and samples collected for chapters 4 and 5 
is presented in Figure 2.2. 
 
Chapter 6 encompasses a preliminary investigation of the intra-tumoral mRNA 
expression of a panel of nucleoside transporters, including hENT1, in a small 
cohort of CRC patients prior to 5FU-based chemotherapy (Figure 2.3A). To 
provide mechanistic support for the role of hENT1 in 5FU resistance, cell 
viability of Caco-2 cells will be measured following incubation with 5FU and 
varying concentrations of a hENT1 inhibitor.  
 
Finally, in Chapter 7, the prevalence of KRAS, BRAF, PI3K and EGFR somatic 
mutations will determined among Singapore mCRC patients (Figure 2.3B). DNA 
extracted from 45 pairs of surgically resected tumor and normal mucosa will be 





Figure 2.2 Characteristics of patients recruited and samples collected for 





Figure 2.3 Characteristics of patients recruited and samples collected for (A) 
chapter 6 and (B) chapter 7 
28 
 
2.5 Significance of project 
 
The study of novel screening approaches and predictive biomarkers serves to 
support two important aspects of CRC management, specifically detection and 
treatment. 
 
The chapters on fecal metabonomic and miRNA analyses center on a patient-
friendly strategy for CRC screening. Specifically, the use of fecal samples 
circumvents the need for any invasive procedure. We envision that any positive 
outcome from this exploratory work may translate into clinically useful screening 
modalites that would aid in reducing the mortality from the disease.  
 
Our subsequent study on nucleoside transporters may contribute towards a more 
comprehensive set of biomarkers that predicts patients’ response to the most 
widely used chemotherapeutic agent, 5FU.  Such markers permit the assessment 
of treatment viability for CRC patients prior to commencing 5FU therapy and the 
consideration of more worthwhile alternatives early in the course of treatment. In 
the same light, the understanding of the prevalence of key mutations along the 
EGFR pathway can form the basis for future studies on the utility of these 
mutations as predictors of cetuximab efficacy in the local population. These 
efforts may culminate in more personalized and optimized treatment plans for 









CHAPTER 3  Global GC/TOFMS-based metabonomic profiling 
of lyophilized human feces 
 
3.1 Chapter overview  
 
GC/MS-based fecal metabonomics represents a powerful systems biology 
approach for elucidating metabolic biomarkers of lower GIT diseases like CRC. 
Unlike metabolic profiling of fecal water, the profiling of complete fecal material 
remains under-explored. Here, a GC/TOFMS method was developed and 
validated for the global metabonomic profiling of human feces. Fecal and fecal 
water metabotypes were also profiled and compared. Additionally, the unclear 
influence of blood in stool on the fecal metabotype was investigated 
unprecedentedly. Eighty milligram of lyophilized feces was ultrasonicated with 1 
mL of methanol:water (8:2) for 30 min, followed by centrifugation, drying of 
supernatant, and derivatization by methoximation and trimethylsilylation for 45 
min. Lyophilized feces demonstrated a more comprehensive metabolic coverage 
than fecal water, based on the number of chromatographic peaks. Principal 
component analysis (PCA) indicated occult blood (1 mgHb/g feces) exerted a 
negligible effect on the fecal metabotype. Conversely, a unique metabotype 





=0.794), confirming the potential confounding effect of gross GIT 
bleeding on the fecal metabotype. This pertinent finding highlights the importance 
of prudent interpretation of fecal metabonomic data, particularly in GIT diseases 
where bleeding is prevalent. 
 
3.2 Chapter introduction 
 
As discussed in Chapters 1 and 2, metabolic profiling of feces may represent a 
valuable strategy in the non-invasive detection of CRC. Despite its promising 
application, the global metabolic phenotyping (metabotyping) of human feces is 
inherently a technical challenge owing to the rich amount of structurally diverse 
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compounds contained within the biological matrix. For many years, fecal or fecal 
water metabolic profiling has been limited to analysis using NMR spectroscopy 
[60, 158-165]. While NMR possesses the advantages of being nondestructive and 
requiring minimal sample preparation and short acquisition time, its low 
sensitivity precludes the detection of low-abundance metabolites. To broaden the 
metabolic coverage, complementary analytical platforms such as GC/MS could be 
employed. Previously, GC/MS has been proven to be a useful tool in the profiling 
of complex human tissue biopsies such as colon [47, 49-51], stomach [166, 167], 
esophagus [168] ovary [169, 170], prostate [171, 172], bone [171], breast [173] 
and lungs [174]. These positive attributes render GC/MS suitable for unraveling 
the complex metabolic composition of human feces.  
 
While GC/MS-based metabolic profiling of fecal water has been reported [64-66], 
there exist limited studies on the profiling and identification of metabolites within 
the complete fecal material. We hypothesized that feces might yield a different 
metabolic coverage as compared to fecal water. For reliable GC/MS-based fecal 
metabonomic analysis, method development and validation as well as metabolite 
identification are prerequisites. Previously, Ponnusamy et al [67] profiled whole 
feces from irritable bowel syndrome patients using GC/MS; however method 
development and validation were not described. At the same time that our work 
was being done, Ng et al [68] reported a GC/MS fecal metabonomic method but 
the validation of the method and putative identification of all the metabolites were 
not presented. In addition, gut bleeding is prevalent in many diseases of the lower 
GIT such as CRC and ulcerative colitis. The potential confounding effect of blood 
in stool on the fecal metabotype becomes a clinically valid but underappreciated 
concern. To date, this important factor that influences the accurate interpretation 
of fecal metabonomic data remains unaddressed.   
 
In this chapter, a GC/TOFMS method was developed and validated for the 
metabotyping of human feces. Linearity of the analytical method was assessed, 
and stability of fecal metabolites was evaluated at storage conditions that simulate 
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actual clinical sample management. Notably, fecal and fecal water metabotypes 
were profiled and compared. The effects of occult and gross levels of human 
blood in stool on the fecal metabotype were investigated for the first time.  
 




N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) with 1% 
trimethylchlorosilane (TMCS) and methoxyamine hydrochloride in pyridine 
(MOX) were purchased from Thermo Fisher Scientific (Rockford, IL, USA). 
Spectroscopy grade methanol, chloroform and toluene were obtained from Tedia 
(Fairfield, OH, USA). Standard alkane series (C10-C40) and sodium sulphate were 
products of Sigma-Aldrich Inc. (St. Louis, MO, USA). Water was purified by a 
Milli-Q system (Millipore, Billerica, MA, USA).  
 
3.3.2 Method development  
 
The collection of fecal samples was permitted by the Institutional Review Board 
at the Singapore General Hospital. Human feces was pooled from two male and 
two female adult volunteers (age 19 – 78 years with no known pre-existing 
intestinal inflammatory disease) and lyophilized. The pooled lyophilized feces 
were used for all experiments unless otherwise indicated. For the development of 
the sample preparation method, previously published approaches were adopted as 
references [49, 66]. Various parameters, including 1) the weight of lyophilized 
feces (20, 40, 60 and 80 mg), 2) the duration of ultrasonication (30, 60, 90 and 
120 min), 3) the type of extraction solvent [chloroform:methanol:water (2:5:2), 
acetonitrile:water (8:2), methanol:water (8:2) and methanol:water (4:2)], 4) the 
length of derivatization with MSTFA (30, 45, 60 and 90 min) and 5) the effect of 
methoximation (inclusion or exclusion of the methoximation step in the protocol), 
were explored. All experiments were performed in triplicates. The method was 
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optimized based on the number of chromatographically-resolved and de-
convoluted peaks [with a signal-to-noise (S/N) ratio greater than 180] and the 
total integrated area of these peaks. 
 
3.3.3 Sample preparation and derivatization  
 
In our optimized method, each lyophilized fecal sample (80 mg) was 
ultrasonicated with 1 mL of ice-cold extraction solvent [methanol:water (8:2)] at 
4°C in a bath ultrasonicator (Elma Transsonic 460, Germany) for 30 min, and 
vortex-mixed for 2 min. The samples were then centrifuged at 18 000 g for 15 
min at 4°C and 0.5 mL of the supernatant was extracted carefully and dried at 
50°C under a gentle stream of nitrogen gas (Turbovap LV, Caliper Life Sciences, 
Hopkinton, MA, USA). Toluene (100 μL, kept anhydrous with sodium sulfate) 
was added to the dry residue, and evaporated completely again at 50°C under 
nitrogen gas to remove traces of water. The dried metabolic extract was then 
methoximated with 50 μL of MOX (20 mg/mL) at 60°C for 2 h. Following 
methoximation, 100 μL of MSTFA with 1% TMCS was added and the mixture 
was incubated at 60°C for 45 min to form trimethylsilyl (TMS) derivatives. 
Finally, 100 μL of the cooled TMS derivatives was transferred into a GC vial and 
subjected to GC/TOFMS analysis. 
 
3.3.4 GC/TOFMS analysis  
 
Analysis was carried out on a Pegasus GC/TOFMS (LecoCorp., St. Joseph, MI, 
USA) coupled to an Agilent 7890 gas chromatograph. A DB-1 (30 m × 250 µm 
i.d.) fused silica capillary column (Agilent J&W Scientific, Folsom, CA), with 
0.25 µm film thickness, was used with open split interface. Helium was employed 
as the carrier gas at a constant flow rate of 1.5 mL/min and the injector split ratio 
was adjusted to 1:10. A volume of injection of 1 μL was used. The injector, 
transfer line and ion source temperatures were maintained at 220, 220 and 250°C, 
respectively. Oven temperature was programmed at 70°C for 0.2 min, increased at 
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10°C/min to 270°C where it was sustained for 5 min, and further increased at 
40°C/min to 310°C where it was held for 11 min. The MS was operated in the 
electron impact ionization mode at 70eV. Mass data were acquired in full scan 
mode from m/z 40 to 600 with an acquisition rate of 20 spectra per second. To 
detect retention time shifts and enable kovats retention index (RI) calculation, a 
standard alkane series mixture (C10-C40) was injected periodically during sample 
analysis. RIs are relative retention times normalized to n-alkanes eluted adjacently 
[175].  
 
3.3.5 Data pre-processing and metabolite identification  
 
All gas chromatograms were subjected to baseline correction, de-convolution, 
noise reduction, smoothing, library matching and area calculation using 
ChromaTOF software (version 4.41, LecoCorp.). During metabolite 
identification, method validation and chemometric analysis between fecal and 
fecal water, the following peaks were discarded: artifactual peaks with integral 
areas that were impervious to changes in concentration, poorly resolved peaks, 
peaks with poor shapes, peaks that were not present consistently in all method 
validation experiments, as well as irreproducible peaks with coefficient of 
variation of more than 20%. For the investigation of the influence of blood in 
stool, poorly resolved peaks and peaks with poor shapes were excluded from the 
data analysis.  
 
Metabolites were putatively identified by comparing both the MS spectra and RI 
with those in the National Institute of Standards and Technology (NIST) library. 
If RIs were unavailable in the NIST library, RIs from the Fiehn library, Golm 
Metabolome Database (http://csbdb.mpimp-golm.mpg.de/gmd.html), Human 
Metabolome Database (http://www.hmdb.ca/) as well as reported literature [176] 





3.3.6 Method validation  
 
Validation of linearity and range of dilution were performed in our study using 
the matrix dilution approach [66, 177]. The use of this approach was justified by 
the relatively high abundance of fecal metabolites in a pooled fecal sample (as 
described above). The supernatant of the feces following extraction was diluted 
serially 2, 5, 10 20, 50, 100, 200 and 500 times with methanol:water (8:2). All 
dilutions were made in triplicates. The samples were then processed and analyzed 
as per the protocol described earlier. The range of dilution for each analyte was 
defined as the maximum dynamic order of dilution at which the analyte remained 
detectable (S/N>3). The correlation coefficient (R) of each analyte was obtained 
from the linear regression of the chromatographic peak area against the fecal 
extract dilutions. 
 
For the stability study, freshly collected fecal matter from one adult volunteer was 
used. To evaluate the stability of fecal metabolites between sample collection and 
storage in the deep freezer, fecal samples (n=3) were stored at 4°C and 29°C for 1 
and 2 days before freezing at -80°C. Lyophilization, processing and analysis of 
the samples were performed subsequently as described above. The results 
obtained were compared with those derived from samples that were stored 
immediately at -80°C (n=6). 
 
To examine freeze-thaw stability, the FDA guideline for bioanalytical method 
validation was used as reference [178]. Samples (n=3) were stored at -80°C for 24 
h and thawed unassisted at room temperature (25 ± 1°C). When completely 
thawed, an aliquot from each replicate was reserved for stability testing. This 
constituted the first freeze-thaw cycle. Samples were refrozen subsequently at -
80°C for 12 h. The freeze-thaw cycle was repeated two more times and the 
samples were then lyophilized and analyzed after the third cycle. The results 
obtained were compared with those derived from samples which were not 




To assess long term stability, fecal samples were lyophilized and analyzed after 1 
week (n=3) and 6 weeks (n=3) of storage at -80°C. The resulting data were 
compared with those of samples analyzed on the first day of the study (n=6). In 
the stability study, analytes exhibiting a relative stability of 100 ± 20% in all three 
replicates were considered stable under the investigated storage conditions. 
 
3.3.7 Comparison between fecal and fecal water metabotypes  
 
Fecal water was obtained by homogenizing 80 mg of lyophilized feces in 500 μL 
of water and extracting all aqueous supernatant (250 μL) after centrifugation (18 
000 g for 60 min at 4°C) (illustrated in Supplementary Figure 1). To 250 μL of 
fecal water, 1 mL of ice-cold methanol was added to obtain a final methanol-to-
water ratio of 8:2. To 80 mg of lyophilized feces, 1 mL of ice-cold 
methanol:water (8:2) was added and the mixture was ultrasonicated for 30 min. 
At the same time, a literature control [66] was prepared by adding 500 μL of ice-
cold methanol to 250 μL of fecal water. All experiments were performed in 
triplicates. All samples were processed and analyzed as above. The number of 
chromatographic peaks (with S/N ratio greater than 180) was compared. 
Multivariate analysis was performed as described below. 
 
3.3.8 Investigation of effect of blood on the fecal metabotype  
 
Feces (Bristol stool scale type 4) was collected from an adult volunteer who was 
tested negative in a fecal occult blood test and divided into 3 fractions. To the first 
fraction, an appropriate volume of human blood was spiked to approximate the 
clinical level of occult blood in the feces of CRC patients (1 mgHb/g feces) [179]. 
To the second fraction, a volume of human blood was spiked to simulate the feces 
of patients with gross bleeding in the lower GIT (100 mgHb/g feces). The third 
unspiked fraction served as the control. All three fractions were lyophilized, 
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processed and analyzed as described above (5 analytical replicates per fraction). 
Multivariate analysis was performed as described below. 
 
3.3.9 Multivariate statistical analysis  
 
Normalization to a constant total chromatographic peak area was performed prior 
to chemometric analyses. Chemometric analysis was performed using SIMCA-P 
version 12.0 software (Umetrics, Umeå, Sweden). The normalized data were 
subjected to unsupervised principal component analysis (PCA) to detect outliers 
and inherent grouping trends among fecal and fecal water samples or among neat 
feces, feces with occult blood and feces with gross blood. The data were mean-
centered and unit variance scaled during chemometric data analysis [180]. After 
PCA, supervised partial least square discriminant analysis (PLS-DA) was applied 
to build discriminating models and identify marker metabolites that accounted for 
the differentiation. Validation of the PLS-DA model was performed to check for 
overfitting. During this process, the sample classes (also known as y-variables) 
were shuffled randomly while the X-data were left intact. Model was considered 
valid if Q
2
 value on the actual classification of samples was higher than Q
2
 values 
on 100 randomly permuted classifications. The statistical significance of marker 
metabolites elucidated from all comparisons was further determined by 
independent Welch’s t-test using Microsoft Excel 2007 (p<0.05 was considered 
statistically significant). Heat map was generated using R (www.r-project.org). 
 
3.4 Results  
 
3.4.1 Method development  
 
Optimization of the analytical method was performed with respect to the weight 
of lyophilized feces, duration of ultrasonication, type of extraction solvents, 
duration of derivatization with MSTFA and effect of methoximation. The number 
of chromatographic peaks and total integrated peak area were surrogate indicators 
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of metabolic coverage and analytical sensitivity, respectively. Eighty milligram of 
lyophilized feces produced the best metabolic coverage and overall sensitivity. 
These outcomes were not discernibly affected by the duration of ultrasonication. 
Among the different extraction solvents, methanol:water (8:2) was found to be 
optimal in terms of metabolic coverage. Desirable metabolic coverage and 
sensitivity was achieved at intermediate derivatization periods of 45 and 60 min, 
coupled to methoximation using MOX (Supplementary Figure 2).  
 
From this method, 268 chromatographic peaks were resolved consistently after 
the exclusion of artifactual and irreproducible peaks. Among which, the putative 
identities of 107 peaks were further assigned based on a combinatorial matching 
of mass spectra and RIs. Table 3.1 showed a wide range of metabolites including 
carbohydrates, carboxylic acids, hydroxyl acids, fatty acid esters, polyols, long 
chain alcohols, sterols, phenols, amino acids and other nitrogen-containing 
compounds found in human feces. The detected fecal metabolites ranged from 
endogenous metabolites associated with host (e.g. cholesterol, urea) and gut 
microbes (e.g. 3-indole propanoic acid, benzeneacetic acid, nicotinic acid, benzoic 







Table 3.1 Identified metabolites in human feces and the associated linearity and range of dilution of derivatized metabolites 
No Metabolites Level of identification
a
  R  Range of dilution   No Metabolites Level of identification
a
  R  Range of dilution 
Amino acids and derivatives 
 
Fatty acid ester 
1 Valine (derivatized as 1TMS) 2 0.994 500 
 
57 1-Monopalmitoylglycerol  1 0.991 5 
2 Alanine 2 0.992 5 
 
58 1,3-Dihydroxy-2-propanyl (9E)-9-octadecenoate  1 0.996 10 
3 Leucine 2 0.999 500 
 
59 1,3-Dihydroxy-2-propanyl (9E)-9-octadecenoate 1 0.987 5 
  
     
Fatty acid methyl ester 
4 Isoleucine 2 0.999 500 
 
60 9,12-Octadecadienoic acid, methyl ester, (E,E)- 1 0.997 5 
5 Valine (derivatized as 2TMS) 
b
 1 0.992 500 
 
61 9-Octadecenoic acid (Z)-, methyl ester 1 0.993 5 
  
     
Di-carboxylic acids 
6 Glycine 1 0.998 500 
 
62 Malonic acid 1 0.991 5 
7 Methionine 2 0.992 50 
 
63 2-Methylsuccinic acid 1 0.997 500 
8 Aspartic acid 2 0.995 50 
 
64 Glutaric acid 1 0.997 500 
9 5-Oxoproline (derivatized as 2TMS) 1 0.994 500 
 
65 Adipic acid 1 0.997 50 
10 5-Oxoproline (derivatized as 1TMS) 2 0.970 200 
 
66 trans-trans-Muconic acid  2 0.990 2 
  
     
Hydroxyl acids 
11 Phenylalanine 2 0.989 50 
 
67 3-Hydroxybutyric acid 2 0.996 200 
12 Tyrosine 2 0.977 20 
 
68 4-Hydroxyvaleric acid 2 0.991 10 
Other N-Compounds 
     
  
13 (+)-N-Methylephedrine 3 0.998 500 
 
69 5-Hydroxyhexanoic acid  1 0.994 50 
14 3-hydroxypyridine 2 0.984 500 
 
70 Malic acid 2 0.989 5 
15 4-(Dimethylamino)butanoic acid  3 0.996 100 
 
71 5-(Hydroxymethyl)-2-furoic acid  1 0.993 5 




  2 0.996 50 




  1 0.969 2 
18 Urea 1 0.997 20 
 
74 Threonic acid 2 0.991 2 
19 Pipecolic acid 2 0.985 50 
 
75 4-hydroxycyclohexylacetic acid 3 0.995 20 
20 Nicotinic acid 1 0.996 200 
 
76 2-hydroxyadipic acid 2 0.994 2 
  
     
Polyols 
21 Pyrrole-2-carboxylic acid 2 0.990 10 
 
77 1,3 Propanediol 1 0.996 50 




 1 0.997 500 
23 Thymine
 c
 1 0.978 10 
 
79 Gulono-1,4-lactone 2 0.989 5 
  
      
Long chain alcohols 
24 Pyrrole-2-carboxylic acid  2 0.983 200 
 
80 1-Tetradecanol 1 0.989 5 
25 Thymine
 c
 1 0.994 500 
 
81 1-Pentadecanol  1 0.984 50 




  2 0.992 5 




  1 0.986 50 
28 3-methyl-1H-indole  3 0.971 5 
 
84 1-Heptadecanol 1 0.989 10 
29 5-Hydroxy-indole  2 0.992 50 
 
85 (Z)-10-Pentadecen-1-ol 3 0.994 50 
30 3-Indole propanoic acid 1 0.993 50 
 
86 (E)-9-Tetradecen-1-ol  3 0.997 5 
31 Uridine 1 0.995 50 
 
87 1-Octadecanol 1 0.991 50 
Carbohydrates and derivatives 
  
Long chain alkyls 
32 Glyceraldehyde
 c
 2 0.987 10 
 
88 1-Nonadecene 1 0.993 2 
  




 2 0.998 200 
 
89 Coprostan-3-ol 3 0.990 100 
34 Ribose 2 0.991 10 
 
90 Cholest-5-en-3-ol (Cholesterol)  1 0.998 20 
35 Xylose 2 0.987 500 
 
91 cholestan-3-ol 2 0.991 5 
36 3,4-Dideoxyhexitol  3 0.994 20 
 
92 Cholest-7-en-3-ol  1 0.994 5 
37  6-deoxy-D-galactose 2 0.996 50 
 
93 3-Hydroxycholan-24-oic acid  2 0.991 500 
  




 1 0.998 20 
 
94 Acetophenone 1 0.983 2 
39 Fructose
b
 1 0.988 50 
 
95 3-methylphenol 1 0.962 500 
40 Galactose 2 0.995 20 
 
96 3-Ethylphenol 1 0.990 2 
41 N-Acetyl-b-D-glucosamine 2 0.999 5 
 
97 Benzoic acid 1 0.993 100 
Monocarboxylic acids 
     
  
42 Pentanoic acid 1 0.991 500 
 
98 Benzeneacetic acid 1 0.994 500 
43 4-methyl-pentanoic acid  3 0.990 20 
 
99 4-Methylcatechol 1 0.990 10 
44 Hexanoic acid 1 0.990 500 
 
100 Hydrocinnamic acid  1 0.995 200 
45 2-Furancarboxylic acid 2 0.985 50 
 
101 2'-Hydroxy-6'-methoxyacetophenone 2 0.995 10 
46 Cyclohexanecarboxylic acid 1 0.993 200 
 
102 4-Hydroxyphenylethanol 1 0.993 2 
Long chain monocarboxylic acids 
     
  
47 Tetradecanoic acid 1 0.998 100 
 
103 3-hydroxybenzeneacetic acid  1 0.996 10 
48 Pentadecanoic acid  1 0.991 200 
 
104 4-Hydroxybenzoic acid 1 0.983 2 
49 Pentadecanoic acid 1 0.991 200 
 
105 4-hydroxybenzeneacetic acid  1 0.997 10 
50 (E)-9-Hexadecenoic acid 1 0.989 10 
 
106 Caffeic acid  1 0.987 20 
51 Hexadecanoic acid 1 0.991 200 
 
107 α-Tocopherol (vitamin E) 2 0.994 5 
52 Heptadecanoic acid 1 0.995 5 
     
  
53 Heptadecanoic acid  1 0.994 10 
     
  
54 (9Z,12Z)-9,12-Octadecadienoic acid 1 0.994 200 
     
  
55 (E)-9-octadecenoic acid 1 0.986 200 
     
  
56 Octadecanoic acid  1 0.999 200             
a 
Metabolites were identified based on 1: Matching of mass spectra (similarity index more than 40%) coupled with matching of kovats RI with columns of equivalent chemistry, 2: Matching of mass spectra (similarity index more than 40%) combined with matching of kovats RI with columns of different chemistry (5% 
phenyl/95% dimethylpolysiloxane), 3: Matching of mass spectra only (similarity index more than 80%) or 4: Matching of mass spectra (similarity index more than 40%) and matching of Fiehn RI. 
b
 Metabolites were also validated by reference standards.  
c
 Derivatized metabolites were present as multiple peaks in the chromatogram.  
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3.4.2 Method validation  
 
The range of dilution was found to vary widely across the different analytes ( 
Supplementary Table 1). Interestingly, an appreciable proportion of amino acids 
and derivatives, monocarboxylic acids and long chain acids demonstrated broad 
ranges (≥ 200-fold dynamic order of dilution). On the contrary, fatty acid esters, 
fatty acid methyl esters and hydroxyl acids generally demonstrated narrower 
ranges (2 to 5-fold dynamic order of dilution). In the evaluation of the linear 
response of the GC/MS method, more than 98% of the analytes exhibited good 
correlation coefficients (R) of more than 0.95 (Supplementary Figure 3). The 
range of dilution and R value of individual analytes are presented in Table 3.1. 
 
The stability study revealed that metabolites were highly unstable in human feces 
(Supplementary Figure 4). Out of the 268 analytes, only 28% remained stable up 
to 2 days when kept at 4°C. Expectedly, at room temperature (29°C), the 
proportion of stable analytes further declined to approximately 10%. There was 
no noticeable difference between 1 and 2 days of storage under both conditions. 
The stability upon the first freeze-thaw cycle was 33%, and this deteriorated 
considerably to 18% at the second and third freeze-thaw cycles. Similarly, the 
metabolites exhibited poor stability during long term storage at -80°C (24% 
analytes remaining stable upon 1-week storage). No further depreciation of 
analytes was observed at 6 weeks.  
 
3.4.3 Comparison between fecal and fecal water metabotypes  
 
Lyophilized feces contained metabolites that covered a wider metabolic space, 
generating a larger number of chromatographic peaks (704 peaks) compared to 
fecal water (664 peaks). Representative chromatograms of feces and fecal water 
are shown in Figure 3.1A and B, respectively. In the PCA scores plot (Figure 
3.1C), feces was clearly distinguished from fecal water, regardless of the 







Figure 3.2 illustrates the metabolites that differentiated feces from fecal water 
(extracted with the same solvent system, methanol:water (8:2)), as elucidated by 







Y=0.999] (see Supplementary Figure 5A and B for PLS-DA scores 
plot and validation plot, respectively). While the adoption of feces as the sample 
matrix compromised the detection of more polar metabolites such as amino acids 
and carbohydrates, it augmented the detection of non-polar metabolites such as 


























Figure 3.1 (A) Typical GC/TOFMS chromatogram of pooled feces (B) Typical 
GC/TOFMS chromatogram of pooled fecal water (C) PCA scores plot 
differentiating feces ( ) from fecal water extracted with the same solvent ( ) and 
fecal water extracted with optimal solvent (literature control) ( ) 
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Figure 3.2 Fold change (FC) of marker metabolites in feces versus fecal water 
(extracted with the same solvent); FC>1 = higher levels in feces compared to 
fecal water; FC<1 = lower levels in feces compared to fecal water 
0.1 1 10 100 1000 




9-Octadecenoic acid (Z)-, methyl ester 
1-Monopalmitoylglycerol  























3-Indole propanoic acid 






























































3.4.4 Effects of occult and gross levels of blood on the fecal metabotype  
 
PCA (Figure 3.3A) revealed a clustering trend between neat feces and feces 
spiked with occult blood (1 mgHb/g feces). On the contrary, feces spiked with 
gross level of blood (100 mgHb/g feces) were clearly distinct from neat feces in 




=0.794]. Based on the cross-







(see Supplementary Figure 6A and B for PLS-DA scores plot and validation plot, 
respectively), discriminating metabolites characterizing feces with gross blood 











Figure 3.3 (A) PCA scores plot obtained from neat feces ( ), feces spiked with 
occult (1 mgHb/g feces) blood ( ) and feces spiked with gross (100 mgHb/g 
feces) level of blood ( ) (B) Positive fold-change and chemical class of 





3.5.1 Method development  
 
Fecal metabonomics represents a conceptually attractive approach to characterize 
lower GIT diseases owing to the close proximity of the feces with the molecular 
environment of the colorectum. To the best of our knowledge, this is the first 
study that describes the optimization and validation of a GC/TOFMS method for 
the global metabotyping of human feces. 
 
In method optimization, efforts were directed at developing a convenient method 
that confers the widest metabolic coverage and highest analytical sensitivity. To 
this end, important parameters such as the weight of lyophilized feces, duration of 
ultrasonication, type of extraction solvent, duration of derivatization and effect of 
methoximation were optimized.  
 
A concurrent study by Ng et al explored the extraction of different fecal weights 
at identical solvent-to-feces ratio [68]. As an equivalent amount of fecal 
homogenate was introduced into the GC/MS in each case, the scalability of the 
extraction process rather than the optimal fecal weight for GC/MS analysis was 
investigated. Conversely, we sought to determine a suitable weight of lyophilized 
feces that yield an optimal detection of the metabolites by GC/TOFMS yet avert 
overloading the detector. Lyophilization was adopted as a mean to eliminate the 
influence of variable water content on the fecal weight. We reason that this could 
also minimize alterations in the lipophilicity of the extraction system which can 
then adversely affect the extraction efficiency. Unlike Ng et al, different fecal 
weights were added with a consistent volume of extraction solvent, following 
which a uniform amount of fecal homogenate was processed. While the highest 
tested dry weight of 80 mg yielded optimal metabolic coverage and sensitivity 
with no observed saturation, higher fecal weights were not tested to facilitate 
sample preparation in microtubes. Our approach also revealed that 
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methanol:water (8:2) generated the widest metabolic coverage and was applied 
consequently in all experiments. 
 
Besides fecal weight and type of extraction solvent, other crucial parameters were 
described in this work for the first time. The duration of ultrasonication had a 
neutral effect on the analytical performance, hence a period of 30 min was 
selected to minimize sample processing time. Chemical derivatization by MSTFA 
is necessary for increasing the volatility of compounds prior to GC/MS analysis. 
Importantly, an appropriate duration of derivatization allows a balance between 
complete derivatization and time-dependent thermal degradation. Between the 
optimal derivatization time periods of 45 and 60 min, the former was selected for 
ease of sample preparation in our study. In addition, the inclusion of MOX was 
determined to exert a favourable effect on the metabolic coverage and sensitivity. 
It was likely that MOX fixed enolizable keto groups present in the fecal 
metabolites, preventing downstream formation of unstable TMS-ethers (see 
Supplementary Figure 7 for a further illustration using galactose). With the 
optimization of the abovementioned parameters, a suitable method was developed 
for the metabotyping of human feces using GC/TOFMS. 
 
The reproducibility of GC/MS analysis and availability of an electron impact 
mass spectral library enable reliable putative peak identification by RI and mass 
spectral matching. Despite these advantages, the inadequate database for RI 
comparison remains a limitation and was reflected in the inability to identify a 
substantial portion of the metabolites in our study. Nevertheless, a myriad of fecal 
metabolites representing diverse chemical classes were identified. More 
importantly, the identification of these metabolites illuminated the promise of the 
method to characterize lower GIT diseases like CRC. For instance, the presence 
of established tissue metabolic biomarkers of CRC [47-49, 51] (e.g. 1-
hexadecanol, uridine, galactose) in the fecal metabotype underscored the potential 
utility of fecal metabotyping in the non-invasive detection of the disease. 
Furthermore, the detection of gut microbial metabolites (e.g. benzeneacetic acid, 
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hydrocinnamic acid, nicotinic acid) yielded opportunity for the interrogation of 
the gut microbial influence on the progression of CRC. Taken together, the 
comprehensive identification of fecal metabolites laid the foundation for 
subsequent characterization of CRC using the developed GC/TOFMS method. 
 
3.5.2 Method validation  
 
In metabonomics, relative quantitation is employed frequently to compare 
metabolite changes between two groups. The levels of many metabolites may 
differ drastically between the groups, spanning as high as 2 to 3 orders of 
magnitude. However the ability to measure the true magnitude of change depends 
on the dynamic range of the analytical method. Dynamic range determination is 
especially important for GC/TOFMS which is prone to detector ion saturation, 
leading to relatively limited dynamic range of measurement compared to 
quadrupole MS. Therefore the range of dilution was validated for each analyte to 
evaluate the detectable magnitude of change. This knowledge is important for the 
credible interpretation of changes in the levels of candidate biomarkers in future 
fecal metabonomic studies. For example, any large dynamic changes in the levels 
of metabolites with broad detectable ranges (e.g. valine, leucine, pentadecanoic 
acid) would expectedly be well elucidated by the method. On the other hand, 
metabonomic scientists have to be mindful that significant perturbations of 
metabolites with small detectable ranges (e.g. 1-monopalmitoylglycerol, threonic 
acid) may not be revealed optimally.  
 
Additionally, linearity of the method is pivotal for accurate relative quantitation. 
The present validation showcased good linearity of the GC/TOFMS method and 
its suitability for semi-quantitative metabotyping of human feces.  
 
Stability of fecal samples was evaluated at storage conditions that simulate actual 
clinical sample management in an outpatient setting. Typically, collection of 
clinical fecal samples involves patient self-collection at home, followed by 
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transfer to the hospital’s deep freezer within 1 to 2 days. During further sample 
transfer and analysis, freeze-thaw may inevitably occur. For timely disease 
detection, clinical samples are generally analyzed within a month. With these 
clinical considerations, we assessed the stability of the metabolites in fecal 
samples stored at 4°C and room temperature (29°C) for 1 and 2 days, after 3 
freeze-thaw cycles, as well as long term storage at -80°C for 1 week and 6 weeks. 
Our data confirmed a clear compromise in the integrity of fecal metabolites under 
various storage conditions, likely due to microbial enzyme activity or intrinsically 
unstable metabolites within the complex fecal environment [181]. Our findings 
emphasized the realistic challenge in fecal metabonomics and the demand for 
more efficient and rapid fecal sample collection, storage and analysis.  
 
3.5.3 Comparison between fecal and fecal water metabotypes  
 
While GC/MS-based metabotyping of fecal water has been actively pursued [64-
66], the profiling of complete fecal material remains under-explored. Fecal water, 
the aqueous component of feces, was postulated to generate a different metabolic 
coverage from feces. To test our hypothesis, we compared the metabotypes of 
feces and fecal water using similar extraction solvent (methanol-to-water 8:2). 
Additionally, a literature control encompassing fecal water extracted using its 
optimal reported solvent was included for a fair comparison [66]. Indeed, 
lyophilized feces demonstrated a more comprehensive metabolic coverage 
compared to fecal water, as evident from the number of chromatographic peaks. 
This observation was possibly derived from the richer content of endogenous 
metabolites encapsulated within the solid residue of the feces. Our observation 
thus underlined the potential of feces in capturing more extensive molecular 
information from the lower GIT than fecal water. Multivariate analysis further 
confirmed the difference in unique metabotype produced by feces where a more 
sensitive detection of non-polar metabolites was observed. The larger separation 
along the first principal component (between feces and fecal water extracted by 
the same solvent) compared to the second component (between fecal water 
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extracted by different solvents) of the PCA also highlighted a more substantial 
influence by the type of sample matrix compared to the extraction solvent on the 
metabotype. In view of its unique metabolic coverage, GC/MS-based fecal 
metabonomics is positively complementary to fecal water metabonomics for the 
characterization of lower GIT diseases. On the other hand, our findings also 
suggested the possibility of analysing the polar fecal metabolites using LC/MS 
coupled to polar column chemistry such as hydrophilic interaction liquid 
chromatography and ion-exchange chromatography. 
 
3.5.4 Effects of occult and gross levels of blood on the fecal metabotype  
 
Gut bleeding is a clinically prevalent phenomenon associated with many GIT 
diseases. For the successful application of fecal metabonomics to the 
characterization of lower GIT diseases, it becomes imperative to delineate the 
impact of blood in stool on the fecal metabotype. Our GC/MS metabonomic data 
indicated clearly that the fecal metabotype was not affected significantly by the 
presence of occult blood. This implied that the method could be used reliably to 
profile the feces of patients where occult bleeding is observed. On the contrary, it 
was evident from our results that gross GIT bleeding could potentially confound 
GC/MS-based fecal metabonomic studies. The observed metabotype of feces with 
gross blood is likely a culmination of the differential distribution of metabolites 
between the blood and feces compartments and their associated analytical matrix 
effects. The former possibility was supported by elevated levels of blood-derived 
metabolites (e.g. proline, glycine, serine) [177] in feces spiked with gross level of 
blood compared to neat feces. Collectively, our findings caution for prudent 
interpretation of fecal metabonomic data, particularly in GIT diseases where 






3.6 Chapter conclusion 
 
A novel GC/TOFMS method was developed and validated for the metabonomic 
profiling of lyophilized human feces where its metabotype was confirmed to be 
more comprehensive than fecal water. With the vast array of detected fecal 
metabolites which could acquire valuable insight into the molecular environment 
of the lower GIT, we envisage the potential application of this method in profiling 
CRC. For the first time, we elucidated the effects of occult and gross bleeding on 
the fecal metabotype, which shed light on an important consideration in clinical 
fecal metabonomic studies. The validated method and valuable information 





CHAPTER 4  Non-invasive fecal metabonomic detection of CRC 
 
4.1 Chapter overview 
 
In this chapter, the role of fecal metabonomics in the non-invasive detection of 
CRC was investigated. GC/TOFMS was utilized for the metabolic profiling of 
feces obtained from 11 CRC patients and 10 healthy subjects. Concurrently, 
matched tumor and normal mucosae surgically excised from CRC patients were 
profiled. CRC patients were differentiated clearly from healthy subjects based on 
their fecal metabonomic profiles [orthogonal partial least squares discriminant 







(cumulative)=0.215]. The robustness of the OPLS-DA model was 
demonstrated by an area of 1 under the receiver operator characteristic curve. 
OPLS-DA revealed fecal marker metabolites (e.g. fructose, linoleic acid and 
nicotinic acid) that provided novel insights into the tumorigenesis of CRC. 
Interestingly, a disparate set of CRC-related metabolic aberrations occurred at the 
tissue level, implying the contribution of processes beyond the direct shedding of 
tumor cells to the fecal metabotype. In summary, this work established proof-of-
principle for GC/TOFMS-based fecal metabonomic detection of CRC and offered 
new perspectives on the underlying mechanisms. 
 
4.2 Chapter introduction 
 
As highlighted in Chapter 1, timely detection of CRC by population screening has 
been a pivotal strategy in the quest to abate disease mortality [9]. Yet, established 
screening methods such as colonoscopy or FOBT are either invasive or lack 
sensitivity and specificity [15]. Fecal DNA [28] and mRNA testing [36] are 
emerging non-invasive techniques, but their wide acceptance awaits further 
optimization and validation with respect to the clinical value in CRC screening. 
These limitations have fuelled ongoing research into complementary fecal-based 
approaches that would facilitate non-invasive screening for CRC. In this respect, 
52 
 
fecal metabonomics represents a conceptually promising approach, given the 
intricate changes in the molecular environment of the gut lumen which could be 
induced by neoplasia and the underlying dysbiosis and reflected as metabolic 
alterations in the feces. To date, no clinical studies have explored the use of 
GC/TOFMS for the non-invasive fecal metabolic profiling of CRC.  
 
In the previous chapter, a GC/TOFMS method was developed and validated for 
the metabonomic profiling of lyophilized human feces. Using the developed 
method, the current chapter aimed to investigate the metabolic composition of 
feces from CRC patients and healthy subjects and determine if GC/TOFMS-based 
metabonomics could be a viable approach for the non-invasive detection of the 
disease. Additionally, tumor specimens and their matched normal mucosae from 
the same cohort of CRC patients were analyzed and compared to examine the 
concordance and variation of metabolic alterations at the fecal and tissue levels. 
 
4.3 Materials and Methods 
 
4.3.1 Clinical population and samples 
 
Eleven CRC patients (Duke stages B – C) and 10 healthy subjects were recruited 
at the outpatient specialist clinic from September 2011 – June 2012. All subjects 
were Han Chinese. The inclusion criteria for CRC patients were a diagnosis of 
sporadic CRC and an intention to undergo surgical tumor resection. Exclusion 
criterion was treatment with neoadjuvant chemotherapy or radiotherapy. 
Randomly selected healthy subjects were eligible for this study if a colonoscopy 
was performed within the past 5 months to confirm the absence of CRC or pre-
cancerous polyps. Exclusion criteria consisted of a history of CRC, a history of 
polyps within the last 3 years, the presence of inherited CRC syndromes (e.g. 
Lynch syndrome and familial adenomatous polyposis) and a family history of 
hereditary CRC. In both groups, subjects did not have co-existent inflammatory 
bowel disease. The clinical characteristics of the enrolled CRC patients and 
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healthy subjects were summarized in Table 4.1. This study was approved by the 
Institutional Review Board at the Singapore General Hospital (2009/723/B). All 
subjects provided informed consent prior to participation in the study. 
 
Table 4.1 Clinical characteristics of CRC patients and healthy subjects 
Characteristics CRC patients  
(n=11) 
Healthy subjects  
(n=10) 
Age, years   
   Mean 64.5 57.4 
   Range 56-80 48-79 
Sex, no. (%)   
   Male 7 (63.6) 4 (40.0) 
   Female 4 (36.4) 6 (60.0) 
Tumor site, no. (%)  
   Sigmoid 2 (18.2)  
   Rectosigmoid 2 (18.2)  
   Rectum 7 (63.6)  
Dukes' stage no. (%)  
   B 6 (54.5)  
   C 5 (45.5)  
Tumor differentiation   
   Well differentiated  1 (9.1)  
   Moderately differentiated  10 (90.9)   
 
 
Fecal specimens were collected domestically by CRC patients prior to surgical 
resection and by healthy subjects within a month of enrolment into the study. 
Subjects were given detailed instructions for sample collection. Briefly, a 
representative aliquot of feces was collected in a sealed plastic container. Care 
was taken to avoid contact with toilet water and urine. The specimens were 
transported to the hospital on the same day, or otherwise, kept at 4°C and brought 
to the hospital within 2 days. All specimens were stored at -80°C immediately 
upon receipt at the hospital and were not subjected to any freeze-thaw. 
 
Surgical tissues resected from the same cohort of CRC patients were snap-frozen 
in liquid nitrogen, microdissected and stored at -80°C until analysis. Careful 
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microdissection of the excised tissue ensured that at least 90% of the tumor 
specimen comprised cancer cells. Matched normal mucosa samples were obtained 
from excised tissue at least 5 cm away from the edges of the tumor. The tumor 
specimens were also subjected to routine histological examination by a blinded 
pathologist to identify the stage and grade of the cancer. Due to limited sample 







 Hemoglobin was purchased from R-Biopharm (Bensheim, 
Germany). All other materials were obtained as described in chapter 3 (section 
3.3.1) 
 
4.3.3 Immunochemical FOBT 
 
Fecal hemoglobin (Hb) levels were measured using RIDASCREEN
®
 
Hemoglobin, an enzyme-linked immunosorbent assay-based immunochemical 
FOBT, according to the manufacturer’s instructions. Absorbance (extinction at 
450 nm, reference wavelength of 620 nm) was measured on an Infinite M200 
microplate reader (Tecan, Austria). RIDA®SOFT Win Software was used to 
convert absorbance values into Hb concentrations (mg Hb /g stool). Fecal Hb 
levels were stratified into the following categories: a) Not detected, b) below 0.05 
mg Hb /g stool, c) 0.05 – 1 mg Hb /g stool, and d) higher than 1 mg Hb /g stool. 
 
4.3.4 GC/TOFMS metabonomic profiling of feces 
 
The sample preparation protocol previously developed in Chapter 3 was adopted 
with slight modifications. Briefly, fecal samples were freeze-dried and 80 mg of 
each lyophilized sample was ultrasonicated with 1 mL of ice-cold methanol:water 
(8:2) mixture in a bath ultrasonicator  at 4°C for 30 min, and vortex-mixed for 2 
55 
 
min. The samples were centrifuged subsequently at 18 000 g at 4°C for 20 min. A 
0.5 mL of the supernatant was obtained carefully. Additionally, quality control 
(QC) samples were prepared by combining equal volumes of supernatant from all 
CRC and healthy subjects. Each sample and QC supernatant was concentrated to 
complete dryness at 50°C under a gentle stream of nitrogen gas. Toluene (100 μL, 
kept anhydrous with sodium sulfate) was added to the dry residue, and dried fully 
again at 50°C under nitrogen gas. Methoximation of the dried metabolic extract 
was performed with 50 μL of MOX (20 mg/mL) at 60°C for 2 h. Following 
methoximation, 100 μL of MSTFA with 1% TMCS was introduced and the 
mixture was incubated at 60°C for 45 min to produce trimethylsilyl derivatives. 
Finally, 100 μL of the cooled products was subjected to GC/TOFMS analysis.  
 
4.3.5 GC/TOFMS metabonomic profiling of tissue 
 
Tissue samples were processed using the method described by Mal et al [49], with 
slight modifications. Fresh frozen tissue (approximately 20 mg) was ultra-
sonicated with 1 mL of ice-cold chloroform:methanol:water (2:5:2) mixture in a 
bath ultrasonicator at 4°C for 150 min. After vortex-mixing for 2 min, the samples 
were centrifuged at 18 000 g at 4°C for 6 min. A 0.65 mL of supernatant was 
extracted. Separately, QC samples were prepared by pooling equal volumes of 
supernatant from all tumor tissues and normal mucosae. Drying of the 
supernatants was accomplished as described above. Derivatization was performed 
using 100 μL of MSTFA with 1% TMCS followed by incubation at 70°C for 30 
min to produce trimethylsilyl derivatives. Finally, 50 μL of the cooled products 
was subjected to GC/TOFMS analysis.  
 
4.3.6 GC/TOFMS analysis  
 
GC/TOFMS analysis was carried out on a Pegasus GC/TOFMS (LecoCorp., St. 
Joseph, MI, USA) connected to an Agilent 7890 gas chromatograph. A DB-1 (30 
m × 250 µm i.d.) fused silica capillary column (Agilent J&W Scientific, Folsom, 
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CA), with 0.25 µm film thickness, was operated with open split interface. Helium 
was employed as the carrier gas at a constant flow rate of 1.5 mL/min. The 
injector split ratio was set at 1:20 and 1:6 for fecal and tissue metabonomic 
analysis, respectively. A volume of 1 μL was injected. The injector, transfer line 
and ion source temperatures were held at 220, 280 and 250°C, respectively. Oven 
temperature was programmed at 70°C for 0.2 min, escalated at 9°C/min to 270°C 
where it remained for 5 min, and further increased at 40°C/min to 310°C where it 
was maintained for 11 min. The MS functioned in the electron impact ionization 
mode at 70eV. Mass data were acquired in full scan mode from m/z 40 to 600 
with an acquisition rate of 20 spectra per second. Detector voltages were 1500V 
and 1650V for fecal and tissue metabonomic analysis, respectively. During the 
analysis, samples from CRC and healthy subjects were randomized, along with 
QC samples, to avoid analytical bias. To detect retention time shifts and facilitate 
kovats RI calculation, a standard alkane series mixture (C10-C40) was injected at 
regular intervals. RIs are relative retention times normalized to n-alkanes eluted 
adjacently [175].  
 
4.3.7 Data pre-processing  
 
All gas chromatograms were subjected to baseline correction, de-convolution, 
noise reduction, smoothing, library matching and area calculation using 
ChromaTOF software (version 4.41, LecoCorp.). Only peaks with S/N ratio larger 
than 150 were analyzed. The following peaks were further discarded: artifactual 
peaks that were similarly present in blank samples, poorly resolved peaks and 
peaks with poor shapes. 
 
Analytes were identified putatively by comparing both the MS spectra and RI 
with those in the NIST library. If RIs were unavailable in the NIST library, RIs 
from the Fiehn library, Golm Metabolome Database (http://csbdb.mpimp-
golm.mpg.de/gmd.html), Human Metabolome Database (http://www.hmdb.ca/) as 
well as reported literature [176] were utilized for comparison.  
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 4.3.8 Statistical analysis  
 
Normalization to a constant total chromatographic peak area was made prior to 
chemometric analyses. Irreproducible peaks defined by a coefficient of variation 
greater than 30% among QC samples were excluded from further analysis. 
Chemometric analysis was carried out using SIMCA-P version 12.0 software 
(Umetrics, Umeå, Sweden). The normalized data were mean-centered, unit 
variance scaled [180] and subjected to unsupervised PCA to observe for outliers 
and inherent grouping trends. Following PCA, supervised orthogonal partial least 
squares discriminant analysis (OPLS-DA) was applied to build discriminating 
models and elucidate differential analytes that contributed to the separation. For 
fecal metabonomic profiling, two separate models were constructed. The first 
model (model 1) was built using the fecal metabolic profiles of all subjects 
regardless of the levels of blood in their stool measured using the FOBT. In the 
second model (model 2), fecal samples containing blood beyond 1 mg Hb /g stool 





. The goodness-of-prediction parameter Q
2
 described the predictive 
ability of the model under 7-fold cross validation. A quantitative measure of the 
fraction of the variation in the dataset that could be explained by the model, also 




To examine the robustness of the OPLS-DA models in classifying CRC patients 
and healthy subjects, and distinguishing tumor tissue from normal mucosae, 
receiver operator characteristic (ROC) analysis was performed using the cross-
validated predicted Y-values. Corresponding areas under the curves (AUCs) were 
determined. To check for overfitting of data in the OPLS-DA models, response 
permutation testing was performed with 100 repetitions. The validation was 
carried out on the parent partial list squares discriminant analysis (PLS-DA) 
models that contained the same number of components. During this process, the 
sample classes (also known as y-variables) were shuffled randomly while the X-
data were left intact. The validity of the models was 1) inversely related to the 
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number of permuted classifications with Q
2
 values exceeding that on the actual 
classification of samples, and 2) indicated by a negative y-intercept of the 




Based on OPLS-DA, a list of differential analytes was identified using the 
following criteria: 1) variable importance for projection (VIP) score of more than 
1, 2) p value of less than 0.05 in the relevant t-tests and 3) absolute fold change of 
more than 2. Specifically, independent Welch’s t-test was used to compare 
analytes from fecal samples of CRC patients and healthy subjects, while paired 
samples t-test was used to compare analytes from tumor tissue and matched 




4.4.1 Immunochemical FOBT  
 
Fecal specimens from 3 CRC patients (CRC 4, CRC 6 and CRC 7, Supplementary 
Table 2) contained levels of blood equivalent to more than 1 mg Hb /g stool. The 
remaining patients had occult levels (less than 1 mg Hb/g stool) of blood in their 
stool except for CRC 3 whose FOBT yielded undetectable level of blood in stool 
(Supplementary Table 2). All 10 healthy subjects had undetectable or occult 
levels (less than 1 mg Hb/g stool) of blood in their stool. 
 
4.4.2 Fecal metabonomic profiling of CRC 
 
Figure 4.1A shows representative GC/TOFMS chromatograms of fecal specimens 
from a CRC patient and a healthy subject. After the exclusion of artifactual and 
irreproducible peaks, 398 well-resolved chromatographic peaks were detected. 
 
Separate models were constructed with and without the inclusion of patients with 
blood in stool beyond 1 mg Hb /g stool (models 1 and 2 respectively). The 
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performance statistics of the models were displayed in Table 4.2. For PCA models 
1 and 2, QC samples were clustered closely confirming the analytical validity of 
the method. This observation also confirmed that the clustering trends observed 
among the clinical observations (CRC patients versus healthy subjects) were due 
to biological rather than analytical variations. While partial discrimination 
between CRC patients and healthy subjects was observed in the PCA scores plots 
(see Figure 4.1B for an illustration of PCA model 2), both OPLS-DA models 
clearly distinguished the two groups. As shown in Table 4.2, OPLS-DA model 1 







Y=0.995 (1 predictive and 3 Y-orthogonal components) and the CRC patients 
and healthy subjects were classified accurately. On the other hand, OPLS-DA 







Y=0.996 (1 predictive and 3 Y-orthogonal components) (Table 4.2 and 
Figure 4.1C). The robustness of both OPLS-DA models 1 and 2 was demonstrated 
by an area of 1 under the ROC curves. Permutation testing further indicated that 
both models were valid, as exhibited by the negative y-intercept of the Q
2
 
regression lines (see Figure 4.1D for validation plot of OPLS-DA model 2). 
Nevertheless, it is important to note that OPLS-DA model 2 showed superior 
performance in terms of the number of permuted classifications with Q
2
 
exceeding that on the actual classification of samples as compared to OPLS-DA 
model 1 (2 versus 17, Table 4.2). A total of 9 differential analytes characterizing 
feces of CRC patients were uncovered based on OPLS-DA model 2, among 
which, 3 marker metabolites (fructose, linoleic acid and nicotinic acid) were 
putatively identified. All 3 identified metabolites were found at lower levels in the 
feces of CRC patients compared to healthy subjects (Table 4.3,Figure 4.3). 
 
4.4.3 Tissue metabonomic profiling of CRC  
 
Tumor tissue was clearly distinct from matched normal mucosae in the PCA 
scores plot (Figure 4.2A). Based on a validated OPLS-DA model (see Figure 4.2B 
for OPLS-DA plot and Figure 4.2C for ROC curve), 33 analytes that 
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differentiated the two groups were elucidated. The putative identities of 9 marker 
metabolites are presented in Table 4.3. Glucose, galactose, 3-phosphoglycerate, 
citric acid, inosine and creatinine were reduced while uracil, uridine and proline 




Table 4.2 Performance statistics of models 1 (all samples included) and 2 (fecal samples containing blood beyond 1 mg Hb /g stool 
excluded) 
Model No of 
samples 
included 






























  N (Q
2










1 CRC (n=11), 
Hl (n=10) 
0.212 0.139 Yes  0.373 0.995 0.215 1 17 Negative 
2 CRC (n=8), 
Hl (n=10) 
0.222 0.138 Yes  0.407 0.996 0.35 1 2 Negative 
 
a
 ROC analysis was performed using the cross-validated predicted Y-values. Corresponding AUCs were determined.  
b
 Permutation testing was performed on the parent PLS-DA models that contained the same number of components.  
c
 Number of permuted classifications with Q
2
 values exceeding that on the actual classification of samples  
d




































Figure 4.1 Fecal metabonomic profile of CRC patients and healthy subjects (A) Typical GC/TOFMS chromatograms of fecal 
specimens from a CRC patient and a healthy subject (Hl) (B) PCA model 2 differentiating CRC patients from healthy subjects (Hl)  
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Figure 4.2 Tissue metabonomic profile of tumor tissue and matched normal 
mucosae (A) PCA scores plot discriminating CRC tumor (T) from matched 
normal mucosae (M) (B) OPLS-DA scores plot discriminating CRC tumor (T) 
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Table 4.3 Fecal and tissue marker metabolites characterizing CRC 
Fecal marker metabolites differentiating CRC patients and healthy subjects  







   Nicotinic acid 0.25 91 1269.3 
   Fructose 
d
 0.26 / 0.27 84 / 82 1928.4 / 1937.8 
   Linoleic acid  0.31 92 2200.9 
 
a Fold change less than 1 indicates lower level in the feces of CRC patients compared to healthy subjects. 
b S.I.: Similarity Index (the percentage by which the mass spectrum of the analyte matches that in the library) 
c R.I.: Retention Index of the derivatized metabolites 
d Derivatized metabolites were present as multiple peaks in the chromatogram. 
 
Tissue marker metabolites differentiating CRC tumor and matched normal 
mucosae  







   Glucose 0.10  88 1940.0 
   Galactose 0.11 78 1894.9 
   3-phosphoglycerate 0.32 82 1824.2 
   Citric acid 0.35  85 1843.7 
   Uracil 4.06 90 1328.6 
   Uridine 3.21  60 2445.2 
   Inosine  0.46 82 2583.4 
   Proline 2.12  88 1155.9 
   Creatinine  0.49 87 1558.3 
 
a Fold change more than 1 indicates higher level in the tumor tissue compared with matched normal mucosae; 
fold change less than 1 indicates lower level in the tumor tissue compared with matched normal mucosae. 
b S.I.: Similarity Index (the percentage by which the mass spectrum of the analyte matches that in the library) 








Figure 4.3 Fold change of (A) nicotinic acid, (B) fructose (first peak), (C) fructose 
(second peak) and (D) linoleic acid relative to healthy subjects. Horizontal lines 
denote mean fold changes. Statistical significance (p<0.05) was established for all 





4.5.1 Fecal metabonomic profiling of CRC 
 
Developing an accurate and non-invasive screening tool has been a longstanding 
goal in the management of CRC. Herein, we evaluated for the first time the use of 
a GC/TOFMS-based fecal metabonomic approach in detecting CRC. 
 
Preliminary unsupervised PCA revealed a partial separation between the CRC 
patients and healthy subjects. The lack of complete separation between the two 
groups was not unexpected as the large inter-individual variability in terms of diet 
and gut microbial activity might possibly dilute the disease-related metabotype. 
To circumvent the systematic variation unrelated to pathological status and 
enhance class separation, a supervised OPLS-DA was employed [182, 183]. The 
resultant OPLS-DA models were robust in discriminating CRC patients from 
healthy subjects, as evident from the good Q
2
 and area under the ROC curves. Of 
note, CRC 3, a CRC patient who had undetectable blood in stool and might thus 
constitute a false-negative in conventional FOBT-based screening of CRC, was 
identified correctly in the OPLS-DA model (Supplementary Table 2). Our current 
findings illuminated the potential utility of GC/MS-based fecal metabonomics in 
accurately identifying CRC patients. Furthermore, it reiterated the role of 
metabonomics as a powerful systems biology tool in disease classification even 
with a small sample size of approximately 20 subjects [184-186]. Future studies 
may involve an external validation to further assess the predictive power of the 
model. Subjects with other cancer stages may also be included to ascertain the 
generalizability of the data. In addition, the effect of inter-individual dietary 
variation on the performance of the models may be explored so as to understand 
its influence on the disease metabotypes. Besides fecal metabonomic profiling, 
GC/MS-based analyses of fecal water may also be pursued to provide 




Gut bleeding is a clinically prevalent phenomenon associated with CRC and other 
gut diseases. One of the strengths of our study was the additional consideration of 
the influence of blood in stool on the fecal metabonomic analysis. This crucial 
concept was elucidated in chapter 3 demonstrating that gross bleeding (100 
mgHb/g feces) could potentially confound GC/MS-based fecal metabonomic 
studies while occult blood (1 mgHb/g feces) exerted a negligible effect on the 
fecal metabotype. Efforts were hence undertaken in the current study to construct 
and compare models with and without the inclusion of fecal samples containing 
blood beyond 1 mg Hb /g stool. Our data clearly verified the ability of fecal 
metabonomic analysis to reliably differentiate CRC patients from healthy subjects 
regardless of the presence of samples containing blood beyond 1 mg Hb /g stool. 
Nevertheless, further comparison of Q
2
 and the outcome of permutation testing 
between models 1 and 2 indicated that class separation was slightly obscured in 
the presence of fecal samples containing blood beyond 1 mg Hb /g stool. The 
latter finding reinforced the variation conferred by gross blood that could 
influence the fecal metabotype characterizing CRC. Importantly, to accurately 
glean mechanistic insights into CRC pathogenesis, marker metabolites were 
extracted from model 2 that was constructed independently of the presence of 
blood-related metabolites.   
 
4.5.2 Comparison of metabolic alterations at fecal and tissue levels 
 
Fecal markers can be broadly classified as exfoliated markers, secreted markers 
and leaked markers [28]. Exfoliated markers are derived from the shedding of 
colonocytes at the gut luminal surface; secreted markers are emanated from the 
epithelial cells lining the colonic lumen; and leaked markers are products of 
disturbed blood or lymph vessels following tumor growth. The use of model 2 
precluded the possibility of leaked markers being elucidated. To shed light on 
whether the unique fecal metabotype of CRC patients originated, specifically, 
from the exfoliated tumor cells, the metabolic aberrations at both fecal and tissue 
levels were examined. Corroborating with previous studies [47-51, 54] , our tissue 
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metabonomic analysis showed elevated amino acids (e.g. proline) and nucleic 
acid constituents (e.g. uracil, uridine) and decreased carbohydrates (e.g. glucose, 
galactose) in the tumor reflective of their higher proliferative state. Interestingly, 
this set of marker metabolites was not manifested at the downstream fecal level. 
The discordant set of tissue and fecal markers implied that the unique metabotype 
differentiating exfoliated tumor cells from normal colonocytes was possibly 
diluted in the feces by other contributors to the fecal profile, for instance the 
abundant shedding of normal colonocytes. In other words, the fecal metabotype of 
CRC patients were possibly defined more extensively by processes beyond the 
direct shedding of tumor cells. These complex processes remained to be 
determined, although possible postulations were CRC-related dysbiosis of gut 
microbiota that led to changes in microbial metabolism at the colonic lumen or 
the occurrence of distinct metabolic fluxes between tumor cells and the colonic 
lumen. Following recent reports that suggested that morphologically normal 
colonocytes in CRC patients harbor metabolic changes induced by adjacent tumor 
activity [53, 187], it may also be possible that the exfoliation of these cells 
contribute to the discrete fecal metabotype of CRC patients. Importantly, our 
intriguing finding opened new perspectives for future investigations into the 
origin of fecal metabolic markers and the multifactorial manifestation of CRC. 
 
4.5.3 Marker metabolites from fecal metabonomic profiling 
 
Based on the fecal marker metabolites unravelled by GC/MS-based 
metabonomics (model 2), further insights into the pathogenesis of CRC were 
yielded. While it might be premature to draw any conclusive association between 
the marker metabolites and their dysregulated pathways, the relevance of these 
markers was underscored by several prior studies.  
 
Extensive expression of GLUT-5, a fructose transporter, has been implicated in 
different types of cancers, including CRC [188], presumably in response to their 
heightened energy consumption. As both CRC and healthy subjects were not 
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restricted in terms of dietary carbohydrate intake, the reduced fecal level of 
fructose observed in CRC patients might correspond with the augmented uptake 
via GLUT-5 in the colon. Linoleic acid has been shown recently to inhibit the 
growth of CRC cells by mediating oxidative stress and mitochondrial dysfunction 
[189]. The finding of a decreased level of linoleic acid in the feces of CRC 
patients was potentially significant given its reported anti-oncogenic effect. 
Nevertheless, the mechanistic cause of the alteration remained unclear and may be 
of considerable interest in future studies. Finally, the diminished fecal level of 
nicotinic acid in CRC patients was in agreement with the previously established 
link between nicotinic acid deficiency and genomic instability [190]. The former 
raised the possibility of a suppression in the activity of nicotinic acid-producing 
bacteria such as bifidobacteria [191] in relation to CRC. While further studies are 
required to substantiate the functional significance of these metabolic aberrations, 
the current work provided novel insights into the role of both tumor cells and gut 
microbes in CRC tumorigenesis.  
 
Few previous reports on NMR-based fecal water analyses have identified 
metabolites such as acetate and butyrate as predominant markers differentiating 
CRC patients from healthy subjects [60, 61]. Notably, a different set of 
discriminating metabolites was uncovered in our study. The use of GC/MS hence 
contributed towards a broadened metabolic space for the discovery of fecal CRC 
markers.  
 
4.6 Chapter conclusion 
 
This proof-of-concept study highlighted the ability of a GC/MS-based fecal 
metabonomic approach to accurately identify patients with CRC. Despite the 
small sample size, the discovery of a unique metabotype characterizing CRC 
opened new avenues in the non-invasive detection of the disease. In addition, the 
elucidation of marker metabolites provided a mechanistic handle to delineate the 
biochemical underpinnings of the disease.  
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CHAPTER 5  Global fecal miRNA profiling in the identification 
of biomarkers for CRC screening among Asians 
 
5.1 Chapter overview 
 
Fecal miRNAs are increasingly explored as non-invasive markers of CRC. 
However, its holistic profile in Asian CRC patients remained elusive.  Here, the 
global human fecal miRNAs was assayed in Asian Chinese CRC patients and 
healthy subjects to elucidate novel fecal screening markers. Surgically resected 
tumor and matched normal mucosae were analyzed concurrently. Potential fecal 
miRNA markers were further confirmed using real time PCR in 17 CRC patients 
and 28 healthy subjects. Additionally, the influence of blood in stool on fecal 
miRNA levels was investigated unprecedentedly. Global miRNA profiling by 
microarray uncovered 17 fecal markers (p<0.05) differentially regulated in CRC. 
Fecal miR-223 and miR-451 represented robust markers in distinguishing CRC 
patients from healthy subjects, as evident from areas under the receiver operator 
characteristic curves of 0.939 and 0.971, respectively. Blood in stool affected 
fecal miR-451, miR-223 and miR-135b levels to varying extent and substantially 
impacted the interpretation of the clinical data. Interestingly, a discrete set of 
aberrant miRNAs occurred within the tumor, implying the presence of 
contributors beyond the exfoliation of tumor cells to the fecal miRNA profile. In 
summary, the utility of a global miRNA screening approach was successfully 
demonstrated in elucidating screening markers for CRC. Particularly, fecal miR-
223 and miR-451 hold promise in detecting CRC. 
 
5.2 Chapter introduction 
 
The preceding chapter discussed the use of a novel fecal metabonomic approach 
for the non-invasive detection of CRC. Similarly involved in the post-
transcriptional manifestations of CRC, fecal miRNAs represent potential 




While targeted profiling of selected fecal miRNAs have been explored [91, 94-
98], a holistic understanding of the global fecal miRNA profile in CRC patients is 
lacking, particularly in Asian patients. Furthermore, it remains to be determined if 
the global miRNA profile characterizing the feces of CRC patients reflects, or 
differs from, that within the colorectal tumor. In addition, gut bleeding is a 
clinically prevalent phenomenon of CRC. With the significant presence of 
miRNAs in the plasma, platelets and blood cells [192, 193], the potential impact 
of blood in stool on the fecal miRNA profile needs to be addressed.  
 
In this chapter, the global human fecal miRNA profiles were characterized in 
CRC patients and healthy subjects in Singapore to elucidate fecal markers for 
non-invasive detection of the disease. Independently, tissue miRNA profiles were 
also characterized and compared between cancer and matched normal mucosae 
resected from the same cohort of CRC patients. The effect of blood in stool on the 




5.3.1 Clinical population and samples 
 
CRC patients (n=17) and healthy subjects (n=28) were recruited at the outpatient 
specialist clinic from September 2011 – February 2013. All subjects were Han 
Chinese. The inclusion criterion for CRC patients was the diagnosis of sporadic 
CRC where surgical tumor resection has not been performed. Exclusion criterion 
was treatment with neoadjuvant chemotherapy or radiotherapy. Randomly 
selected healthy subjects were eligible for this study if a colonoscopy was 
performed within the past 5 months to confirm the absence of CRC or pre-
cancerous polyps. Exclusion criteria consisted of a history of CRC, a history of 
polyps within the last 3 years, the presence of inherited CRC syndromes (e.g. 
Lynch syndrome and familial adenomatous polyposis) and a family history of 
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hereditary CRC. In both groups, subjects did not have co-existent inflammatory 
bowel disease. This study was approved by the Institutional Review Board at the 
Singapore General Hospital (2010/042/B). All subjects provided informed 
consent prior to participation in the study. 
 
Fecal specimens and surgical colorectal tissue were collected, processed and 
stored as described in the previous chapter (section 4.3.1) 
 
5.3.2 Study design  
 
The study was implemented in 2 phases, namely phase I, biomarker screening; 
and phase II, biomarker confirmation. 
 
Phase I: biomarker screening 
 
Global profiling by microarray was performed on the fecal miRNAs extracted 
from 8 CRC (stage B – C) patients and 8 healthy subjects.  Concurrently, the 
platform was employed to compare the miRNA profiles of tumors (n=8) and 
paired normal mucosa (n=8) surgically excised from the same cohort of CRC 
patients. The differential miRNA expression patterns established from the fecal 
and tissue analyses were compared. 
 
Phase II: biomarker confirmation 
 
Selected fecal markers identified from phase I were confirmed subsequently by 
real time PCR. In phase IIa, the validation of the real time PCR approach to 
biomarker confirmation was performed using miR-135b, an established fecal 
marker for CRC [92, 95, 99].  This positive control was measured in a randomly 
chosen subset of 9 CRC patients and 19 healthy subjects. In phase IIb, the CRC-
related dysregulation of selected fecal miRNAs shown in phase I was confirmed 
on an extended cohort of CRC patients (n=17) and healthy subjects (n=28). The 
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robustness of these markers in discriminating CRC subjects from healthy subjects 






 miRNA isolation kit was purchased from Ambion (Austin, TX, 
USA). TaqMan® MicroRNA Assays, Taqman® microRNA RT kit and Taqman® 
Universal PCR Master Mix (2X) with no AmpErase UNG were products of 
Applied Biosystems (Foster City, CA, USA). QIAshredder was supplied by 
Qiagen (Hilden, Germany). Nuclease-free water was obtained from Invitrogen 
(Carlsbad, CA, USA).  
 
5.3.4 Total RNA extraction from feces and colorectal tissue 
 
Total RNA (including miRNAs) was isolated from approximately 50 mg of 
frozen feces (sampled from 3 different points of the fecal mass) or 20 mg of fresh 
frozen tissue using the mirVana
TM
 miRNA isolation kit. Briefly, the samples were 
homogenized by plastic pestle on ice in 600 μL of lysis buffer. The homogenate 
was passed through QIAshredder and centrifuged at 18 000 g for 2 min. 
Subsequent steps were performed in accordance with manufacturer’s instruction. 
Total RNA was then quantified using NanoDrop (Thermo, Wilmington, DE). 
Quality of the RNA was determined using Agilent bioanalyzer 2100 (Agilent 
Technologies). 
 
5.3.5 Microarray-based profiling (Phase I) 
 
Labeling and hydridization 
 
Microarray analysis was performed on Agilent Human miRNA 8x60K format v16 
(based on Sanger mirBase version 16.0) by Genomax Technologies, Singapore. 
Each array contained probes interrogating 1347 miRNAs. In the analysis, 
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miRNAs were labeled with Agilent miRNA Complete Labelling and Hyb Kit. 
Briefly, total RNA (100 ng) was phosphorylated with Calf Intestinal Alkaline 
Phosphatase before ligating with Cyanine3-pCp by T4 RNA Ligase. Labeled 
RNA was dried completely using vacuum centrifugation and reconstituted in 17 
μL of nuclease-free water and hybridized onto Agilent SurePrint G3 Human 
miRNA 8x60K microarray for 20 h at 55°C. After hybridization, the microarray 
slide was washed before scanning on the Agilent High Resolution Microarray 
Scanner (C-model). Raw signal data were extracted with Agilent Feature 




Data were pre-processed by logarithmic transformation and normalization to the 
90
th
 percentile. Only miRNAs present in at least 75% of samples in any 1 out of 2 
conditions, at raw signal intensities greater than 20, were analyzed. 
 
5.3.6 Selection of endogenous controls for real time PCR 
 
To the processed data from the fecal miRNA microarray, the following cutoffs 
were applied: 1) Small coefficient of variation of less than 25% across samples, 2) 
minimal fold change in the range of 0.8 – 1.25 between groups and 3) raw signal 
intensity greater than 100. Selection of appropriate endogenous control was done 
based on the commercial availability of Taqman® real time PCR assays and the 
absence of publications on their dysregulation in CRC. Finally, candidate 
endogenous controls were verified on real time PCR. GeNorm Algorithm was 
utilized to determine M value, a measure of expression stability [194]. Suitable 







5.3.7 Real time PCR-based profiling (phase II) 
 
Primers for reverse transcription and real time PCR were provided by TaqMan® 
MicroRNA Assays. The assays target miR-223 (assay ID: 002295), miR-451 
(assay ID: 001141), miR-135b (assay ID: 002261), miR-1202 (assay ID: 002858), 
miR-4257 (assay ID: 244369) and miR-3937 (assay ID: 462743). Total RNA (10 
ng) was reverse-transcribed using Taqman® microRNA RT kit, according to the 
manufacturer’s instructions. The PCR reaction mix contained 1.33 μL of cDNA, 1 
μL of primers, 10 μL of Taqman® Universal PCR Master Mix (2X) with no 
AmpErase UNG and 7.67 μL of nuclease-free water. The thermal cycling 
procedure encompassed pre-cycling heat activation at 95
o
C for 10 min, followed 
by 40 cycles of denaturation at 95°C for 15 s and annealing/extension at 60°C for 
60 s, in a CFX96 real time PCR system (Bio-Rad, Hercules, CA, USA). Reactions 
were performed in triplicates. Data were obtained as average Ct values, and 




5.3.8 Validation of real time PCR method for clinical profiling 
 
The amplification efficiencies of 3 target miRNAs (miR-223, miR-451 and miR-
135b) and 2 endogenous controls (miR-1202 and miR-4257) were examined. In 
the PCR reaction, primers were added to five different cDNA concentrations that 
were diluted serially. The generated Ct values were then plotted against the 
logarithm of cDNA concentrations. Amplification efficiency was derived from the 
slope of the log-linear portion of the calibration curve (efficiency = 10
-1/slope 
-1). 
No-template-control (NTC) and no-reverse-transcription (NRT) control were 
included.  
 
5.3.9 Investigation of effect of blood on the fecal miRNA levels 
 
Feces (Bristol stool scale type 4) was collected from a healthy subject who was 
tested negative by FOBT. Blood was spiked into feces to simulate different 
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clinical levels of blood in stool, namely 0.1 mg Hb /g stool (occult), 1 mg Hb /g 
stool (occult), 10 mg Hb /g stool and 100 mg Hb /g stool (gross).  Unspiked neat 
feces and blood served as controls. The experiment was performed in triplicates. 
RNA was isolated, reverse-transcribed and analyzed by real time PCR as detailed 
above. The normalized levels of miR-451, miR-223 and miR-135b were 
expressed as a ratio with respect to neat feces.  
 
5.3.10 Statistical analysis 
 
In microarray-based profiling, data pre-processing, filtering, univariate t-test and 
fold change analysis were performed using Genespring GX 11.5. Specifically, 
independent samples t-test was used to compare miRNAs from fecal samples of 
CRC patients and healthy subjects, while paired samples t-test was used to 
compare miRNAs from tumor tissue and matched normal mucosae. Multivariate 
PLS-DA was performed using SIMCA-P version 11.0 software (Umetrics, Umeå, 
Sweden). The validity of the PLS-DA model was ascertained by response 
permutation testing (100 repetitions). A list of differential miRNAs was identified 
based on VIP score of more than 1.2 in the PLS-DA coupled to p value of less 
than 0.05 in the t-tests. Heat map was generated using R (www.r-project.org). 
 
In real time PCR-based profiling, univariate analysis of relative levels of miRNAs 
was accomplished using the Relative Expression Software Tool (REST© 2009) 
(Qiagen, Hilden, Germany). Statistical significance was established at p<0.05. 
Multivariate logistic regression was performed using MedCalc version 12.7 
(Ostend, Belgium) using 
Δ
Ct values. To evaluate the robustness of the markers in 
classifying CRC patients and healthy individuals, ROC analyses was performed 
using the predicted Y-values from the regression model. Corresponding areas 





5.4.1 Patient characteristics 
 
A total of 45 participants including 17 CRC patients and 28 healthy subjects were 
recruited. The clinical characteristics of the participants are summarized in Table 
5.1. Noticeably, there was an uneven distribution of age (p<0.005, independent 
samples t-test) and sex (p<0.01, χ2 test) between the groups. These factors were 
hence adjusted in subsequent analysis. Among the CRC patients, the cancer stages 
ranged from Dukes’ stages B to D. Most tumors were moderately differentiated. 
 
Table 5.1 Clinical characteristics of CRC patients and healthy subjects 




Age, years   
   Mean 63.7 55.1 
   Range 46-80 36-79 
Sex, no. (%)   
   Male 13 (76.5) 10 (35.7) 
   Female 4 (23.5) 18 (64.3) 
Tumor site, no. (%)   
   Ascending colon 1 (5.9)  
   Sigmoid 4 (23.5)  
   Rectosigmoid 3 (17.6)  
   Rectum 9 (52.9)  
Dukes' stage no. (%)   
   B 8 (47.1)  
   C 7 (41.2)  
   D  2 (11.8)  
Tumor differentiation   
   Well differentiated 2 (11.8)  
   Moderately differentiated 14 (82.4)  
   Poorly differentiated 1 (5.9)  
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5.4.2 Elucidation of CRC-related miRNA profiles in feces and tissue (Phase I) 
 
In the microarray-based fecal miRNA expression analysis, 277 miRNAs were 
detected after the exclusion of low or non-uniform signals. Univariate tests 
uncovered 17 human fecal miRNA markers characterizing CRC (p<0.05), even 
though multivariate analysis did not differentiate CRC patients from healthy 
subjects. Figure 5.1A shows the heat map of these 17 fecal miRNAs and their 
associated fold changes relative to healthy subjects. Among the fecal miRNAs, 
miR-451 was the most prominently dysregulated. 
 
In the global tissue miRNA profiling, 287 miRNAs were detected. Tumor miRNA 
signature was clearly distinct from matched normal mucosa as shown in the PLS-







5.1B). Based on PLS-DA, 79 discriminating human miRNAs were uncovered 














Figure 5.1 Fecal and tissue miRNA markers characterizing CRC (A) Heat map 
showing 17 fecal miRNAs characterizing CRC (p<0.05) and their associated fold 
changes and directions of change (relative to healthy subjects) (B) PLS-DA scores 
plot differentiating tumor ( ) and matched normal mucosa ( ) (3 latent variables) 
(C) Heat map showing 79 tumor miRNAs characterizing CRC (p<0.05 and 

















Colored according to classes in M2
R2X[1] = 0.343738            R2X[2] = 0.213729            




















5.4.3 Candidate endogenous controls for real time PCR 
 
Besides uncovering differentially expressed miRNAs, an additional capability of 
microarray analysis was to identify consistently expressed fecal miRNAs that may 
serve as normalizers on subsequent real time PCR analysis, given the lack of 
reports on this subject. Seventeen stably expressed candidate human miRNAs 
with suitable signal intensity, coefficient of variation across samples and fold 
change between groups were shortlisted. Three miRNAs, miR-3937, miR-4257 
and miR-1202 were further selected based on the commercial availability of 
Taqman® real time PCR assays and the absence of published dysregulation in 
CRC. While miR-3937 showed a Ct value greater than 40, miR-1202 and miR-
4257 were detected and confirmed as suitable endogenous controls (M value < 
1.5) by real time PCR (Supplementary Figure 8). Fecal miR-1202 and miR-4257 
were hence employed as endogenous controls in subsequent real time PCR 
analyses. 
 
5.4.4 Validation of real time PCR method for clinical profiling  
 
Real time PCR provides a quantitative tool to support clinical profiling of specific 
miRNA markers identified from the earlier global profiling. Firstly, reaction 
efficiencies of all amplifications were determined to be between 84.8 and 105.7%, 
ascertaining minimal presence of PCR inhibitors. R
2
 coefficients of the calibration 
curves were above 0.9. Corresponding NRT controls verified negligible 
amplification of genomic DNA.  
 
MiR-135b, an established fecal marker for CRC [92, 95, 99], was used as a probe 
for validating the real time PCR approach to biomarker confirmation. Concurring 
with previous reports, fecal miR-135b was significantly up-regulated in CRC 
patients compared with healthy subjects. A mean fold change of 7.25 (p<0.05) 




5.4.5 Biomarker confirmation of miR-223 and miR-451 using real time PCR 
(Phase II) 
  
After validating the real time PCR approach, the CRC-related dysregulation of 
fecal miR-223 and miR-451 was confirmed in the complete cohort of 17 CRC 
patients and 28 healthy subjects. From a univariate analysis, the levels of fecal 
miR-223 and miR-451 were appreciably higher in CRC patients compared to 
healthy subjects (17.5 and 102 times higher for miR-223 (p<0.001) and miR-451 
(p<0.001), respectively, Figure 5.2). Logistic regression analyses with age, sex 
and fecal miRNAs as independent variables further revealed both fecal miR-223 
and miR-451 as potential screening markers (p<0.01). ROC analyses of the 
regression models showed AUCs of 0.939 (95% C.I.: 0.825 – 0.988) and 0.971 
(95% C.I.: 0.871 – 0.998), respectively (Figure 5.3). Based on ROC, fecal miR-
223 produced a sensitivity of 76.5% and specificity of 96.4%, while fecal miR-
451 yielded a sensitivity of 88.2% and specificity of 100.0%, in detecting CRC.  
 
 
Figure 5.2 Fold change of (A) miR-451 and (B) miR-223b relative to healthy 
subjects. Horizontal lines denote mean fold changes. Difference in levels of miR-













Figure 5.3 Receiver operator characteristic (ROC) analysis. ROC curves based on 
logistic regression models (age- and sex-adjusted) using (A) fecal miR-451 and 
(B) fecal miR-223 for discriminating CRC patients from healthy subjects  
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5.4.6 Effect of blood in stool on the fecal levels of miRNA 
 
MiR-451, miR-223 and miR-135b were present in human blood (Figure 5.4), with 
miR-451 and miR-223 being particularly abundant. Fecal miR-451 level was 
increased significantly (p<0.05) by the presence of blood at concentrations as low 
as 0.1 mg Hb /g stool. Fecal miR-223 level was unaffected by occult levels of 
blood at concentrations up to 1 mg Hb /g stool, but was progressively increased 
(p<0.05) at 10 mg Hb /g stool and beyond. On the contrary, fecal miR-135b 






Figure 5.4 Fold change (FC) in fecal miRNA levels relative to neat feces at 
different levels of blood in stool; FC>1 = higher levels compared to neat feces.  
Each measurement represents mean fold change ± standard error (n=3). Statistical 
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The search for a reliable, non-invasive fecal-based screening tool has been an 
ongoing endeavour in the management of CRC. In this study, we adopted a non-
targeted microarray-based approach as a mean to uncover novel fecal miRNA 
markers for detecting CRC in the Asian population. 
 
5.5.1 Unique fecal and tissue miRNA markers characterizing CRC 
 
The choice of a microarray designed based on the newer Sanger mirBase version 
16.0 conferred a broad analytical space for the comprehensive evaluation of fecal 
and tissue miRNAs. In fecal miRNA profiling, multivariate analysis did not aid in 
differentiating CRC patients from healthy subjects. The dilution of the disease-
related signature was not unexpected considering the plausible inter-individual 
variations in miRNA expression and the complex nature of the fecal biomatrice. 
Nevertheless, a univariate analysis unravelled 17 fecal miRNA markers, most of 
which were previously unreported in the context of CRC. On the other hand, 
higher expression of fecal miR-223 in CRC patients concurred with Caucasian 
data [92, 99]. Taken together, the findings from our global survey of miRNAs 
confirmed and complement existing knowledge on fecal miRNA markers of CRC.  
 
Similar to fecal miRNA profiling, both well-characterized and novel markers 
were elucidated from the global study of miRNAs in paired tumor and normal 
mucosa. Some differentially expressed miRNAs corresponded to oncomirs well-
defined in the pathogenesis of CRC. For example, miR-135b targets APC; the 
miR-17-92 cluster suppresses thrombospondin-1 (Tsp-1) and connective tissue 
growth factor (CTGF); and miR-145 inhibits Myc. APC. Tsp-1, CTGF and Myc  
are regulators along the Wnt signaling pathway known to be altered in CRC [33, 
80-88]. On the other hand, we also uncovered oncomirs not known to correlate 
with colorectal carcinogenesis: e.g. miR-99a and miR-100 that regulate mTOR in 
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various kinds of cancer [195-197], as well as newer miRNAs whose functions 
remain unclear [e.g. miR-3648].   
 
Interestingly, unlike a prior Caucasian report [99], these global miRNA 
aberrations within the tumor were not represented within the fecal miRNA 
profiles of CRC patients in our study. Osborn et al previously defined fecal 
markers from three sources: exfoliated markers, secreted markers and leaked 
markers [28]. Exfoliated markers stem from the shedding of colonocytes at the 
gut luminal surface; secreted markers are released by the epithelial cells lining the 
colonic lumen; and leaked markers originate from disturbed blood or lymph 
vessels as a result of tumor growth. Our microarray data hereby demonstrated that 
the unique fecal miRNA profile characterizing CRC in Asian patients was 
possibly associated with processes beyond the direct exfoliation of tumor cells in 
feces. These complex mechanisms remained unclear, although possible 
speculations were shedding of normal colonocytes that harbored altered miRNA 
profiles and the presence of leaked markers from blood in stool of CRC patients. 
In particular, the former postulation was supported by a recent report that alluded 
to changes in the miRNA milieu of normal mucosae given its interaction with the 
adjacent tumor [198]. Notably, our observation posed intriguing possibilities for 
future research into the origin of fecal miRNA markers and the multiple features 
of CRC. 
 
5.5.2 Fecal miR-223 and miR-451 confirmed as clinical markers of CRC 
 
Following phase I screening, biomarker confirmation (phase II) was performed on 
fecal miR-451, a novel and the most differentially expressed fecal marker 
identified in the microarray analysis. Fecal miR-223 was also included to confirm 
the observed upregulation that had mirrored Caucasian findings [92, 99]. From a 
univariate analysis, fecal miR-223 and miR-451 were noticeably higher in CRC 
patients compared with healthy subjects, corroborating with findings from phase 
I. Multivariate and ROC analyses further ratified the potential of fecal miR-223 
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and miR-451 as biomarkers for non-invasive detection of CRC. In future studies, 
non-CRC subjects with other diseases of the lower GIT, for instance 
inflammatory bowel disease, could be included to assess the specificity of these 
fecal markers for CRC. 
 
Current literature provides plausible targets for these miRNAs but divided opinion 
of their influence on oncological phenotypes. For miR-223, it was shown to target 
tumor suppressor erythrocyte membrane protein band 4.1-like 3 (EPB41L3) in 
gastric cancer, hence promoting invasion and metastasis [199]. Conversely, it 
repressed artemin, a tumor promoter, in esophageal carcinoma cells [200] and 
inhibited cell proliferation through regulation of Forkhead box O-1 (FOXO1) 
expression in HCT-116 colorectal cancer cell line [201]. Hence miR-223 
appeared to exert different influence depending on the cancer type. MiR-451 
regulated LKB1 signaling via direct targeting of calcium-binding protein 39 
(CAB39) in glioma cells [202, 203]. Its over-expression under high glucose 
condition permitted unrestrained mTOR activity and thereby promoted cell 
growth [202, 203]. Yet in esophageal cancer cell line, high levels of miR-451 
downregulated BCL-2, AKT and pAKT and increased apoptosis [204]. Similarly 
in acute lymphoblastic leukemia, miR-451 repressed Myc expression [205] while 
in DLD-1 colorectal cancer cell line, miR-451 reduced cell proliferation through 
modulation of macrophage migration inhibitory factor (MIF) expression [206]. 
Therefore, the exact pathological role of miR-451 will require further 
investigation and to be contextualized by appropriately considering the influence 
of their tumor-specific microenvironment. For now, their clinical value mainly 
rests on their differential expression in patients’ fecal material to serve as markers 







5.5.3 Interpretation of fecal miRNA changes considering the influence of blood in 
stool 
 
As gut bleeding is a clinically prevalent phenomenon of CRC, miRNAs of blood-
origin becomes a pertinent factor in the mechanistic interpretation of fecal 
miRNA alterations in CRC patients. To our knowledge, this is the first study that 
investigated the influence of blood in stool on fecal miRNA analysis. Our in vitro 
data established evidently that blood in stool affected the levels of three fecal 
markers, miR-451, miR-223 and miR-135b, to varying extent. Substantial 
amounts of miR-451 and miR-223 in the blood were consistent with their reported 
abundance in erythrocytes and myeloid cells, respectively [192]. These interesting 
findings impacted the interpretation of our clinical findings, as discussed below. 
 
Fecal miR-451 level was enriched significantly by the presence of both occult and 
gross levels of blood. Considering the propensity of gut bleeding in CRC, the data 
implied that the observed upregulation of fecal miR-451 in CRC patients may be 
attributed predominantly to blood in their stool. In another words, it pointed 
towards the potential role of blood-borne miRNAs as sensitive fecal occult blood 
markers, or leaked markers, of CRC. On this basis, future work may be extended 
to correlating fecal miR-451 with clinical fecal blood levels and comparing its 
detection sensitivity with existing FOBTs.   
 
Conversely, fecal miR-223 level was unaffected by occult levels of blood up to 1 
mg Hb/g stool. Based on this data, coupled with the likelihood of gross gut 
bleeding in some CRC patients, it was postulated that blood in stool accounted 
partially for the clinical upregulation of fecal miR-223. A separate analysis was 
conducted on samples documented to contain less than 1 mg Hb /g stool of blood 
(8 CRC patients and 10 healthy subjects). This pilot investigation reinforced the 
pronounced elevation of miR-223 in the feces of CRC patients notwithstanding 
the absence of blood beyond 1 mg Hb /g stool (Supplementary Text 1). Despite 
the small cohort size, it underscored the presence of alternative contributors to the 
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upregulation of fecal miR-223 in CRC. That said, as we did not observe 
dysregulation of miR-223 at the tumor level (Supplementary Table 3) in phase I, 
fecal miR-223 was unlikely a tumor-derived exfoliated marker. Collectively, 
these findings may stimulate future investigations into additional mechanisms for 
fecal miR-223 perturbation, for instance the shedding of adjacent normal 
colonocytes and other non-parenchymal cells.  
 
In contrast to fecal miR-451 and miR-223, fecal miR-135b level was impervious 
to varying amounts of blood, suggesting that blood in stool did not mediate the 
upregulation of fecal miR-135b in CRC patients. Rather, fecal miR-135b was 
likely a tumor-derived exfoliated marker, as supported by the parallel 
upregulation at the tumor level (Supplementary Table 3).  
 
In light of the varying degree of influence exerted by the presence of blood in 
stool on different fecal miRNA markers, we propose that similar experiments be 
incorporated in the future design of clinical fecal miRNA profiling studies. This 
approach may also be considered in advancing existing studies where miRNAs 
highly expressed in blood (e.g. miR-92a in erythrocytes [192]) have been reported 
as fecal markers of CRC [91, 92, 95, 99]. From these efforts, a more 
comprehensive insight into the alterations of potential fecal miRNA markers 
could be gleaned.  
 
5.6 Chapter conclusion 
 
Overall, this study highlighted the utility of a holistic miRNA screening approach 
in elucidating potential screening markers for CRC in the Asian population. Fecal 
miR-223 and miR-451 were further confirmed as biomarkers that may facilitate 
the non-invasive screening of CRC. The current work also illustrated the 
importance of delineating the influence of blood in stool and integrating these 
findings during the interpretation of clinical fecal miRNA data. Collectively, in 
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this and the preceding chapter, the exploration of novel fecal-based strategies 




CHAPTER 6  Investigating the role of nucleoside transporters in 
the resistance of CRC to 5FU therapy 
 
6.1 Chapter overview 
 
Resistance to 5FU poses a constant challenge to the management of CRC. 
Consistent efforts were called for to identify molecular markers that can 
effectively predict patients’ response. This study investigated the role of 
nucleoside transporters, particularly hENT1, in predicting clinical treatment 
outcome with 5FU-based therapy. Expression of a panel of nucleoside 
transporters in biopsied tumors from 7 CRC patients was measured by real time 
PCR prior to 5FU-based chemotherapy. To provide mechanistic support for the 
role of hENT1 in 5FU resistance, cell viability of Caco-2 cells was measured 
following incubation with 5FU and varying concentrations of a hENT1 inhibitor. 
Biopsied tumors were further subjected to global metabonomic profiling using 
GC/MS. High hENT1 levels in tumor tissue correlated with poor clinical response 
to 5FU. Corroborating with the clinical findings, chemical inhibition of hENT1 in 
Caco-2 cells resulted in an augmentation of 5FU efficacy. Metabonomic profiling 
revealed that the pre-treatment metabotype associated with non-responders to 







Y=0.996]. This is the first clinical report on 
the relationships of intratumoral expression of nucleoside transporters and tumor 
metabotype with response to 5FU among CRC patients. Coupled to the in vitro 
findings, our preliminary data suggested hENT1 to be a potential co-determinant 
of clinical response to 5FU.  
 
6.2 Chapter introduction 
 
Besides timely detection of CRC by the use of non-invasive screening strategies, 
the relatively high incidence and mortality rate of CRC have prompted efforts by 
clinician and scientists alike to enhance the therapeutic management of CRC. As 
91 
 
underscored in Chapter 1, 5FU has been the cornerstone drug for the treatment of 
CRC. Despite its widespread use, a large percentage of patients fail to respond to 
treatment with 5FU [102, 103]. This challenge has aroused considerable interest 
in identifying relevant predictive markers of response. 
 
While prior studies have focused primarily on TS, the main cellular target of 5FU, 
as well as metabolic enzymes such as TP and DPD, as predictors of resistance  
[113-125], the role of cellular transporters in 5FU response among CRC patients 
remained unclear. To fill this knowledge gap, this chapter aimed to investigate the 
correlation of tissue expression levels of hENT1, as well as other related 
nucleoside transporters (hENT2-4 and hCNT1-2), to clinical 5FU response. In 
particular, the role of hENT1 in 5FU response was substantiated using a CRC cell 
culture model. Additionally, as nucleoside transporters are known to mediate the 
cellular flux of numerous physiological nucleosides, our secondary aim was to 
examine if there exist unique tissue metabotypes associated with responders and 
non-responders to 5FU treatment.  
 




MirVana miRNA isolation kit and SYBR Green PCR master mix were purchased 
from Applied Biosystems (Foster City, CA, USA and Warrington, UK). DNA 
free kit was obtained from Ambion (Austin, TX, USA). QIAshredder was 
supplied by Qiagen (Hilden, Germany). SuperScript First-Strand Synthesis 
System was a product of Invitrogen (Carlsbad, CA, USA). All primers were 
synthesized by 1st BASE (Singapore). MSTFA with 1% TMCS was obtained 
from Thermo Fisher Scientific (Rockford, IL, USA). Spectroscopy grade 
methanol and chloroform were obtained from Tedia (Fairfield, OH, USA). All 
other reagents were obtained from Sigma Chemical Co. (St. Louis, MO, USA). 




6.3.2 Clinical population and tissue samples 
 
This study was approved by the Institutional Review Board at the Singapore 
General Hospital. Seven patients were recruited from June – October 1998 based 
on a diagnosis of resectable CRC and subsequently underwent 5FU chemotherapy 
after surgical resection. Microdissected tumor mucosae were snap-frozen in liquid 
nitrogen upon resection and stored at -80
o
C until analysis. Response to 5FU was 
defined as no documented recurrence within 5 years of treatment.  
 
6.3.3 Isolation of total RNA from colorectal tissue 
 
Fresh frozen colorectal tumor tissue (20 – 25 mg) was homogenized at -20oC with 
600 μL lysis buffer provided by mirVana miRNA isolation kit using a plastic 
pestle. The homogenate was passed through QIAshredder and centrifuged at 
18000 g for 2 min. Subsequent steps were performed in accordance with 
manufacturer’s instruction. After total RNA isolation, DNase treatment was 
performed twice (1 μL DNase per treatment) using AmbionTM DNA free kit. Total 
RNA was then quantified and the quality was ascertained (OD260/280 within 1.8-
2.1) using NanoDrop (Thermo, Wilmington, DE). 
 
6.3.4 Reverse transcription and real time PCR 
 
cDNA was synthesized from 1 g total RNA using the SuperScript First-Strand 
Synthesis System as per manufacturer’s protocol. Quantitative real time PCR was 
performed using CFX96 real time PCR system (Bio-Rad, Hercules, CA, USA) 
with SYBR Green master mix and primers (Supplementary Table 4). Triplicates 
were prepared with 4 μL of 10-fold prediluted cDNA. The thermal cycling 
condition comprised an initial denaturation at 95
o
C (10 min), followed by 40 
cycles at 95
o
C (15 s) and 60
o
C (60 s). Melt curves were generated to verify the 
purity of the amplicons. Data were obtained as average Ct values, and normalized 
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against the endogenous controls as 
Δ
Ct. Transcript differences between 5FU 
responders and non-responders were measured as fold changes using the 






Ct of responders – ΔCt of non-
responders).  
 
6.3.5 Validation of real time PCR method for clinical profiling 
 
The amplification efficiencies of 6 target genes (hENT1-4 and hCNT1-2) and 2 
endogenous controls (18S and GAPDH) (Supplementary Table 4) were examined. 
Each pair of primers was added to five different cDNA concentrations that were 
diluted serially. The generated Ct values were then plotted against the logarithm 
of cDNA concentrations. Amplification efficiency was derived from the slope of 
the log-linear portion of the calibration curve (efficiency = 10
-1/slope 
-1). Primer 
concentrations were optimized to provide a good Ct value with minimal non-
specific amplification. NTC and NRT control were included. Size of amplicons 
was verified by gel electrophoresis alongside a DNA ladder. 
 
6.3.6 Cell culture 
 
Human colon carcinoma cells, Caco-2, was obtained from American Type Culture 
Collection (Manassas, VA, USA). Cells were maintained in Dulbecco’s modified 
Eagle’s medium with 10% fetal bovine serum, 25 mM glutamine and HEPES 
buffer, at 37
o
C with 5% CO2 and 95% air.  
 
6.3.7 Detection of hENT1 transcript in Caco-2 cells 
 
RNA was isolated from Caco-2 cells using mirVana miRNA isolation kit as per 
manufacturer’s instructions. DNase treatment (once with 1 uL DNase), 
assessment of quantity and quality of total RNA, cDNA synthesis (from 43 ng of 
total RNA) and quantitative real time PCR were performed as described above. 
NTC and NRT were included. Expression of hENT1 was compared with a tumor 
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tissue sample using the comparative Ct method (endogenous controls GAPDH 
and B actin (Supplementary Table 4) were used).   
 
6.3.8 In vitro effect of hENT1 inhibition on the cytotoxicity of 5FU 
 
Caco-2 cells (passages 11-20) were seeded in 96-well plates. After 24 h, the 
medium was exchanged with fresh culture medium containing 20 μM of 5FU 
together with 0, 0.1, 0.5, 1, 5 and 10 μM of 6-[(4-Nitrobenzyl)thio]-9-β-D-
ribofuranosylpurine (NBMPR). In a separate negative control, 5FU was omitted. 
Final dimethylsulfoxide concentration was kept at 0.1% v/v. After 72 h of 
incubation, cell viability was determined by a 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay [207]. Absorbance was measured at 
570 nm on an Infinite M200 microplate reader (Tecan, Austria). Cell viability was 
expressed as a percentage of the untreated group. 
 
6.3.9 GC/MS metabonomic profiling of tumor tissue 
 
Fresh frozen colorectal tumor tissue (approximately 20 mg) was ultra-sonicated 
with 1 mL of chloroform-methanol-water 2:5:2 (v/v) mixture for 100 min, 
followed by centrifugation, collection of supernatant, drying, derivatization using 
MSTFA with 1% TMCS for 30 min and analysis on a two-dimensional GC/MS, 
as described previously by Mal et al [47]. Two QC samples (pooled extract) were 
interspersed among samples during the analysis. 
 
6.3.10 Statistical analysis 
 
Analysis of relative mRNA expression of nucleoside transporters was 
accomplished using the Relative Expression Software Tool (REST© 2009) 
(Qiagen). For metabonomic profiling, PCA, PLS-DA and model validation were 
performed using SIMCA-P v12.0 software (Umetrics, Umea, Sweden). Model 
was considered valid if Q
2





 values on 100 randomly permuted classifications. For the in vitro 
study, statistical differences among groups were analyzed using one-way analysis 
of variance and post-hoc Scheffe’s test (SPSS v17.0, Chicago, IL, USA). 




6.4.1 Development and validation of real time PCR method for clinical profiling 
 
A complete validation of the PCR primers and conditions (Supplementary Table 
4) was performed. R
2
 coefficients of the calibration plots were in the range of 
0.957-1.000 and the reaction efficiencies were between 91.2 and 117.5%. The size 
of the amplicons was verified by agarose gel electrophoresis. Corresponding NRT 
controls ascertained negligible amplification of genomic DNA.  
 
6.4.2 Clinical correlation between nucleoside transporter levels and response to 
5FU 
 
In total, tumors from 4 non-responders and 3 responders were profiled (see Table 
6.1 for clinicopathological data). On average, non-responders were found to 
express hENT1 at 40% higher level compared to responders (Figure 6.1A and 
Supplementary Figure 10). On the contrary, other transporters (hENT2, hENT3, 
hENT4, hCNT1 and hCNT2) were expressed at lower levels in non-responders.  
 
6.4.3 Confirmation of hENT1 expression in Caco-2 cells 
 
hENT1 cDNA was successfully amplified, demonstrating the presence of hENT1 
in Caco-2 cells. The absence of amplification in the NRT control demonstrated 
that RNA but not genomic DNA was amplified. The level of expression of 





6.4.4 In vitro effect of hENT1 inhibition on the cytotoxicity of 5FU 
 
Upon the addition of 0.5, 1, 5 and 10 μM of NBMPR, there was a statistically 
significant increase in cell kill mediated by 20 μM 5FU (Figure 6.1C). 
Interestingly, there was a plateau of effect between 0.5 and 5 μM of NBMPR. In 
the negative control, various concentrations of NBMPR, in the absence of 5FU, 
produced no confounding cytotoxicity (Supplementary Figure 11). 
  
6.4.5 GC/MS metabonomic profiling 
 
Responders were clearly distinct from non-responders in the PCA scores plot 
(Figure 6.2A). QC samples were clustered closely confirming the robustness of 







Y=0.996] (see Figure 6.2B for PLS-DA 
scores plot and Figure 6.2C for validation plot). A list of marker metabolites, 
including nucleobases such as uracil and thymine, was identified based on a VIP 
score of more than 1 (Supplementary Table 5). Uracil and thymine were found at 






Table 6.1 Clinicopathological data of responders and non-responders to 5FU therapy 










1 64 M Chinese C Right 
(Transverse colon) 
Poor FOLFOX Yes 
2 60 M Chinese C Right 
(Caecum) 
Moderate FOLFOX Yes 
3 49 F Chinese C Left 
(Sigmoid colon and 
rectum) 
Moderate 5FU continuous 
infusion 
Yes 
4 63 M Chinese C Left 
(Descending colon) 
Moderate 5FU, folinic acid Yes 
5 61 F Chinese C Left 
(Descending colon) 
Moderate 5FU, folinic acid No 
6 47 F Chinese C Right 
(Hepatic flexure) 
Moderate 5FU, folinic acid No 
7 58 M Chinese C Right 
(Caecum) 
Moderate 5FU, folinic acid No 










Figure 6.1 (A) Average fold change (FC) in transcript levels of nucleoside 
transporters; FC>1 = higher levels in non-responders compared to responders; 
FC<1 = lower levels in non-responders compared to responders (B) Relative 
expression of hENT1 in Caco-2 cells with respect to tumor tissue. Each 
measurement represents mean fold change ± standard deviation (n=3). (C) 
Viability of Caco-2 cells incubated with 20 μM 5FU in the presence of varying 
concentrations of NBMPR, a specific hENT1 inhibitor. Cell viability was 
expressed as a percentage against control group with neither 5FU nor NBMPR. 
Each measurement represents mean ± standard deviation (n=5). Three 
independent experiments were performed and a representative graph from one of 
the experiments is shown. Statistical significance (p<0.05) consistently 






























R2X[1] = 0.271915            R2X[2] = 0.241218            
Ellipse: Hotelling T2 (0.95) 
Non-responders
Responders








0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0
100 permutations 2 components     
R2
Q2






Figure 6.2 (A) PCA scores plot discriminating responders from non-responders 
(B) PLS-DA scores plot discriminating responders from non-responders (C) 





6.5.1 Clinical correlation between nucleoside transporter levels and response to 
5FU 
 
While numerous studies have provided insights into various determinants of 
resistance to 5FU in CRC [113-125], the contribution of nucleoside transporters 
may be an underappreciated question. As far as we know, this is the first study 
that profiled comprehensively the transcript levels of all known members of the 
hENT and hCNT families in CRC tissue and correlated the profile with response 
to 5FU. Notably, the level of hENT1 correlated inversely with response to 5FU in 
CRC, a finding that paralleled that in pancreatic cancer described by Tsujie M et 
al [129]. Despite the lack of statistical significance due to the small sample size, 
this finding illuminated the potential clinical role of nucleoside transporters in 
predicting the resistance of CRC to 5FU. 
 
6.5.2 In vitro effect of hENT1 inhibition on the cytotoxicity of 5FU 
 
To support the clinical observation, we assessed the causative role of hENT1 in 
determining response to 5FU by designing an in vitro experiment using a CRC 
cell culture model. The expression of hENT1 in Caco-2 cells was reflective of the 
endogenous amount in cancer patients, indicating its suitability for use as an 
experimental model. Cell viability (MTT) assay was performed following 
incubation of Caco-2 cells with 5FU and varying concentrations of NBMPR. 
NBMPR is a well-established, specific inhibitor for hENT1 which exerts no effect 
on other isoforms of hENT even at concentrations as high as 1 μM [208, 209]. 
Beyond 10 μM, there were suggestions of its effect on hENT2 [127, 210]. While 
it was not the aim of this experiment to explore beyond the effects of hENT1, we 




Our results clearly showed an augmentation of 5FU cytotoxicity in Caco-2 cells 
as a result of hENT1 inhibition by NBMPR. It concurred with our clinical data 
where low hENT1 levels correlated with more sensitive response to 5FU. Our in 
vitro finding substantiated the role of hENT1 in determining response to 5FU. 
Remarkably, there was a plateau of effect by NBMPR between concentration 
levels of 0.5 and 5 μM, suggestive of a saturation of hENT1 binding sites. A 
further potentiation of 5FU cytotoxicity was detected at 10 μM NBMPR, pointing 
towards a possible involvement of hENT2. This interesting observation opened 
possibilities for future research into the role of other nucleoside transporters. 
 
6.5.3 Responder and non-responder metabotypes 
 
Given the differential expression of naturally occurring nucleoside transporters in 
non-responders versus responders, coupled to the existing knowledge about the 
influence of various cellular enzymes on treatment response, we sought to 
understand if the basal metabolic signature may be predictive of treatment 
response. Our GC/MS data demonstrated unique pre-treatment metabotype related 
to the post-treatment response to 5FU. While the sample size was small, our 
preliminary findings underscored the potential role of CRC metabotyping in 
predicting clinical 5FU response. Notably, uracil and thymine, both of which are 
substrates of nucleoside transporters uncovered in emerging studies [211], were 
found at decreased levels in non-responders compared to responders. This 
observation underlined the possibility that the variation of basal hENT1 (as well 
as other nucleoside transporters) in the tumor tissue of 5FU-resistant patients can 
lead to a measurable difference in the tissue equilibrium of physiologic 
nucleobases in these patients. In addition, uracil and thymine are substrates of 
DPD while thymine is a product of TP. The earlier of the two enzymes being key 
regulator for 5FU metabolism, provided an additional hint that these nucleobases 
may serve as competing substrates and affect 5FU metabolism and activity. While 
it is difficult to draw definitive mechanistic association among these metabolites 
based on this study alone, such concordances offer opportunities for future 
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research into the metabolic perturbation related to drug resistance, using larger 
patient pool as well as in vitro experimental designs. 
 
6.6 Chapter conclusion 
 
This is the first clinical report on the relationship between intratumoral expression 
of nucleoside transporters and CRC patients’ response to 5FU. It also 
demonstrated for the first time unique metabotypes associated with the differential 
response to 5FU, including those of the nucleobase family. While the sample size 
was small, our pilot study illuminated new perspectives on the potential role of 






CHAPTER 7  Prevalence of KRAS, BRAF, PI3K and EGFR 
mutations among mCRC patients in Singapore 
 
7.1 Chapter overview 
 
Mutations in oncogenes along the EGFR signaling pathway have been implicated 
in the resistance to cetuximab in mCRC patients. However, the relative 
significance of these mutations based on their frequencies of occurrence in the 
Singapore population remains unclear. In the present study, the prevalence of 
KRAS, BRAF, PI3K and EGFR somatic mutations were determined among 
Singapore mCRC patients. DNA extracted from 45 pairs of surgically resected 
tumor and normal mucosa was subjected to direct sequencing or restriction 
fragment length polymorphism. Associations of the genetic mutations with 
various clinicopathological parameters were also explored. Mutation in either 
codons 12 or 13 of KRAS was confirmed as a prominent phenomenon in the 
Singapore mCRC population at prevalence comparable with that of Caucasian and 
Asian patients [33.3% (90% confidence interval, 21.8% - 44.9%)]. Conversely, 
the prevalence of BRAF (0%), PI3K (2.2%) and EGFR (0%) mutations were low. 
KRAS mutation was not associated with clinicopathological features such as 
patients’ age, sex and ethnicity and the tumor site, differentiation and mucinous 
status. Our study provided an informative context for the prevalence of potential 
molecular determinants of cetuximab resistance and set the stage for future 
Singapore-based studies concerning KRAS mutation status as a predictive marker 
of response.  
 
7.2 Chapter introduction  
 
While 5FU has been an indispensable component of traditional chemotherapy, 
cetuximab has assumed a vital role in the molecularly targeted treatment of 
mCRC patients. Like 5FU, resistance to cetuximab remains a relevant problem 
[106-108]. The identification of predictive markers of cetuximab response is 
104 
 
hence paramount in optimizing the treatment plan and enhancing patients’ 
survival.  
 
Recent studies have identified the association of cetuximab response with various 
mutations in the hotspot regions of key players along the EGFR signaling axis, as 
underlined in Chapter 1. However the relative significance of these genetic 
alterations based on their frequencies of occurrence in the Singapore population 
remains unclear. In this chapter, we aimed to comprehensively profile the 
frequencies of these mutations, namely KRAS, BRAF, PI3K and EGFR, in 
Singapore mCRC patients. The understanding of their prevalence can form the 
rationale for future studies on the utility of these mutations as predictors of 
cetuximab efficacy in the local population. In addition, the relationships between 
gene mutations and various clinicopathological characteristics were examined.  
 
7.3 Materials and methods 
 
7.3.1 Patients and tissue samples 
 
Metastatic CRC patients (Dukes’ Stage D) who underwent surgical tumor 
resection at the Singapore General Hospital between June 2010 and October 2012 
were included in this study. The inclusion criteria were: (i) histologically 
confirmed mCRC (ii) availability of sufficient amounts of tissue samples from the 
primary lesions for mutational analyses and (iii) availability of clinical 
information.  
 
Paired tumor and mucosal tissue were snap-frozen in liquid nitrogen, 
microdissected and stored at -80°C until analysis. Careful microdissection 
ensured that at least 90% of the tumor specimen comprised cancer cells. Matched 
normal mucosa samples were obtained at least 5 cm away from the edges of the 
tumor. Clinicopathological parameters including patients’ age, sex, ethnicity, 
tumor site, degree of histological differentiation and histologic type (mucinous or 
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non-mucinous) were studied. This study was approved by the Institutional Review 
Board at the Singapore General Hospital (2010/041/B).  
 
7.3.2 DNA extraction and PCR amplification 
 
Genomic DNA was extracted from tissue samples using QIAmp DNA Mini Kit 
(QIAGEN, Alameda, CA), according to the manufacturer’s protocol, and 
subjected to PCR to amplify KRAS exons 2 and 3, BRAF exons 11 and 15, PI3K 
exons 9 and 20 and EGFR exons 18, 19 and 21. The primers for PCR 
amplification are listed in Supplementary Table 6. 
 
Each PCR reaction contained approximately 300 ng of genomic DNA, 2 µL each 
of forward and reverse primers (10 µM), 20 µL of 5 M betaine, 5 µL of 2 mM 
dNTPs,  2 µL of 25 mM MgSO4 and 1 µL of KOD Hot Start DNA polymerase 
(Novagen, Japan) in a final volume of 50 µL. PCR cycling consisted of an initial 
denaturation at 94
o
C for 2 min, 35 cycles of denaturation at 94
o





C (Supplementary Table 6) for 30 s and elongation at 
68
o
C for 1 min, followed by a final extension at 68
o
C for 5 min. PCR products 
were then verified by 1.5% agarose gel electrophoresis and purified using 
Multiscreen
®
 PCRµ96 plate (Millipore, Ireland) prior to either direct gene 
sequencing or restriction fragment length polymorphism (RFLP) analyses of the 




Table 7.1 Mutational analysis methods for KRAS, BRAF, PI3K and EGFR genes 
Genes  Mutations Analysis Methods  
KRAS  Codon 12, 13 (Exon 2) 
Codon 61 (Exon 3) 
Gene  Sequencing  
BRAF  Codon 439, 459 (Exon 11) 
Codon 600, 601 (Exon 15) 
Gene Sequencing  
PI3K  Codon 542, 545 ( Exon 9) 
Codon 1043, 1047 (Exon 20) 
Gene Sequencing  
EGFR  G719S (Exon 18) 
L858R (Exon 21) 
Deletions (Exon 19) 
RFLP  
RFLP  
Gene Sequencing  
 
7.3.3 Gene sequencing 
 
Purified PCR products of KRAS exons 2 and 3, BRAF exons 11 and 15, PI3K 
exons 9 and 20 and EGFR exon 19 were sequenced with BigDye
®
 Terminator 
v3.1 Cycle Sequencing Kit as per the manufacturer’s instructions (Applied 
Biosystems, Foster City, CA, USA), purified and analyzed with a 3730 ABI 
capillary electrophoresis system (Applied Biosystems, Foster City). All 
sequencing reactions were performed using forward primers as stated in 
Supplementary Table 6, except PI3K exon 9 and exon 20 in which 5’-
GGGAAAAATATGACAAAGAAAGCTATA-3’ and 5’- 
TTGCTCCAAACTGACCAAAC-3’ were used respectively. DNA of normal 
mucosae from each patient was also amplified and sequenced alongside matched 
tumor DNA samples to rule out the occurrence of non-somatic mutations or 
polymorphisms.  
 
7.3.4 Restriction fragment length polymorphism (RFLP) analysis  
 
The presence of G719S (EGFR exon18) and L858R (EGFR exon 21) mutations 
were determined by RFLP analysis using restriction endonucleases DdeI and 
Sau96I [213] respectively. Purified PCR products (15uL) was digested with 10 
units of DdeI or Sau96I in a total volume of 20 µL at 37
o
C for 2 h and 
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electrophoresed through a 2.5% agarose gel. Upon digestion by restriction 
enzyme DdeI, wild type allele of EGFR exon 18 produced fragments at 27 and 
221 bp while mutant G719S allele yielded fragments at 27, 92 and 129 bp (Figure 
7.1A). SW48 cell line which harbors a heterozygous G719S mutation [214] was 
run alongside as a positive control.  Upon digestion by Sau96I, wild type allele of 
EGFR exon 21 yielded fragments at 55 and 176 bp while mutant L858R allele 
produced three fragments (55 bp, 86 bp and 90 bp) (Figure 7.1B). 
 
 
Figure 7.1 Expected gel electrophoresis image for (A) G719S and (B) L858R. 
DdeI and Sau96I were used to for G719S and L858R assays respectively. 
 
7.3.5 Statistical analysis 
 
The normal approximation method was used to construct 90% confidence interval 
(CI) in estimating the prevalence of genetic mutation. Associations of genetic 
mutations with clinicopathological parameters such as sex, ethnicity, tumor 
location, tumor differentiation and histologic type were explored using chi square 
or Fisher’s exact test (SPSS version 16, SPSS Inc, Chicago, IL, USA). 
Associations with age were evaluated using independent samples t-test. A 
Bonferroni correction for multiple testing was performed and statistical 






7.4.1 Patient characteristics 
 
A total of 45 mCRC patients were enrolled into the study. Supplementary Table 7 
summarized the clinicopathological characteristics of these recruited patients. 
Importantly, the studied population encompassed the major ethnic groups in 
Singapore (34 Chinese, 7 Malays and 4 Indians) and reflected the prevailing 
percentage distribution. Tumors were located predominantly in the sigmoid colon 
(46.7%), rectum (35.6%) and rectosigmoid region (13.3%) and were either 
moderately or poorly differentiated.    
 
7.4.2 KRAS mutational profiling 
 
Tumor KRAS mutation was identified in 15 patients, giving rise to a prevalence 
of 33.3% [90% CI, 21.8–44.9%]. Eleven mutations (73.3%) were found in codon 
12 while 4 mutations occurred in codon 13 (26.7%). The types of gene mutations 
detected in KRAS were tabulated in Table 7.2. The most frequently observed 
mutations was a GGT > GAT transition (G12D). In contrast, no mutations were 
detected in codon 61 of exon 3. All normal mucosae did not exhibit any mutation, 
ascertaining that all tumor mutations were somatic in nature. 
 
Table 7.2 Types of KRAS mutation detected in codons 12 and 13  
KRAS exon 2  
Wild type  
(amino acid)  
Point mutation  
(amino acid)  
No of mutation 
(%)  
Codon 12  GGT (G)  GAT (D)  7 (46.7)  
GGT (G)  GTT (V)  2 (13.3)  
GGT (G)  AGT (S)  1 (6.7)  
GGT (G)  GCT (A)  1 (6.7)  
Codon 13  GGC (G)  GAC (D)  4 (26.7)  
G: Glycine; D: Aspartic acid; V: Valine; S: Serine; A: Alanine  
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7.4.3 Correlation of KRAS gene mutations with clinicopathological 
characteristics 
 
There were no statistically significant differences in terms of age, sex, ethnicity, 
tumor site, tumor differentiation, and mucinous status between patients with and 
without KRAS mutations (p>0.008, Table 7.3). 
 
7.4.4 PI3K mutational profiling 
 
Of the 45 tumor samples, only 1 sample (2.2%) harbored a somatic mutation in 
the PI3K gene. The observed PI3K mutation was a heterozygous GAG > GCG 
transversion in codon 545 of exon 9 (E545A). It was found in a sigmoid colonic 
tumor displaying KRAS wild type, resected from a 30-year old female patient of 
Chinese ethnicity, the youngest patient in the cohort. 
 
7.4.5 BRAF and EGFR mutational profiling 
 
No mutation (0/45 samples) was detected in codons 439, 459, 600 and 601 of the 
BRAF gene. Similarly, all samples exhibited wild type status at codons 719 and 
858 of the EGFR gene. No deletional mutation was observed at EGFR exon 19.  
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(n=15) p value 
a
 
Age, years (± standard 
deviation) 
       Mean 59 56.6 (±10.2) 64.5 (±8.9) 0.013  
Sex, no. (%) 
       Male 29 16 (55.2)  13 (44.8)  0.028   
   Female 16 14 (87.5)  2 (12.5)  
 Ethnicity, no. (%) 
       Chinese 34 23 (67.6)  11 (32.4)  0.137 
   Malay 7 6 (85.7)  1 (14.3)  
    Indian 4 1 (25.0)  3 (75.0)  
 Tumor site, no. (%) 
       Sigmoid colon 21 18 (85.7)  3 (14.3)  0.030 
    Rectum 16 8 (50.0)  8 (50.0)  
Tumor differentiation, no. 
(%) 
       Moderate 39 29 (74.4)  10 (25.6)  0.012 
   Poor 6 1 (16.7)  5 (83.3)  
 
Histologic type, no. (%) 
       Mucinous 6 2 (33.3) 4 (66.7) 0.157 
   Non-mucinous 39 28 (71.8) 11 (28.2) 
 
     
a










Mutations in KRAS, BRAF and PI3K, the key regulatory proteins downstream of 
EGFR, play vital roles in colorectal carcinogenesis and have been closely linked 
with clinical resistance to cetuximab. To shed light on the importance of these 
genetic alterations in the Singapore mCRC context, their heretofore undefined 
local prevalence was characterized. 
 
7.5.1 Substantial occurrence of KRAS mutation 
 
In our study, the frequency of KRAS mutation (33.3%) resembled that in both 
Asian and Caucasian mCRC patients (20-50%) [147-153, 215-218]. For 
comparison, representative studies from Japan, China and Europe, in which direct 
sequencing of KRAS were conducted at similar codons, were summarized in 
Supplementary Table 8. The substantial occurrence of KRAS mutation provided a 
strong basis for future investigations on its utility as a predictor of cetuximab 
efficacy in the Singapore population. Notably, the observed mutations resided 
exclusively in codons 12 and 13 of exon 2, consistent with reports on its 
preponderance (90%) in exon 2 and infrequent occurrence at codon 61 of exon 3 
[219]. Importantly, codons 12 and 13 of exon 2 encode for two adjacent glycine 
residues situated in close proximity with the catalytic site of KRAS. Mutations of 
these codons abolished the intrinsic GTPase activity of the KRAS protein [219], 
leading to its constitutive activation and tumor growth. Within exon 2, the 
distribution of mutations between codons 12 and 13 was also congruent with prior 
reports in mCRC patients in which approximately 70% of the mutations occurred 
at codon 12 [147, 216, 217]. In addition, G12D (GGT > GAT) was shown to be 
the most predominant mutation type, in concordance with evidence from Chinese 
and Caucasian mCRC patients [148, 149, 216]. Taken together, codons 12 and 13 
represent potential hotspots for future Singapore-based studies investigating the 




7.5.2 Correlation of KRAS gene mutations with clinicopathological 
characteristics 
 
A majority of studies, stemming from both Caucasian and Asian CRC 
populations, found no relationship between prevalence of KRAS mutation 
determined by direct sequencing and various clinicopathological parameters 
including patients’ sex and age as well as tumor location, histologic type and 
differentiation [150, 153, 189, 220, 221]. Analogous findings were also evident 
among Asian mCRC patients [222]. Similarly, various clinicopathological 
parameters of Singapore mCRC patients investigated herein did not correlate 
significantly with the occurrence of KRAS mutation. While it was unclear if the 
lack of significant differences was a result of the small sample size, the current 
study provided valuable pilot data that would facilitate sample size calculations in 
future studies to ascertain the presence or absence of these relationships.  
 
7.5.3 Rare occurrence of BRAF, PI3K and EGFR mutations 
 
Encoding a downstream effector of KRAS in the MAPK pathway, BRAF is 
another gene that has been studied extensively in relation to CRC. BRAF V600E 
mutation has been documented to occur at a lower rate (0-10%) than KRAS 
mutations in both Caucasian and Asian mCRC patients [147, 217, 218, 223]. This 
observation was reflected in our study where no BRAF mutation was detected. On 
the other hand, the mutation rate of the gene for PI3K (2.2%), a regulator of 
PI3K/AKT signaling, appeared slightly lower than that in the Chinese and 
Caucasian mCRC population (approximately 10%) [149, 150, 217, 218]. The low 
observed frequency of PI3K gene mutation may possibly be explained by 
geographical influences or a difference in hotspot codons in Singapore patients.  
 
As EGFR gene mutation has been a crucial determinant of the sensitivity of 
NSCLC to EGFR tyrosine kinase inhibitors, it was of interest to determine its 
mutation rate in mCRC patients. In our study, however, neither missense (G719S 
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in exon 18 and L858R in exon 21) nor deletional mutations (in exon 19) was 
identified. Specifically, although EGFR G719S mutation, a NSCLC-relevant 
somatic mutation, was previously uncovered in SW48 colon cancer cell line 
[214], our data suggested this mutation was not clinically prevalent in the context 
of mCRC. The paucity of EGFR somatic mutations in Singapore mCRC patients 
resonated with findings in the Caucasian counterparts [212]. It highlighted the 
presence of a different set of genetic alterations that drives the progression of 
mCRC in contrast to NSCLC. The non-existence of EGFR mutations also cast a 
clearer light on the general lack of response towards anti-EGFR therapy. 
Nevertheless in the realm of cetuximab predictive therapeutics, our analyses 
demonstrated collectively that BRAF, PI3K and EGFR assume less significant 
roles, owing to their rarity of occurrence, compared to KRAS among Singapore 
mCRC patients. 
 
7.5.4 Limitations of the study 
 
One of the limitations of the study was the small sample size that led to large 
confidence interval for the prevalence estimate. Further studies with an expanded 
cohort of Singapore mCRC patients may help enhance the precision of the data. 
Additionally, in view of the heterogeneity of CRC tumors, multiple sampling 
from different sites within the same tumor may be valuable in future studies to 
validate the mutation statuses. Despite these limitations, the current study 
provided a preliminary but imperative insight into the relative importance of 
various genetic mutations in the local mCRC population. 
 
7.6 Chapter conclusion 
 
In this chapter, the frequencies of KRAS, BRAF, PI3K and EGFR mutations were 
determined in the Singapore mCRC population where KRAS mutation was 
confirmed as a prominent phenomenon. Our study thereby laid the foundation for 
future predictive biomarker studies related to cetuximab response in the local 
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mCRC population. Both this and the previous chapter represented important steps 





CHAPTER 8  Conclusions and future perspectives  
 
CRC is one of the most frequently occurring malignancies and leading causes of 
cancer-related death worldwide. Numerous challenges exist pertaining to the 
detection and treatment of this prevalent disease. In particular, current screening 
modalities such as FOBT and colonoscopy either lack sensitivity and specificity 
or are too invasive and costly. Additionally, resistance to fundamental therapies 
such as 5FU and cetuximab calls for effective strategies for a priori prediction of 
clinical response. To address these challenges, our overall goal was to evaluate 
new approaches and identify molecular markers that can facilitate the non-
invasive fecal-based screening of CRC and enhance the clinical prediction of 
treatment response.  
 
In Chapter 3, a novel GC/TOFMS method was successfully developed and 
validated for the metabotyping of human feces. The influence of a clinically 
prevalent phenomenon of blood in stool on the fecal metabotype was also 
evaluated for the first time. The developed method and the information gleaned 
from Chapter 3 laid the foundation for the characterization of the fecal 
metabonomic profiles of CRC patients and healthy subjects in Chapter 4. The 
work in Chapter 4 established proof-of-principle that GC/MS-guided fecal 
metabonomics could distinguish CRC patients from healthy subjects and be a 
viable approach for the non-invasive detection of CRC. In addition, the 
elucidation of fecal marker metabolites, fructose, linoleic acid and nicotinic acid 
that were downregulated in CRC, offered intriguing perspectives on the 
biochemical underpinnings of the disease.  
 
Following fecal metabonomic analysis, the role of post-transcriptional 
perturbations as fecal markers was further explored in Chapter 5. Therein, we 
demonstrated the potential utility of global miRNA profiling in uncovering fecal 
screening markers for CRC. Fecal miR-223 and miR-451 were further confirmed 
as effective biomarkers, with substantially higher levels found in Asian CRC 
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patients compared to healthy subjects. Notably, the influence of blood in stool 
was delineated and integrated unprecedentedly in the interpretation of clinical 
fecal miRNA data. Taken together, concerted efforts from Chapters 3, 4 and 5 
have contributed new fecal-based strategies for the non-invasive population 
screening of CRC. 
 
Studies related to CRC screening in Chapters 4 and 5 carried several limitations 
and offer opportunities for future research. Firstly, a majority of the recruited 
patients possessed distal tumors, consistent with the anatomical distribution of the 
disease in Singapore [224]. Nevertheless, as fecal-based identification of proximal 
cancers is known to be more challenging [18, 30, 225], it will be interesting to 
determine if fecal miRNA and metabonomic analyses are amenable for the 
detection of these lesions. Secondly, the value of a screening tool is enhanced if it 
exhibits the ability to detect earlier lesions of the disease. It may also prove 
valuable in CRC prevention if it can additionally identify pre-cancerous lesions to 
allow their removal before a cancer develops. Future clinical studies can therefore 
be extended to profile patients with stage A cancers and premalignant polyps. 
Thirdly, to further substantiate the association of CRC with the fecal miRNA and 
metabolic perturbations, follow-up fecal samples can be collected and assessed 
for restoration of the healthy phenotype few months after surgical tumor 
resection. Fourthly, a major drawback of the current study was the small sample 
size. A larger patient cohort will confer greater statistical power and elucidate 
more markers in future global profiling studies. Additionally, as CRC is a 
heterogenous disease, the combined analysis of fecal DNA, miRNA and 
metabonomic analyses may be a valuable screening approach that can be 
evaluated in future clinical trials. Lastly, it will be of considerable interest to 
assess the performance of the test among average-risk, asymptomatic subjects in a 
screening setting. With these efforts, a more effective population screening test 




In the therapeutic setting, nucleoside transporters showed promise as predictive 
markers of clinical response to the widely used therapy, 5FU. Particularly, high 
transcript level of hENT1 correlated with poor response to 5FU in CRC patients 
in Chapter 6. Corroborating with the clinical findings, in vitro chemical inhibition 
of hENT1 potentiated 5FU-mediated cytotoxicity. Additionally, metabonomic 
profiling revealed unique pre-treatment metabotypes associated with the 
differential response to 5FU, including those of the nucleobase family. Despite 
the small sample size, our pilot study illuminated the potential role of nucleoside 
transporters in determining clinical treatment outcome with 5FU therapy. 
 
Importantly, the clinical data from Chapter 6 offer several perspectives for further 
research. For instance, the population distribution of the levels of nucleoside 
transporters should be characterized to appraise their capacity for patient 
stratification, following which their predictive value can be validated in 
prospective studies, in combination with previously studied markers such as TS. 
Chapter 6 has also shed promising light on the potential application of tissue 
metabonomics in predicting clinical 5FU response, which merits further 
investigation in large-scale studies. In recent years, the clinical utility of serum 
metabonomic profiling in predicting treatment outcomes have been demonstrated 
in various disease settings [226, 227]. Unlike invasive tissue sampling, the ease of 
serum collection may enable serial snapshots of the cancer metabonome. Serum 
metabonomics may hence be applied in future studies to monitor the metabolic 
perturbations associated with acquired drug resistance during the course of 5FU 
therapy.  Mechanistically, our study also opens avenues for further investigations. 
Following chemical inhibition of hENT1, biological alterations of the levels of 
hENT1 and other nucleoside transporters may be attempted using shRNA and 
viral transfection to further ascertain their causal relationship with 5FU resistance. 
The transport kinetics of 5FU and their metabolites, as well as changes in 
endogenous metabolites, can also be characterized in these models to delineate the 
mechanisms of resistance mediated by the nucleoside transporters. These studies 
118 
 
may offer additional insights into the underlying determinants of 5FU resistance 
in CRC patients. 
 
In Chapter 7, the frequencies of key mutations along the EGFR pathway were 
comprehensively profiled.  While BRAF, PI3K and EGFR mutations were rare, 
KRAS mutation was revealed as a prevalent feature present in a-third of 
Singapore mCRC patients. The study has set the stage for future local studies on 
the role of KRAS as a predictor of response to the targeted therapy, cetuximab. 
Collectively, the findings from chapters 6 and 7 represented modest but important 
advances in the field of personalized CRC therapy. 
  
In conclusion, this thesis provided a deeper insight into promising molecular 
biomarkers and approaches for the non-invasive detection of CRC and prediction 
of treatment response, and contributed significantly to the continuous endeavor 






















1. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: 
IARC CancerBase No. 10 [http://globocan.iarc.fr] 
2. Moghimi-Dehkordi B, Safaee A: An overview of colorectal cancer 
survival rates and prognosis in Asia. World J Gastrointest Oncol 2012, 
4(4):71-75. 
3. Sung JJ, Lau JY, Goh KL, Leung WK: Increasing incidence of 
colorectal cancer in Asia: implications for screening. Lancet Oncol 
2005, 6(11):871-876. 
4. Wong MT, Eu KW: Rise of colorectal cancer in Singapore: an 
epidemiological review. ANZ J Surg 2007, 77(6):446-449. 
5. Singapore Cancer Registry Interim Report: Trends in Cancer 
Incidence in Singapore 2007-2011. In. Singapore: National Registry of 
Diseases Office (NRDO), Health Promotion Board; 2011. 
6. World Health Organization Mortality Database 
[http://apps.who.int/healthinfo/statistics/mortality/whodpms/] 
7. American Cancer Society Cancer Facts and Figures 
[http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/do
cuments/document/acspc-031941.pdf] 
8. National Cancer Institute Surveillance Epidemiology and End Results 
(SEER) Stat Fact Sheets: Colon and Rectum 
[http://seer.cancer.gov/statfacts/html/colorect.html] 
9. Noninvasive Testing for Colorectal Cancer: A Review: Stool Tests 
[http://www.medscape.com/viewarticle/506175_2] 
10. Mandel JS, Church TR, Ederer F, Bond JH: Colorectal cancer mortality: 
effectiveness of biennial screening for fecal occult blood. J Natl Cancer 
Inst 1999, 91(5):434-437. 
11. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, 
Ederer F: Reducing mortality from colorectal cancer by screening for 
fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J 
Med 1993, 328(19):1365-1371. 
12. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, 
Balfour TW, James PD, Mangham CM: Randomised controlled trial of 
faecal-occult-blood screening for colorectal cancer. Lancet 1996, 
348(9040):1472-1477. 
13. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L: Cochrane 
systematic review of colorectal cancer screening using the fecal occult 
blood test (hemoccult): an update. Am J Gastroenterol 2008, 
103(6):1541-1549. 
14. Young GP, Macrae FA, St John DJB: Clinical methods for early 
detection: Basis, use and evaluation. In: Prevention and Early Detection 
of Colorectal Cancer. edn. Edited by Young GP, Rozen P, Levin B. 
London: Saunders; 1996: 241-270. 
120 
 
15. Ransohoff DF, Sandler RS: Clinical practice. Screening for colorectal 
cancer. N Engl J Med 2002, 346(1):40-44. 
16. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME: Fecal 
DNA versus fecal occult blood for colorectal-cancer screening in an 
average-risk population. N Engl J Med 2004, 351(26):2704-2714. 
17. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, Han DS: 
Comparison of guaiac-based and quantitative immunochemical fecal 
occult blood testing in a population at average risk undergoing 
colorectal cancer screening. Am J Gastroenterol 2010, 105(9):2017-
2025. 
18. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y: A 
comparison of the immunochemical fecal occult blood test and total 
colonoscopy in the asymptomatic population. Gastroenterology 2005, 
129(2):422-428. 
19. Ayling RM: New faecal tests in gastroenterology. Ann Clin Biochem 
2012, 49(Pt 1):44-54. 
20. Iskandar HN, Ciorba MA: Biomarkers in inflammatory bowel disease: 
current practices and recent advances. Transl Res 2012, 159(4):313-
325. 
21. Judd TA, Day AS, Lemberg DA, Turner D, Leach ST: Update of fecal 
markers of inflammation in inflammatory bowel disease. J 
Gastroenterol Hepatol 2011, 26(10):1493-1499. 
22. Miller S, Steele S: Novel molecular screening approaches in colorectal 
cancer. J Surg Oncol 2012, 105(5):459-467. 
23. Zheng X, Xie G, Zhao A, Zhao L, Yao C, Chiu NH, Zhou Z, Bao Y, Jia 
W, Nicholson JK: The footprints of gut microbial-mammalian co-
metabolism. J Proteome Res 2011, 10(12):5512-5522. 
24. Tagore KS, Lawson MJ, Yucaitis JA, Gage R, Orr T, Shuber AP, Ross 
ME: Sensitivity and specificity of a stool DNA multitarget assay panel 
for the detection of advanced colorectal neoplasia. Clin Colorectal 
Cancer 2003, 3(1):47-53. 
25. Whitney D, Skoletsky J, Moore K, Boynton K, Kann L, Brand R, Syngal 
S, Lawson M, Shuber A: Enhanced retrieval of DNA from human fecal 
samples results in improved performance of colorectal cancer 
screening test. J Mol Diagn 2004, 6(4):386-395. 
26. Matsushita H, Matsumura Y, Moriya Y, Akasu T, Fujita S, Yamamoto S, 
Onouchi S, Saito N, Sugito M, Ito M et al: A new method for isolating 
colonocytes from naturally evacuated feces and its clinical application 
to colorectal cancer diagnosis. Gastroenterology 2005, 129(6):1918-
1927. 
27. Ahlquist DA, Sargent DJ, Loprinzi CL, Levin TR, Rex DK, Ahnen DJ, 
Knigge K, Lance MP, Burgart LJ, Hamilton SR et al: Stool DNA and 
occult blood testing for screen detection of colorectal neoplasia. Ann 
Intern Med 2008, 149(7):441-450, W481. 
28. Osborn NK, Ahlquist DA: Stool screening for colorectal cancer: 
molecular approaches. Gastroenterology 2005, 128(1):192-206. 
121 
 
29. Itzkowitz SH, Jandorf L, Brand R, Rabeneck L, Schroy PC, 3rd, Sontag S, 
Johnson D, Skoletsky J, Durkee K, Markowitz S et al: Improved fecal 
DNA test for colorectal cancer screening. Clin Gastroenterol Hepatol 
2007, 5(1):111-117. 
30. Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L, 
Schroy PC, 3rd, Sontag S, Johnson D, Markowitz S et al: A simplified, 
noninvasive stool DNA test for colorectal cancer detection. Am J 
Gastroenterol 2008, 103(11):2862-2870. 
31. Ahlquist DA, Zou H, Domanico M, Mahoney DW, Yab TC, Taylor WR, 
Butz ML, Thibodeau SN, Rabeneck L, Paszat LF et al: Next-generation 
stool DNA test accurately detects colorectal cancer and large 
adenomas. Gastroenterology 2012, 142(2):248-256; quiz e225-246. 
32. Pawa N, Arulampalam T, Norton JD: Screening for colorectal cancer: 
established and emerging modalities. Nat Rev Gastroenterol Hepatol 
2011, 8(12):711-722. 
33. Slaby O, Svoboda M, Michalek J, Vyzula R: MicroRNAs in colorectal 
cancer: translation of molecular biology into clinical application. Mol 
Cancer 2009, 8:102. 
34. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois 
RN: Up-regulation of cyclooxygenase 2 gene expression in human 
colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 
107(4):1183-1188. 
35. Kawasaki T, Nosho K, Ohnishi M, Suemoto Y, Glickman JN, Chan AT, 
Kirkner GJ, Mino-Kenudson M, Fuchs CS, Ogino S: Cyclooxygenase-2 
overexpression is common in serrated and non-serrated colorectal 
adenoma, but uncommon in hyperplastic polyp and sessile serrated 
polyp/adenoma. BMC Cancer 2008, 8:33. 
36. Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, Miura N, 
Sugimura H, Kajimura M, Hishida A: Fecal Cyclooxygenase 2 Plus 
Matrix Metalloproteinase 7 mRNA Assays as a Marker for Colorectal 
Cancer Screening. Cancer Epidem Biomar 2009, 18(6):1888-1893. 
37. Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, Kozu 
T, Baba H, Matsumura Y: Detection of colorectal cancer cells from 
feces using quantitative real-time RT-PCR for colorectal cancer 
diagnosis. Cancer Sci 2008, 99(10):1977-1983. 
38. Yamao T, Matsumura Y, Shimada Y, Moriya Y, Sugihara K, Akasu T, 
Fujita S, Kakizoe T: Abnormal expression of CD44 variants in the 
exfoliated cells in the feces of patients with colorectal cancer. 
Gastroenterology 1998, 114(6):1196-1205. 
39. Davidson LA, Jiang YH, Lupton JR, Chapkin RS: Noninvasive detection 
of putative biomarkers for colon cancer using fecal messenger RNA. 
Cancer Epidemiol Biomarkers Prev 1995, 4(6):643-647. 
40. Imperiale TF: Noninvasive screening tests for colorectal cancer. Dig 
Dis 2012, 30 Suppl 2:16-26. 
41. Kroemer G, Pouyssegur J: Tumor cell metabolism: cancer's Achilles' 
heel. Cancer Cell 2008, 13(6):472-482. 
122 
 
42. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. 
Cell 2011, 144(5):646-674. 
43. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the 
Warburg effect: the metabolic requirements of cell proliferation. 
Science 2009, 324(5930):1029-1033. 
44. Benjamin DI, Cravatt BF, Nomura DK: Global profiling strategies for 
mapping dysregulated metabolic pathways in cancer. Cell Metab 2012, 
16(5):565-577. 
45. Nicholson JK, Lindon JC, Holmes E: 'Metabonomics': understanding 
the metabolic responses of living systems to pathophysiological stimuli 
via multivariate statistical analysis of biological NMR spectroscopic 
data. Xenobiotica 1999, 29(11):1181-1189. 
46. Lindon JC, Holmes E, Nicholson JK: So what's the deal with 
metabonomics? Anal Chem 2003, 75(17):384A-391A. 
47. Mal M, Koh PK, Cheah PY, Chan EC: Metabotyping of human 
colorectal cancer using two-dimensional gas chromatography mass 
spectrometry. Anal Bioanal Chem 2012, 403(2):483-493. 
48. Ong ES, Zou L, Li S, Cheah PY, Eu KW, Ong CN: Metabolic profiling 
in colorectal cancer reveals signature metabolic shifts during 
tumorigenesis. Mol Cell Proteomics 2010. 
49. Mal M, Koh PK, Cheah PY, Chan ECY: Development and validation of 
a gas chromatography/mass spectrometry method for the metabolic 
profiling of human colon tissue. Rapid Commun Mass Sp 2009, 
23(4):487-494. 
50. Denkert C, Budczies J, Weichert W, Wohlgemuth G, Scholz M, Kind T, 
Niesporek S, Noske A, Buckendahl A, Dietel M et al: Metabolite 
profiling of human colon carcinoma--deregulation of TCA cycle and 
amino acid turnover. Mol Cancer 2008, 7:72. 
51. Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, Cavill R, 
Nicholson JK, Keun HC: Metabolic profiling of human colorectal 
cancer using high-resolution magic angle spinning nuclear magnetic 
resonance (HR-MAS NMR) spectroscopy and gas chromatography 
mass spectrometry (GC/MS). J Proteome Res 2009, 8(1):352-361. 
52. Mirnezami R, Jimenez B, Li JV, Kinross JM, Veselkov K, Goldin RD, 
Holmes E, Nicholson JK, Darzi A: Rapid Diagnosis and Staging of 
Colorectal Cancer via High-Resolution Magic Angle Spinning Nuclear 
Magnetic Resonance (HR-MAS NMR) Spectroscopy of Intact Tissue 
Biopsies. Ann Surg 2013. 
53. Jimenez B, Mirnezami R, Kinross J, Cloarec O, Keun HC, Holmes E, 
Goldin RD, Ziprin P, Darzi A, Nicholson JK: 1H HR-MAS NMR 
spectroscopy of tumor-induced local metabolic "field-effects" enables 
colorectal cancer staging and prognostication. J Proteome Res 2013, 
12(2):959-968. 
54. Piotto MM, F. M.; Dillmann, B.; Imperiale, A.; Neuville, A.; Brigand, C. ; 
Bellocq, J. P.; Elbayed, K.; Namer, I. J.  : Metabolic characterization of 
primary human colorectal cancers using high resolution magic angle 
123 
 
spinning 1H magnetic resonance spectroscopy. Metabolomics 2009, 
5(3): 292-301  
55. Lean CL, Newland RC, Ende DA, Bokey EL, Smith IC, Mountford CE: 
Assessment of human colorectal biopsies by 1H MRS: correlation 
with histopathology. Magn Reson Med 1993, 30(5):525-533. 
56. Warburg O: On the origin of cancer cells. Science 1956, 123(3191):309-
314. 
57. Chen W, Liu F, Ling Z, Tong X, Xiang C: Human intestinal lumen and 
mucosa-associated microbiota in patients with colorectal cancer. PLoS 
One 2012, 7(6):e39743. 
58. Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS: 
Real-time polymerase chain reaction quantification of specific 
butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis 
in the feces of patients with colorectal cancer. J Gastroenterol Hepatol 
2008, 23(8 Pt 1):1298-1303. 
59. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L: 
Structural segregation of gut microbiota between colorectal cancer 
patients and healthy volunteers. Isme J 2012, 6(2):320-329. 
60. Monleon D, Morales JM, Barrasa A, Lopez JA, Vazquez C, Celda B: 
Metabolite profiling of fecal water extracts from human colorectal 
cancer. NMR Biomed 2009, 22(3):342-348. 
61. Bezabeh T, Somorjai R, Dolenko B, Bryskina N, Levin B, Bernstein CN, 
Jeyarajah E, Steinhart AH, Rubin DT, Smith IC: Detecting colorectal 
cancer by 1H magnetic resonance spectroscopy of fecal extracts. NMR 
Biomed 2009, 22(6):593-600. 
62. Girlanda R, Cheema AK, Kaur P, Kwon Y, Li A, Guerra J, Matsumoto 
CS, Zasloff M, Fishbein TM: Metabolomics of Human Intestinal 
Transplant Rejection. Am J Transplant 2012. 
63. Cao H, Huang H, Xu W, Chen D, Yu J, Li J, Li L: Fecal metabolome 
profiling of liver cirrhosis and hepatocellular carcinoma patients by 
ultra performance liquid chromatography-mass spectrometry. Anal 
Chim Acta 2011, 691(1-2):68-75. 
64. Poroyko V, Morowitz M, Bell T, Ulanov A, Wang M, Donovan S, Bao N, 
Gu S, Hong L, Alverdy JC et al: Diet creates metabolic niches in the 
"immature gut" that shape microbial communities. Nutr Hosp 2011, 
26(6):1283-1295. 
65. Gao X, Pujos-Guillot E, Martin JF, Galan P, Juste C, Jia W, Sebedio JL: 
Metabolite analysis of human fecal water by gas 
chromatography/mass spectrometry with ethyl chloroformate 
derivatization. Anal Biochem 2009, 393(2):163-175. 
66. Gao X, Pujos-Guillot E, Sebedio JL: Development of a quantitative 
metabolomic approach to study clinical human fecal water 
metabolome based on trimethylsilylation derivatization and GC/MS 
analysis. Anal Chem 2010, 82(15):6447-6456. 
124 
 
67. Ponnusamy K, Choi JN, Kim J, Lee SY, Lee CH: Microbial community 
and metabolomic comparison of irritable bowel syndrome faeces. J 
Med Microbiol 2011, 60(Pt 6):817-827. 
68. Ng JS, Ryan U, Trengove RD, Maker GL: Development of an 
untargeted metabolomics method for the analysis of human faecal 
samples using Cryptosporidium-infected samples. Mol Biochem 
Parasitol 2012, 185(2):145-150. 
69. Pasikanti KK, Ho PC, Chan EC: Gas chromatography/mass 
spectrometry in metabolic profiling of biological fluids. J Chromatogr 
B Analyt Technol Biomed Life Sci 2008, 871(2):202-211. 
70. Lu J, Zhou J, Bao Y, Chen T, Zhang Y, Zhao A, Qiu Y, Xie G, Wang C, 
Jia W: Serum metabolic signatures of fulminant type 1 diabetes. J 
Proteome Res 2012, 11(9):4705-4711. 
71. Li X, Xu Z, Lu X, Yang X, Yin P, Kong H, Yu Y, Xu G: Comprehensive 
two-dimensional gas chromatography/time-of-flight mass 
spectrometry for metabonomics: Biomarker discovery for diabetes 
mellitus. Anal Chim Acta 2009, 633(2):257-262. 
72. Ye G, Zhu B, Yao Z, Yin P, Lu X, Kong H, Fan F, Jiao B, Xu G: Analysis 
of urinary metabolic signatures of early hepatocellular carcinoma 
recurrence after surgical removal using gas chromatography-mass 
spectrometry. J Proteome Res 2012, 11(8):4361-4372. 
73. Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu 
QH, Chiong E, Chan EC: Noninvasive urinary metabonomic diagnosis 
of human bladder cancer. J Proteome Res 2010, 9(6):2988-2995. 
74. Caldeira M, Perestrelo R, Barros AS, Bilelo MJ, Morete A, Camara JS, 
Rocha SM: Allergic asthma exhaled breath metabolome: a challenge 
for comprehensive two-dimensional gas chromatography. J 
Chromatogr A 2012, 1254:87-97. 
75. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and 
function. Cell 2004, 116(2):281-297. 
76. Hwang HW, Mendell JT: MicroRNAs in cell proliferation, cell death, 
and tumorigenesis. Br J Cancer 2006, 94(6):776-780. 
77. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev 
Cancer 2006, 6(11):857-866. 
78. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M: microRNAs 
in cancer management. Lancet Oncol 2012, 13(6):e249-258. 
79. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in 
cancer. Nat Rev Cancer 2006, 6(4):259-269. 
80. Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, 
Sugihara K, Mori M: Over- and under-expressed microRNAs in human 
colorectal cancer. Int J Oncol 2009, 34(4):1069-1075. 
81. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, 
Abajo A, Navarro A, Moreno I, Monzo M et al: Identification by Real-
time PCR of 13 mature microRNAs differentially expressed in 
colorectal cancer and non-tumoral tissues. Mol Cancer 2006, 5:29. 
125 
 
82. Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, Chen HY, Sun XF: 
Clinicopathological significance of microRNA-31, -143 and -145 
expression in colorectal cancer. Dis Markers 2009, 26(1):27-34. 
83. Chen Y, Song Y, Wang Z, Yue Z, Xu H, Xing C, Liu Z: Altered 
expression of MiR-148a and MiR-152 in gastrointestinal cancers and 
its clinical significance. J Gastrointest Surg 2010, 14(7):1170-1179. 
84. Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova 
M, Nenutil R, Vyzula R: Altered expression of miR-21, miR-31, miR-
143 and miR-145 is related to clinicopathologic features of colorectal 
cancer. Oncology 2007, 72(5-6):397-402. 
85. Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, 
Kure EH: Differential expression of miRNAs in colorectal cancer: 
comparison of paired tumor tissue and adjacent normal mucosa using 
high-throughput sequencing. PLoS One 2012, 7(4):e34150. 
86. Faltejskova P, Svoboda M, Srutova K, Mlcochova J, Besse A, Nekvindova 
J, Radova L, Fabian P, Slaba K, Kiss I et al: Identification and 
functional screening of microRNAs highly deregulated in colorectal 
cancer. J Cell Mol Med 2012, 16(11):2655-2666. 
87. Xu XM, Qian JC, Deng ZL, Cai Z, Tang T, Wang P, Zhang KH, Cai JP: 
Expression of miR-21, miR-31, miR-96 and miR-135b is correlated 
with the clinical parameters of colorectal cancer. Oncol Lett 2012, 
4(2):339-345. 
88. Mazeh H, Mizrahi I, Ilyayev N, Halle D, Brucher B, Bilchik A, Protic M, 
Daumer M, Stojadinovic A, Itzhak A et al: The Diagnostic and 
Prognostic Role of microRNA in Colorectal Cancer - a 
Comprehensive review. J Cancer 2013, 4(3):281-295. 
89. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J: 
Systematic analysis of microRNA expression of RNA extracted from 
fresh frozen and formalin-fixed paraffin-embedded samples. Rna 
2007, 13(10):1668-1674. 
90. Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived 
exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 
2008, 110(1):13-21. 
91. Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, Lee CW, Wong YN, Chan 
FK, Yu J, Sung JJ: Detection of miR-92a and miR-21 in stool samples 
as potential screening biomarkers for colorectal cancer and polyps. 
Gut 2011. 
92. Kalimutho M, Del Vecchio Blanco G, Di Cecilia S, Sileri P, Cretella M, 
Pallone F, Federici G, Bernardini S: Differential expression of miR-144* 
as a novel fecal-based diagnostic marker for colorectal cancer. J 
Gastroenterol 2011. 
93. Peacock O, Lee AC, Larvin M, Tufarelli C, Lund JN: MicroRNAs: 
relevant tools for a colorectal surgeon? World J Surg 2012, 36(8):1881-
1892. 
94. Ahmed FE, Jeffries CD, Vos PW, Flake G, Nuovo GJ, Sinar DR, Naziri 
W, Marcuard SP: Diagnostic microRNA markers for screening 
126 
 
sporadic human colon cancer and active ulcerative colitis in stool and 
tissue. Cancer Genomics Proteomics 2009, 6(5):281-295. 
95. Koga Y, Yasunaga M, Takahashi A, Kuroda J, Moriya Y, Akasu T, Fujita 
S, Yamamoto S, Baba H, Matsumura Y: MicroRNA expression profiling 
of exfoliated colonocytes isolated from feces for colorectal cancer 
screening. Cancer Prev Res (Phila) 2010, 3(11):1435-1442. 
96. Link A, Balaguer F, Shen Y, Nagasaka T, Lozano JJ, Boland CR, Goel A: 
Fecal MicroRNAs as Novel Biomarkers for Colon Cancer Screening. 
Cancer Epidem Biomar 2010, 19(7):1766-1774. 
97. Yamazaki N, Koga Y, Yamamoto S, Kakugawa Y, Otake Y, Hayashi R, 
Saito N, Matsumura Y: Application of the Fecal MicroRNA Test to the 
Residuum from the Fecal Occult Blood Test. Jpn J Clin Oncol 2013. 
98. Li JM, Zhao RH, Li ST, Xie CX, Jiang HH, Ding WJ, Du P, Chen W, 
Yang M, Cui L: Down-regulation of fecal miR-143 and miR-145 as 
potential markers for colorectal cancer. Saudi Med J 2012, 33(1):24-29. 
99. Ahmed FE, Ahmed NC, Vos PW, Bonnerup C, Atkins JN, Casey M, 
Nuovo GJ, Naziri W, Wiley JE, Mota H et al: Diagnostic MicroRNA 
Markers to Screen for Sporadic Human Colon Cancer in Stool: I. 
Proof of Principle. Cancer Genomics Proteomics 2013, 10(3):93-113. 
100. Leslie A, Steele RJ: Management of colorectal cancer. Postgrad Med J 
2002, 78(922):473-478. 
101. Adjuvant chemotherapy for resected stage II colon cancer 
[http://www.uptodate.com/contents/adjuvant-chemotherapy-for-resected-
stage-ii-colon-cancer] 
102. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, 
Chollet P, Llory JF, Letourneau Y, Coudert B et al: Phase III multicenter 
randomized trial of oxaliplatin added to chronomodulated 
fluorouracil-leucovorin as first-line treatment of metastatic colorectal 
cancer. J Clin Oncol 2000, 18(1):136-147. 
103. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek 
P, Jandik P, Iveson T, Carmichael J, Alakl M et al: Irinotecan combined 
with fluorouracil compared with fluorouracil alone as first-line 
treatment for metastatic colorectal cancer: a multicentre randomised 
trial. Lancet 2000, 355(9209):1041-1047. 
104. Systemic chemotherapy for metastatic colorectal cancer: Completed 
clinical trials [http://www.uptodate.com/contents/systemic-
chemotherapy-for-metastatic-colorectal-cancer-completed-clinical-trials] 
105. Wu C, Goldberg RM: Colorectal cancer in 2012: Revisiting landmark 
trials and identifying new therapies. Nat Rev Clin Oncol 2013, 10(2):71-
72. 
106. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, 
Berry SR, Krahn M, Price T, Simes RJ et al: Cetuximab for the 
treatment of colorectal cancer. N Engl J Med 2007, 357(20):2040-2048. 
107. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, 
Bets D, Mueser M, Harstrick A, Verslype C et al: Cetuximab 
127 
 
monotherapy and cetuximab plus irinotecan in irinotecan-refractory 
metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345. 
108. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ: 
Phase II trial of cetuximab in patients with refractory colorectal 
cancer that expresses the epidermal growth factor receptor. J Clin 
Oncol 2004, 22(7):1201-1208. 
109. Longley DB, McDermott U, Johnston PG: Predictive markers for 
colorectal cancer: current status and future prospects. Clin Colorectal 
Cancer 2003, 2(4):223-230. 
110. Carli D, Honorat M, Cohen S, Megherbi M, Vignal B, Dumontet C, Payen 
L, Guitton J: Simultaneous quantification of 5-FU, 5-FUrd, 5-FdUrd, 
5-FdUMP, dUMP and TMP in cultured cell models by LC-MS/MS. J 
Chromatogr B Analyt Technol Biomed Life Sci 2009, 877(27):2937-2944. 
111. Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of 
action and clinical strategies. Nat Rev Cancer 2003, 3(5):330-338. 
112. Diasio RB, Harris BE: Clinical pharmacology of 5-fluorouracil. Clin 
Pharmacokinet 1989, 16(4):215-237. 
113. Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, 
Danenberg PV, Leichman L: Thymidylate synthase gene and protein 
expression correlate and are associated with response to 5-
fluorouracil in human colorectal and gastric tumors. Cancer Res 1995, 
55(7):1407-1412. 
114. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei 
DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB et al: Colorectal 
tumors responding to 5-fluorouracil have low gene expression levels of 
dihydropyrimidine dehydrogenase, thymidylate synthase, and 
thymidine phosphorylase. Clin Cancer Res 2000, 6(4):1322-1327. 
115. Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, 
Lionetto R, Maley F, Sobrero A: Immunohistochemical quantitation of 
thymidylate synthase expression in colorectal cancer metastases 
predicts for clinical outcome to fluorouracil-based chemotherapy. J 
Clin Oncol 1999, 17(6):1760-1770. 
116. Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression 
and prognosis in colorectal cancer: a systematic review and meta-
analysis. J Clin Oncol 2004, 22(3):529-536. 
117. Iacopetta B, Grieu F, Joseph D, Elsaleh H: A polymorphism in the 
enhancer region of the thymidylate synthase promoter influences the 
survival of colorectal cancer patients treated with 5-fluorouracil. Br J 
Cancer 2001, 85(6):827-830. 
118. Park CM, Lee WY, Chun HK, Cho YB, Yun HR, Heo JS, Yun SH, Kim 
HC: Relationship of polymorphism of the tandem repeat sequence in 
the thymidylate synthase gene and the survival of stage III colorectal 
cancer patients receiving adjuvant 5-flurouracil-based chemotherapy. 
J Surg Oncol 2010, 101(1):22-27. 
119. Farina-Sarasqueta A, Gosens MJ, Moerland E, van Lijnschoten I, 
Lemmens VE, Slooter GD, Rutten HJ, van den Brule AJ: TS gene 
128 
 
polymorphisms are not good markers of response to 5-FU therapy in 
stage III colon cancer patients. Anal Cell Pathol (Amst) 2010, 33(1):1-
11. 
120. Metzger R, Danenberg K, Leichman CG, Salonga D, Schwartz EL, 
Wadler S, Lenz HJ, Groshen S, Leichman L, Danenberg PV: High basal 
level gene expression of thymidine phosphorylase (platelet-derived 
endothelial cell growth factor) in colorectal tumors is associated with 
nonresponse to 5-fluorouracil. Clin Cancer Res 1998, 4(10):2371-2376. 
121. Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan 
WL, Zeps N, Joseph D et al: Prognostic significance of thymidylate 
synthase, dihydropyrimidine dehydrogenase and thymidine 
phosphorylase protein expression in colorectal cancer patients treated 
with or without 5-fluorouracil-based chemotherapy. Ann Oncol 2008, 
19(5):915-919. 
122. Mader RM, Sieder AE, Braun J, Rizovski B, Kalipciyan M, Mueller MW, 
Jakesz R, Rainer H, Steger GG: Transcription and activity of 5-
fluorouracil converting enzymes in fluoropyrimidine resistance in 
colon cancer in vitro. Biochem Pharmacol 1997, 54(11):1233-1242. 
123. Tsuji T, Sawai T, Takeshita H, Nakagoe T, Hidaka S, Yamaguchi H, 
Yasutake T, Nagayasu T, Tagawa Y: Tumor dihydropyrimidine 
dehydrogenase expression is a useful marker in adjuvant therapy with 
oral fluoropyrimidines after curative resection of colorectal cancer. 
Cancer Chemother Pharmacol 2004, 54(6):531-536. 
124. Cohen V, Panet-Raymond V, Sabbaghian N, Morin I, Batist G, Rozen R: 
Methylenetetrahydrofolate reductase polymorphism in advanced 
colorectal cancer: a novel genomic predictor of clinical response to 
fluoropyrimidine-based chemotherapy. Clin Cancer Res 2003, 
9(5):1611-1615. 
125. Fernandez-Peralta AM, Daimiel L, Nejda N, Iglesias D, Medina Arana V, 
Gonzalez-Aguilera JJ: Association of polymorphisms MTHFR C677T 
and A1298C with risk of colorectal cancer, genetic and epigenetic 
characteristic of tumors, and response to chemotherapy. Int J 
Colorectal Dis 2010, 25(2):141-151. 
126. Afzal S, Jensen SA, Vainer B, Vogel U, Matsen JP, Sorensen JB, 
Andersen PK, Poulsen HE: MTHFR polymorphisms and 5-FU-based 
adjuvant chemotherapy in colorectal cancer. Ann Oncol 2009, 
20(10):1660-1666. 
127. Kong W, Engel K, Wang J: Mammalian nucleoside transporters. Curr 
Drug Metab 2004, 5(1):63-84. 
128. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD: The 
equilibrative nucleoside transporter family, SLC29. Pflugers Arch 
2004, 447(5):735-743. 
129. Tsujie M, Nakamori S, Nakahira S, Takahashi Y, Hayashi N, Okami J, 
Nagano H, Dono K, Umeshita K, Sakon M et al: Human equilibrative 
nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in 
human pancreatic cancer. Anticancer Res 2007, 27(4B):2241-2249. 
129 
 
130. Yoshinare K, Kubota T, Watanabe M, Wada N, Nishibori H, Hasegawa H, 
Kitajima M, Takechi T, Fukushima M: Gene expression in colorectal 
cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 
surgical specimens. Cancer Sci 2003, 94(7):633-638. 
131. Hu X, Chen W, Xu J: Downregulation of human equilibrative 
nucleoside transporter 1 by RNAi enhances 5-fluorouracil response in 
pancreatic cancer. Hepatogastroenterology 2010, 57(104):1567-1572. 
132. Kobayashi H, Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, 
Sueda T: Human equilibrative nucleoside transporter 1 expression 
predicts survival of advanced cholangiocarcinoma patients treated 
with gemcitabine-based adjuvant chemotherapy after surgical 
resection. Ann Surg 2012, 256(2):288-296. 
133. Vecchione L, Jacobs B, Normanno N, Ciardiello F, Tejpar S: EGFR-
targeted therapy. Exp Cell Res 2011, 317(19):2765-2771. 
134. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, 
Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S et al: K-ras 
mutations and benefit from cetuximab in advanced colorectal cancer. 
N Engl J Med 2008, 359(17):1757-1765. 
135. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, 
Tejpar S, Kisker O, Stroh C, Rougier P: KRAS status and efficacy in the 
first-line treatment of patients with metastatic colorectal cancer 
(mCRC) treated with FOLFIRI with or without cetuximab: The 
CRYSTAL experience J Clin Oncol 2008, 26(15S):2. 
136. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, 
Shchepotin I, Maurel J, Cunningham D, Tejpar S et al: Cetuximab plus 
irinotecan, fluorouracil, and leucovorin as first-line treatment for 
metastatic colorectal cancer: updated analysis of overall survival 
according to tumor KRAS and BRAF mutation status. J Clin Oncol 
2011, 29(15):2011-2019. 
137. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, 
Nippgen J, Stroh C, Celik I, Koralewski P: KRAS status and efficacy of 
first-line treatment of patients with metastatic colorectal cancer 
(mCRC) with FOLFOX with or without cetuximab: The OPUS 
experience J Clin Oncol 2008, 26(15S):4000. 
138. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G, Zubel 
A, Celik I, Schlichting M, Koralewski P: Efficacy according to 
biomarker status of cetuximab plus FOLFOX-4 as first-line treatment 
for metastatic colorectal cancer: the OPUS study. Ann Oncol 2011, 
22(7):1535-1546. 
139. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, 
Hayes DF, McAllister PK, Morton RF, Schilsky RL: American Society of 
Clinical Oncology provisional clinical opinion: testing for KRAS gene 
mutations in patients with metastatic colorectal carcinoma to predict 
response to anti-epidermal growth factor receptor monoclonal 
antibody therapy. J Clin Oncol 2009, 27(12):2091-2096. 
130 
 
140. Class Labeling Changes to anti-EGFR monoclonal antibodies, 
cetuximab (Erbitux) and panitumumab (Vectibix): KRAS Mutations 
[http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProducts
andTobacco/CDER/ucm172905.htm] 
141. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, 
Rougier P, Lievre A, Landi B, Boige V et al: Analysis of PTEN, BRAF, 
and EGFR status in determining benefit from cetuximab therapy in 
wild-type KRAS metastatic colon cancer. J Clin Oncol 2009, 
27(35):5924-5930. 
142. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, 
Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P 
et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the 
efficacy of cetuximab plus chemotherapy in chemotherapy-refractory 
metastatic colorectal cancer: a retrospective consortium analysis. 
Lancet Oncol 2010, 11(8):753-762. 
143. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, 
Heelan R, Rusch V, Fulton L et al: EGF receptor gene mutations are 
common in lung cancers from "never smokers" and are associated 
with sensitivity of tumors to gefitinib and erlotinib. Proceedings of the 
National Academy of Sciences of the United States of America 2004, 
101(36):13306-13311. 
144. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, 
Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG et al: 
Activating Mutations in the Epidermal Growth Factor Receptor 
Underlying Responsiveness of Non-Small-Cell Lung Cancer to 
Gefitinib. New England Journal of Medicine 2004, 350(21):2129-2139. 
145. Eck MJ, Yun C-H: Structural and mechanistic underpinnings of the 
differential drug sensitivity of EGFR mutations in non-small cell lung 
cancer. Biochimica et Biophysica Acta (BBA) - Proteins &amp; 
Proteomics 2010, 1804(3):559-566. 
146. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, 
Yamamoto S, Nokihara H, Yamamoto N, Sekine I et al: Epidermal 
growth factor receptor gene mutations and increased copy numbers 
predict gefitinib sensitivity in patients with recurrent non-small-cell 
lung cancer. J Clin Oncol 2005, 23(28):6829-6837. 
147. Gao J, Wang TT, Yu JW, Li YY, Shen L: Wild-Type KRAS and BRAF 
Could Predict Response to Cetuximab in Chinese Colorectal Cancer 
Patients. Chin J Cancer Res 2011, 23(4):271-275. 
148. Li F-H, Shen L, Li Z-H, Luo H-Y, Qiu M-Z, Zhang H-Z, Li Y-H, Xu R-H: 
Impact ofKRASmutation and PTEN expression on cetuximab-treated 
colorectal cancer. World Journal of Gastroenterology 2010, 16(46):5881. 
149. Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, Tang J, Chen Q: 
KRAS, BRAF and PIK3CA mutations and the loss of PTEN 




150. Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M, Enomoto M, 
Uetake H, Sugihara K: PIK3CA mutation is predictive of poor survival 
in patients with colorectal cancer. Int J Cancer 2007, 121(8):1771-1778. 
151. Kimura T, Okamoto K, Miyamoto H, Kimura M, Kitamura S, Takenaka 
H, Muguruma N, Okahisa T, Aoyagi E, Kajimoto M et al: Clinical 
benefit of high-sensitivity KRAS mutation testing in metastatic 
colorectal cancer treated with anti-EGFR antibody therapy. Oncology 
2012, 82(5):298-304. 
152. Ito Y, Yamada Y, Asada K, Ushijima T, Iwasa S, Kato K, Hamaguchi T, 
Shimada Y: EGFR L2 domain mutation is not correlated with 
resistance to cetuximab in metastatic colorectal cancer patients. J 
Cancer Res Clin Oncol 2013, 139(8):1391-1396. 
153. Nakanishi R, Harada J, Tuul M, Zhao Y, Ando K, Saeki H, Oki E, Ohga 
T, Kitao H, Kakeji Y et al: Prognostic relevance of KRAS and BRAF 
mutations in Japanese patients with colorectal cancer. Int J Clin Oncol 
2012. 
154. Pang NK, Nga ME, Chin SY, Ismail TM, Lim GL, Soong R, Salto-Tellez 
M: KRAS and BRAF mutation analysis can be reliably performed on 
aspirated cytological specimens of metastatic colorectal carcinoma. 
Cytopathology 2011, 22(6):358-364. 
155. Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, Kudahetti SC, 
Stankiewicz E, Xue L, Beltran L et al: Distinct genomic alterations in 
prostate cancers in Chinese and Western populations suggest 
alternative pathways of prostate carcinogenesis. Cancer Res 2010, 
70(13):5207-5212. 
156. Menendez P, Villarejo P, Padilla D, Menendez JM, Montes JA: 
Diagnostic and prognostic significance of serum microRNAs in 
colorectal cancer. J Surg Oncol 2013, 107(2):217-220. 
157. Wang H, Tso VK, Slupsky CM, Fedorak RN: Metabolomics and 
detection of colorectal cancer in humans: a systematic review. Future 
Oncol 2010, 6(9):1395-1406. 
158. Bezabeh T, Somorjai RL, Smith IC: MR metabolomics of fecal extracts: 
applications in the study of bowel diseases. Magn Reson Chem 2009, 47 
Suppl 1:S54-61. 
159. Jacobs DM, Deltimple N, van Velzen E, van Dorsten FA, Bingham M, 
Vaughan EE, van Duynhoven J: (1)H NMR metabolite profiling of feces 
as a tool to assess the impact of nutrition on the human microbiome. 
NMR Biomed 2008, 21(6):615-626. 
160. Marchesi JR, Holmes E, Khan F, Kochhar S, Scanlan P, Shanahan F, 
Wilson ID, Wang Y: Rapid and noninvasive metabonomic 
characterization of inflammatory bowel disease. J Proteome Res 2007, 
6(2):546-551. 
161. Le Gall G, Noor SO, Ridgway K, Scovell L, Jamieson C, Johnson IT, 
Colquhoun IJ, Kemsley EK, Narbad A: Metabolomics of fecal extracts 
detects altered metabolic activity of gut microbiota in ulcerative colitis 
and irritable bowel syndrome. J Proteome Res 2011, 10(9):4208-4218. 
132 
 
162. Hong YS, Hong KS, Park MH, Ahn YT, Lee JH, Huh CS, Lee J, Kim IK, 
Hwang GS, Kim JS: Metabonomic understanding of probiotic effects 
in humans with irritable bowel syndrome. J Clin Gastroenterol 2011, 
45(5):415-425. 
163. Sellitto M, Bai G, Serena G, Fricke WF, Sturgeon C, Gajer P, White JR, 
Koenig SS, Sakamoto J, Boothe D et al: Proof of concept of 
microbiome-metabolome analysis and delayed gluten exposure on 
celiac disease autoimmunity in genetically at-risk infants. PLoS One 
2012, 7(3):e33387. 
164. Pettersson J, Karlsson PC, Choi YH, Verpoorte R, Rafter JJ, Bohlin L: 
NMR metabolomic analysis of fecal water from subjects on a 
vegetarian diet. Biol Pharm Bull 2008, 31(6):1192-1198. 
165. Saric J, Wang Y, Li J, Coen M, Utzinger J, Marchesi JR, Keiser J, 
Veselkov K, Lindon JC, Nicholson JK et al: Species variation in the 
fecal metabolome gives insight into differential gastrointestinal 
function. J Proteome Res 2008, 7(1):352-360. 
166. Song H, Wang L, Liu HL, Wu XB, Wang HS, Liu ZH, Li Y, Diao DC, 
Chen HL, Peng JS: Tissue metabolomic fingerprinting reveals 
metabolic disorders associated with human gastric cancer morbidity. 
Oncol Rep 2011, 26(2):431-438. 
167. Wu H, Xue R, Tang Z, Deng C, Liu T, Zeng H, Sun Y, Shen X: 
Metabolomic investigation of gastric cancer tissue using gas 
chromatography/mass spectrometry. Anal Bioanal Chem 2010, 
396(4):1385-1395. 
168. Wu H, Xue R, Lu C, Deng C, Liu T, Zeng H, Wang Q, Shen X: 
Metabolomic study for diagnostic model of oesophageal cancer using 
gas chromatography/mass spectrometry. J Chromatogr B Analyt 
Technol Biomed Life Sci 2009, 877(27):3111-3117. 
169. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, 
Niesporek S, Konsgen D, Dietel M, Fiehn O: Mass spectrometry-based 
metabolic profiling reveals different metabolite patterns in invasive 
ovarian carcinomas and ovarian borderline tumors. Cancer Res 2006, 
66(22):10795-10804. 
170. Buckendahl AC, Budczies J, Fiehn O, Darb-Esfahani S, Kind T, Noske A, 
Weichert W, Sehouli J, Braicu E, Dietel M et al: Prognostic impact of 
AMP-activated protein kinase expression in ovarian carcinoma: 
correlation of protein expression and GC/TOF-MS-based 
metabolomics. Oncol Rep 2011, 25(4):1005-1012. 
171. Thysell E, Surowiec I, Hornberg E, Crnalic S, Widmark A, Johansson AI, 
Stattin P, Bergh A, Moritz T, Antti H et al: Metabolomic 
characterization of human prostate cancer bone metastases reveals 
increased levels of cholesterol. PLoS One 2010, 5(12):e14175. 
172. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, 
Laxman B, Mehra R, Lonigro RJ, Li Y et al: Metabolomic profiles 
delineate potential role for sarcosine in prostate cancer progression. 
Nature 2009, 457(7231):910-914. 
133 
 
173. Budczies J, Denkert C, Muller BM, Brockmoller SF, Klauschen F, 
Gyorffy B, Dietel M, Richter-Ehrenstein C, Marten U, Salek RM et al: 
Remodeling of central metabolism in invasive breast cancer compared 
to normal breast tissue - a GC-TOFMS based metabolomics study. 
BMC Genomics 2012, 13:334. 
174. Hori S, Nishiumi S, Kobayashi K, Shinohara M, Hatakeyama Y, Kotani 
Y, Hatano N, Maniwa Y, Nishio W, Bamba T et al: A metabolomic 
approach to lung cancer. Lung cancer 2011, 74(2):284-292. 
175. Vandendool H, Kratz PD: A Generalization of the Retention Index 
System Including Linear Temperature Programmed Gas-Liquid 
Partition Chromatography. J Chromatogr 1963, 11:463-471. 
176. Verner P: Separation, quantification and identification of non-volatile 
organic acids in body fluids by gas chromatography. J Pharm Biomed 
Anal 1988, 6(2):131-150. 
177. A J, Trygg J, Gullberg J, Johansson AI, Jonsson P, Antti H, Marklund SL, 
Moritz T: Extraction and GC/MS analysis of the human blood plasma 
metabolome. Anal Chem 2005, 77(24):8086-8094. 
178. Guidance for industry: bioanalytical method validation. In., edn.: 
FDA, US Department of Health and Human Services; 2001. 
179. Kovarova JT, Zavoral M, Zima T, Zak A, Kocna P, Kohout P, Granatova 
J, Vanickova Z, Vranova J, Suchanek S et al: Improvements in 
colorectal cancer screening programmes - quantitative 
immunochemical faecal occult blood testing - how to set the cut-off for 
a particular population. Biomed Pap Med Fac Univ Palacky Olomouc 
Czech Repub 2012, 156(2):143-150. 
180. van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der 
Werf MJ: Centering, scaling, and transformations: improving the 
biological information content of metabolomics data. BMC Genomics 
2006, 7:142. 
181. Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, 
Gordon JI, Relman DA, Fraser-Liggett CM, Nelson KE: Metagenomic 
analysis of the human distal gut microbiome. Science 2006, 
312(5778):1355-1359. 
182. Trygg J, Holmes E, Lundstedt T: Chemometrics in metabonomics. J 
Proteome Res 2007, 6(2):469-479. 
183. Wiklund S, Johansson E, Sjostrom L, Mellerowicz EJ, Edlund U, 
Shockcor JP, Gottfries J, Moritz T, Trygg J: Visualization of GC/TOF-
MS-based metabolomics data for identification of biochemically 
interesting compounds using OPLS class models. Anal Chem 2008, 
80(1):115-122. 
184. Calvani R, Miccheli A, Capuani G, Tomassini Miccheli A, Puccetti C, 
Delfini M, Iaconelli A, Nanni G, Mingrone G: Gut microbiome-derived 
metabolites characterize a peculiar obese urinary metabotype. Int J 
Obes (Lond) 2010, 34(6):1095-1098. 
185. Vallejo M, Garcia A, Tunon J, Garcia-Martinez D, Angulo S, Martin-
Ventura JL, Blanco-Colio LM, Almeida P, Egido J, Barbas C: Plasma 
134 
 
fingerprinting with GC-MS in acute coronary syndrome. Anal Bioanal 
Chem 2009, 394(6):1517-1524. 
186. Sharif AW, Williams HR, Lampejo T, Khan SA, Bansi DS, Westaby D, 
Thillainayagam AV, Thomas HC, Cox IJ, Taylor-Robinson SD: 
Metabolic profiling of bile in cholangiocarcinoma using in vitro 
magnetic resonance spectroscopy. HPB (Oxford) 2010, 12(6):396-402. 
187. Righi V, Durante C, Cocchi M, Calabrese C, Di Febo G, Lecce F, Pisi A, 
Tugnoli V, Mucci A, Schenetti L: Discrimination of healthy and 
neoplastic human colon tissues by ex vivo HR-MAS NMR 
spectroscopy and chemometric analyses. J Proteome Res 2009, 
8(4):1859-1869. 
188. Godoy A, Ulloa V, Rodriguez F, Reinicke K, Yanez AJ, Garcia Mde L, 
Medina RA, Carrasco M, Barberis S, Castro T et al: Differential 
subcellular distribution of glucose transporters GLUT1-6 and GLUT9 
in human cancer: ultrastructural localization of GLUT1 and GLUT5 
in breast tumor tissues. J Cell Physiol 2006, 207(3):614-627. 
189. Zlobec I, Bihl MP, Schwarb H, Terracciano L, Lugli A: 
Clinicopathological and protein characterization of BRAF- and K-
RAS-mutated colorectal cancer and implications for prognosis. 
International Journal of Cancer 2010, 127(2):367-380. 
190. Kirkland JB: Niacin requirements for genomic stability. Mutat Res 
2012, 733(1-2):14-20. 
191. Mayo B, van Sinderen D: Bifidobacteria: Genomics and Molecular 
Aspects: Caister Acad. Press; 2010. 
192. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, 
Tait JF, Tewari M: Blood cell origin of circulating microRNAs: a 
cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 
2012, 5(3):492-497. 
193. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van 
Zandwijk N, Reid G: Haemolysis during sample preparation alters 
microRNA content of plasma. PLoS One 2011, 6(9):e24145. 
194. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe 
A, Speleman F: Accurate normalization of real-time quantitative RT-
PCR data by geometric averaging of multiple internal control genes. 
Genome Biol 2002, 3(7):RESEARCH0034. 
195. Sun J, Chen Z, Tan X, Zhou F, Tan F, Gao Y, Sun N, Xu X, Shao K, He J: 
MicroRNA-99a/100 promotes apoptosis by targeting mTOR in human 
esophageal squamous cell carcinoma. Med Oncol 2013, 30(1):411. 
196. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, Cassandrini P, 
Zamboni G, Maciejewski R: Deregulation of miR-100, miR-99a and 
miR-199b in tissues and plasma coexists with increased expression of 
mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 
2012, 12:369. 
197. Chen Z, Jin Y, Yu D, Wang A, Mahjabeen I, Wang C, Liu X, Zhou X: 
Down-regulation of the microRNA-99 family members in head and 
neck squamous cell carcinoma. Oral Oncol 2012, 48(8):686-691. 
135 
 
198. Huang ZM, Yang J, Shen XY, Zhang XY, Meng FS, Xu JT, Zhang BF, 
Gao HJ: MicroRNA expression profile in non-cancerous colonic tissue 
associated with lymph node metastasis of colon cancer. J Dig Dis 2009, 
10(3):188-194. 
199. Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, Sun L, Ji G, Shi Y, Han Z 
et al: miRNA-223 promotes gastric cancer invasion and metastasis by 
targeting tumor suppressor EPB41L3. Mol Cancer Res 2011, 9(7):824-
833. 
200. Li S, Li Z, Guo F, Qin X, Liu B, Lei Z, Song Z, Sun L, Zhang HT, You J 
et al: miR-223 regulates migration and invasion by targeting Artemin 
in human esophageal carcinoma. J Biomed Sci 2011, 18:24. 
201. Wu L, Li H, Jia CY, Cheng W, Yu M, Peng M, Zhu Y, Zhao Q, Dong 
YW, Shao K et al: MicroRNA-223 regulates FOXO1 expression and 
cell proliferation. FEBS Lett 2012, 586(7):1038-1043. 
202. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S: 
microRNA-451: A conditional switch controlling glioma cell 
proliferation and migration. Cell Cycle 2010, 9(14):2742-2748. 
203. Godlewski J, Nowicki MO, Bronisz A, Nuovo G, Palatini J, De Lay M, 
Van Brocklyn J, Ostrowski MC, Chiocca EA, Lawler SE: MicroRNA-451 
regulates LKB1/AMPK signaling and allows adaptation to metabolic 
stress in glioma cells. Mol Cell 2010, 37(5):620-632. 
204. Wang T, Zang WQ, Li M, Wang N, Zheng YL, Zhao GQ: Effect of miR-
451 on the biological behavior of the esophageal carcinoma cell line 
EC9706. Dig Dis Sci 2013, 58(3):706-714. 
205. Li X, Sanda T, Look AT, Novina CD, von Boehmer H: Repression of 
tumor suppressor miR-451 is essential for NOTCH1-induced 
oncogenesis in T-ALL. J Exp Med 2011, 208(4):663-675. 
206. Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, 
Diaz-Gonzalez JA, Ramirez N, Sola JJ et al: microRNA-451 regulates 
macrophage migration inhibitory factor production and proliferation 
of gastrointestinal cancer cells. Clin Cancer Res 2009, 15(7):2281-2290. 
207. Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, Chen Y, Wang X, Jiang Y, 
Fang X: Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-
caprolactone) nanoparticles as dual-targeting drug delivery system 
for brain glioma. Biomaterials 2011, 32(18):4293-4305. 
208. F M Muggia FMM: New Drugs, Concepts and Results in Cancer 
Chemotherapy: Springer Netherlands 1991. 
209. Boleti H, Coe IR, Baldwin SA, Young JD, Cass CE: Molecular 
identification of the equilibrative NBMPR-sensitive (es) nucleoside 
transporter and demonstration of an equilibrative NBMPR-
insensitive (ei) transport activity in human erythroleukemia (K562) 
cells. Neuropharmacology 1997, 36(9):1167-1179. 
210. Woodahl EL, Wang J, Heimfeld S, Ren AG, McCune JS: Imatinib 
inhibition of fludarabine uptake in T-lymphocytes. Cancer Chemother 
Pharmacol 2008, 62(4):735-739. 
136 
 
211. Yao SY, Ng AM, Cass CE, Baldwin SA, Young JD: Nucleobase 
transport by human equilibrative nucleoside transporter 1 (hENT1). J 
Biol Chem 2011, 286(37):32552-32562. 
212. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di 
Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene copy number 
for epidermal growth factor receptor (EGFR) and clinical response to 
antiEGFR treatment in colorectal cancer: A cohort study. Lancet 
Oncology 2005, 6(5):279-286. 
213. Brevet M, Johnson ML, Azzoli CG, Ladanyi M: Detection of EGFR 
mutations in plasma DNA from lung cancer patients by mass 
spectrometry genotyping is predictive of tumor EGFR status and 
response to EGFR inhibitors. Lung Cancer 2011, 73(1):96-102. 
214. Ruhe JE, Streit S, Hart S, Wong CH, Specht K, Knyazev P, Knyazeva T, 
Tay LS, Loo HL, Foo P et al: Genetic alterations in the tyrosine kinase 
transcriptome of human cancer cell lines. Cancer Res 2007, 
67(23):11368-11376. 
215. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, 
Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S et al: Wild-
type BRAF is required for response to panitumumab or cetuximab in 
metastatic colorectal cancer. J Clin Oncol 2008, 26(35):5705-5712. 
216. Frattini M, Saletti P, Romagnani E, Martin V, Molinari F, Ghisletta M, 
Camponovo A, Etienne LL, Cavalli F, Mazzucchelli L: PTEN loss of 
expression predicts cetuximab efficacy in metastatic colorectal cancer 
patients. Br J Cancer 2007, 97(8):1139-1145. 
217. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, 
Movilia A, Luoni M, Boldorini R, Alabiso O et al: Increased detection 
sensitivity for KRAS mutations enhances the prediction of anti-EGFR 
monoclonal antibody resistance in metastatic colorectal cancer. Clin 
Cancer Res 2011, 17(14):4901-4914. 
218. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, 
Tomasic G, Penna C, Ducreux M et al: KRAS mutation status is 
predictive of response to cetuximab therapy in colorectal cancer. 
Cancer Res 2006, 66(8):3992-3995. 
219. Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A: Clinical 
relevance of EGFR- and KRAS-status in colorectal cancer patients 
treated with monoclonal antibodies directed against the EGFR. 
Cancer Treatment Reviews 2009, 35(3):262-271. 
220. Chaiyapan W, Duangpakdee P, Boonpipattanapong T, Kanngern S, 
Sangkhathat S: Somatic mutations of K-ras and BRAF in Thai 
colorectal cancer and their prognostic value. Asian Pac J Cancer Prev 
2013, 14(1):329-332. 
221. Wu CM, Tang R, Wang JY, Changchien CR, Hsieh LL: Frequency and 
spectrum of K-RAS codons 12 and 13 mutations in colorectal 




222. Kim ST, Park KH, Kim JS, Shin SW, Kim YH: Impact of KRAS 
Mutation Status on Outcomes in Metastatic Colon Cancer Patients 
without Anti-Epidermal Growth Factor Receptor Therapy. Cancer 
Res Treat 2013, 45(1):55-62. 
223. Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, 
Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S et al: Wild-
type BRAF is required for response to panitumumab or cetuximab in 
metastatic colorectal cancer. Journal of Clinical Oncology 2008, 
26(35):5705-5712. 
224. Trends In Cancer Incidence In Singapore 1968 – 2007. In.: Health 
Promotion Board. 
225. Davies RJ, Miller R, Coleman N: Colorectal cancer screening: 
prospects for molecular stool analysis. Nat Rev Cancer 2005, 5(3):199-
209. 
226. Tenori L, Oakman C, Claudino WM, Bernini P, Cappadona S, Nepi S, 
Biganzoli L, Arbushites MC, Luchinat C, Bertini I et al: Exploration of 
serum metabolomic profiles and outcomes in women with metastatic 
breast cancer: a pilot study. Mol Oncol 2012, 6(4):437-444. 
227. Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H, 
Bogdanov MB, Churchill E, Krishnan RR, Rush AJ et al: Pretreatment 
metabotype as a predictor of response to sertraline or placebo in 








Supplementary Text 1. Subgroup analysis of miR-223 using fecal samples 
documented to contain less than 1 mg Hb /g stool of blood (8 CRC patients and 




Immunochemical FOBT  
 
FOBT was conducted for 11 cancer patients and 10 healthy subjects. Fecal Hb 
levels were measured as described in section 4.3.3. Fecal Hb levels were stratified 
into the following categories: a) 1 mg Hb /g stool and below, and b) higher than 1 






Fecal specimens from 3 CRC patients contained levels of blood equivalent to 
more than 1 mg Hb /g stool. The remaining 8 CRC subjects and 10 healthy 





A subgroup analysis of fecal miR-223 was conducted using samples documented 
to contain less than 1 mg Hb /g stool of blood (8 CRC patients and 10 healthy 
subjects). Fecal miR-223 was appreciably higher in CRC patients compared to 















Supplementary Figure 2 Effects of (A) weight of lyophilized feces, (B) duration 
of ultrasonication, (C) different extraction solvents [I: Chloroform:methanol:water 
(2:5:2); II: Acetonitrile:water (8:2); III: Methanol:water (8:2); IV: Methanol:water 
(4:2)], (D) duration of derivatization with MSTFA and (E) inclusion and 
exclusion of methoximation on the number of chromatographic peaks and total 















Supplementary Figure 4 Percentage of analytes that remained stable under various 














Supplementary Figure 5 (A) PLS-DA plot discriminating feces ( ) from fecal 

















Fecal water experiment.M3 (PLS-DA), feces & fecal water 8020
t[Comp. 1]/t[Comp. 2]
Colored according to Obs ID (Class)
R2X[1] = 0.854518            R2X[2] = 0.0733267           
Ellipse: Hotelling T2 (0.95) 
Fecal water extracted with the same solvent
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Supplementary Figure 6 (A) PLS-DA plot discriminating neat feces ( ) from 
feces spiked with gross (100 mgHb/g feces) level of blood ( ) (B) Validation plot 
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Supplementary Figure 7 Probable GC derivatives of galactose in the presence and 
absence of MOX. This example illustrates the use of MOX in converting carbonyl 
groups to non-enolizable methyloxime, thereby preventing downstream formation 
of unstable TMS-ethers. The mass spectra of detected silylated derivatives are 






Supplementary Figure 8 Relative expression of endogenous controls miR-1202 
and miR-4257 across 45 samples. The highest miRNA level was arbitrarily set at 




M = 1.2444 




Supplementary Figure 9 Fold change of miR-135b relative to healthy subjects. 
Horizontal lines denote mean fold changes. Difference between CRC patients and 







Supplementary Figure 10 Relative expression of nucleoside transporters in non-
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Supplementary Figure 11 Viability of Caco-2 cells incubated with varying 
concentrations of NBMPR in the absence of 5FU. Cell viability was expressed as 
a percentage against control group with neither 5FU nor NBMPR. Each 
measurement represents mean ± standard deviation (n=5). Three independent 
experiments were performed and a representative graph from one of the 
experiments is shown. No statistically significant difference was observed among 
the groups in all three experimental sets (p>0.05). 




Supplementary Table 1 Distribution of range of dilution of 268 resolved analytes 
(e.g. range of dilution=2 means that the analyte remained detectable at a 






500  31 (11.6) 
200  17 (6.3) 
100  8 (3.0) 
50  39 (14.6) 
20  42 (15.7) 
10  44 (16.4) 
5  62 (23.1) 






Supplementary Table 2 Clinical characteristics of each CRC patient and healthy 





blood in stool  
(mg Hb /g 
stool) 


































CRC 8 F 67 0.05 - 1  B 
Moderately 
differentiated 
Sigmoid  Yes 










CRC 11 M 75 < 0.05 B 
Moderately 
differentiated  
Rectum  Yes 
Hl 1 F 63 ND 
 
 
   
Hl 2 M 79 < 0.05 
 
 
   
Hl 3 F 70 ND 
 
 
   
Hl 4 M 51 ND 
 
 
   
Hl 5 M 54 < 0.05 
 
 
   
Hl 6 F 48 ND 
 
 
   
Hl 7 F 50 ND 
 
 
   
Hl 8 F 52 ND 
 
 
   
Hl 9 M 53 ND 
 
 
   
Hl 10 F 54 ND   
  
 
    
ND: Not detected (below limit of detection of 0.00042 mg Hb /g stool) 
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Supplementary Table 3 Fold change in tumor tissue (n=8) relative to matched 
normal mucosae (n=8) from phase I microarray analysis 





miR-451 1.26 0.708 
miR-223 1.05 0.272 
miR-135b 11.8 0.004 
 
a 
Fold change more than 1 indicates higher level in the tumor tissue compared 
with matched normal mucosae; fold change less than 1 indicates lower level in the 
tumor tissue compared with matched normal mucosae. 
b 






















Gene F primer sequence 
(5’  3’) 
Concentration 
of F primer 
used in PCR 
reaction (μM) 
R primer sequence 
(5’  3’) 
Concentration 
of R primer 




    
hENT1 TCTCCAACTCTCAGCCCACCAA 1 CCTGCGATGCTGGACTTGACCT 0.1 
hENT2 ATGAGAACGGGATTCCCAGTAG 1 GCTCTGATTCCGGCTCCTT 1 
hENT3 TCCTCAGGCCCAAGACTCAA 1 GGCAGTTGTTCACCCACAGA 1 
hENT4 GGGACCTCCATCGTGTTTGA 1 CTCCACCAGGACGTTGTTCA 1 
hCNT1 CATTACTGATCCGGCCCTACTT 1 TGGCGTAACCTCCGGTCAT 1 
hCNT2 CTTGTGCTCTCGCCTCATCA 1 TTACCCCCTCCTCACTCTTGAA 1 
Endogenous 
controls 
    
18S CGGCTTAATTTGACTCAACACG 0.25 TTAGCATGCCAGAGTCTCGTTC 0.1 
GAPDH ATGTTCGTCATGGGTGTGAA 1 TGTGGTCATGAGTCCTTCCA 1 
Β actin GATCTGGCACCACACCTTCT 1 GGGGTGTTGAAGGTCTCAAA 1 
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Supplementary Table 5 Metabolites differentiating responders and non-
responders of 5FU 
No. Metabolite identity (in derivatized form) VIP 





1 N-(4-Chloro-3,3-dimethyl-2-butylidene)methylamine 1.96 0.32 





(1-piperazinyl)ethyl]- 1.96 5.91 
4 
Ethanol, 1-(methylenecyclopropyl)-1-(methylene-1-
trimethylsilylcyclopropyl)- 1.95 0.75 
5 
L-Proline, 1-(trimethylsilyl)-4-[(trimethylsilyl)oxy]-, 
trimethylsilyl ester, trans- 1.94 0.09 
6 
D-Erythro-Pentofuranose, 2-deoxy-1,3-bis-O-(trimethylsilyl)-, 
bis(trimethylsilyl) phosphate 1.93 2.90 
7 2,4-Dimethyl-2-oxazoline-4-methanol 1.93 2.15 
8 Hexanoic acid, trimethylsilyl ester 1.93 0.73 
9 N-(5-Aminopentyl)-oxalamic acid 1.93 0.07 
10 N-Ethyl-2-isopropoxycarbonylazetidine 1.92 0.15 
11 Mannose, 6-deoxy-2,3,4,5-tetrakis-O-(trimethylsilyl)-, L- 1.90 0.44 
12 Cyclobutanecarbonitrile, 3,3-dimethyl- 1.90 0.67 
13 Triethylamine, 2-chloro-2'-(trimethyl)silyloxy- 1.90 1.23 
14 Aminomaleimide 1.89 
Undetected in 
non-responders 
15 l-Alanine, N-(trimethylsilyl)-, trimethylsilyl ester 1.88 0.70 
16 l-Alanine, N-(trimethylsilyl)-, trimethylsilyl ester 1.88 0.61 
17 Dibutyl phthalate 1.86 1.32 
18 Glycine, N,N-bis(trimethylsilyl)-, trimethylsilyl ester 1.86 1.45 
19 
Gluconic acid, 2-methoxime, tetra(trimethylsilyl)-, 
trimethylsilyl ester 1.86 4.27 
20 L-Aspartic acid, N-(trimethylsilyl)-, bis(trimethylsilyl) ester 1.84 0.27 
21 Analyte 729 1.82 0.20 
22 Decanamide, N-(2-hydroxyethyl)- 1.81 1.39 
23 Triethylamine, 2-chloro-2'-(trimethyl)silyloxy- 1.80 1.32 
24 
9-Octadecenoic acid, 2-[(trimethylsilyl)oxy]-1-
[[(trimethylsilyl)oxy]methyl]ethyl ester 1.80 1.39 
25 Analyte 748 1.79 0.15 
26 2-Piperidinecarboxylic acid, trimethylsilyl ester 1.77 2.17 
27 Triethylamine, 2-chloro-2'-(trimethyl)silyloxy- 1.76 1.25 
28 Benzeneacetamide, N-(trimethylsilyl)- 1.76 1.28 
29 Glycine, N-formyl-, trimethylsilyl ester 1.76 0.27 
30 Glycine, N-(trifluoroacetyl)-, trimethylsilyl ester 1.74 0.21 
31 
Silanamine, 1,1,1-trimethyl-N-(1-methyl-2-phenylethyl)-N-
(trimethylsilyl)-, (ñ)- 1.73 2.97 
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32 1-Piperazineethanamine, 4-methyl- 1.73 1.44 
33 Glycine, N-(trimethylsilyl)-, trimethylsilyl ester 1.73 1.30 
34 Butanoic acid, 3-[(trimethylsilyl)oxy]-, trimethylsilyl ester 1.72 2.21 
35 Acetamide, 2,2,2-trifluoro-N-methyl-N-(trimethylsilyl)- 1.72 1.26 
36 Butanoic acid, 3-[(trimethylsilyl)oxy]-, trimethylsilyl ester 1.70 2.57 
37 Methyltris(trimethylsiloxy)silane 1.68 4.52 
38 2-Butenedioic acid (E)-, bis(trimethylsilyl) ester 1.68 0.67 
39 1-(2-(2-Hydroxyethoxy)ethyl)piperazine 1.67 1.34 
40 Benzene, propyl- 1.67 1.23 
41 1,3,5-Triazepine-1,5-dicarboxaldehyde, perhydro-3-tert-butyl- 1.67 0.45 
42 l-Valine, trimethylsilyl ester 1.66 1.23 
43 
2-[3,4-Dichlorophenyl-4-[[[1-methyl-2-
piperidyl]methyl]amino]-6-trichlomethyl-S-triazine 1.66 0.39 
44 Butane, 2,3-dimethyl-2,3-dinitro- 1.65 1.22 
45 Phenylpropanolamine, bis(trimethylsilyl) 1.64 0.20 
46 l-Isoleucine, N-ethoxycarbonyl-, hexyl ester 1.64 0.73 
47 2-Pentene, 1-bromo-3,4-dimethyl- 1.63 1.30 
48 Cyclopentene, 3-methyl-1-(trimethylsilyloxy)- 1.63 1.16 
49 Creatinine enol N1,N3,O-tris(trimethylsilyl) 1.63 2.78 
50 Benzene, 1,2,3-trimethyl- 1.62 1.49 
51 n-Butylamine, N,N-bis(trimethylsilyl)  1.62 0.43 
52 Cyclohexanol, 4-[(trimethylsilyl)oxy]-, cis- 1.62 1.83 
53 Ethanol, 2,2'-[1,2-ethanediylbis(oxy)]bis-, diacetate 1.61 0.05 
54 Tris(trimethylsilyl)borate 1.60 0.60 
55 Creatinine enol N1,N3,O-tris(trimethylsilyl) 1.60 0.55 
56 Silane, isocyanatotrimethyl- 1.60 0.26 
57 Ethylbis(trimethylsilyl)amine 1.60 1.33 
58 Dodecanamide 1.60 1.28 
59 Pinacolyl alcohol, O-trimethylsilyl 1.59 1.22 
60 Propanamide, N,N-diisopropyl-3-trimethylsilyl- 1.59 0.78 
61 n-Pentadecanoic acid, trimethylsilyl ester 1.59 0.12 
62 1H-Pyrrole-2-carboxaldehyde, 1-methyl- 1.59 1.25 
63 Disilathiane, hexamethyl- 1.59 1.27 
64 Glycine, N,N-bis(trimethylsilyl)-, trimethylsilyl ester 1.58 1.48 
65 Dimethylketene 1.58 0.65 
66 
Butanoic acid, 3-methyl-3-[(trimethylsilyl)oxy]-, trimethylsilyl 
ester 1.57 1.52 
67 
9-Octadecenoic acid, 2-[(trimethylsilyl)oxy]-1-
[[(trimethylsilyl)oxy]methyl]ethyl ester 1.57 1.86 
68 2-Butenedioic acid (E)-, bis(trimethylsilyl) ester 1.56 0.80 
69 Glycine, N-(trimethylsilyl)-, trimethylsilyl ester 1.56 2.40 
70 Analyte 670 1.56 0.25 
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71 Alanine, phenyl-, trimethylsilyl ester, dl- 1.56 1.25 
72 Glucuronolactone, trisO-(trimethylsilyl)- 1.56 1.46 
73 1,3-Pentadiene, 4-(trimethylsilyloxy)- 1.56 1.34 
74 1-Hexene, 4,5-dimethyl- 1.56 3.42 
75 Benzenemethanol, à-(1-aminoethyl)-, (R*,S*)-(ñ)- 1.55 2.19 
76 4,7-Methano-1H-indene, octahydro- 1.55 1.23 
77 2-Butenoic acid, tert-butyldimethylsilyl ester 1.55 1.28 
78 
Propanoic acid, 3-[methyl[2-oxo-2-
[(trimethylsilyl)oxy]ethyl]amino]-3-oxo-, trimethylsilyl ester 1.55 0.81 
79 Parabanic acid, bis-O-(trimethylsilyl)- 1.55 0.66 
80 2-Hydroxypentanediamide 1.55 0.11 
81 Pentasiloxane, dodecamethyl- 1.55 0.58 
82 Formic acid, butyl ester 1.54 1.32 
83 L-Aspartic acid, N-(trimethylsilyl)-, bis(trimethylsilyl) ester 1.54 0.42 
84 2-Butanone, 3-hydroxy- 1.54 
Undetected in 
responders 





bis(trimethylsilyl) phosphate 1.54 0.27 
87 Propanedioic acid, methyl-, bis(trimethylsilyl) ester 1.53 1.30 
88 
Silanamine, 1,1,1-trimethyl-N,N-bis[2-
[(trimethylsilyl)oxy]ethyl]- 1.53 0.33 
89 L-Methionine, ethyl ester 1.53 1.50 
90 Ethylbis(trimethylsilyl)amine 1.53 1.38 
91 2-Octyn-1-ol, 7-[(tetrahydro-2H-pyran-2-yl)oxy]- 1.52 1.58 
92 Methylenecyclopropane, 2-(1-hydroxyethyl)-2-trimethylsilyl- 1.52 1.34 
93 1,4-Dihydrophenacetic acid, 3,5-di-t-butyl-, ethyl ester 1.52 1.27 
94 N,O,O-Tris(trimethylsilyl)-L-threonine 1.52 0.85 
95 
3-(2,5-Bis(benzyloxy)phenyl)-2-formylaminoacrylic acid, 
benzyl ester 1.52 0.42 
96 
Cyclopentanecarboxylic acid, 1-amino-, bis(trimethylsilyl) 
deriv. 1.52 1.14 
97 Decanamide, N-(2-hydroxyethyl)- 1.52 1.27 
98 Butanoic acid, trimethylsilyl ester 1.52 1.25 
99 Pinacolyl alcohol, O-trimethylsilyl 1.51 1.30 
100 Propanetriol, 2-methyl-, tris-O-(trimethylsilyl)- 1.51 1.29 
101 Silanamine, 1,1,1-trimethyl-N-propyl-N-(trimethylsilyl)- 1.51 1.16 
102 4-Ethyl-4-methyl-1-hexene 1.51 1.12 
103 Cyclobutanone 1.51 0.78 
104 Ethanol, 2,2'-[1,2-ethanediylbis(oxy)]bis-, diacetate 1.51 0.30 
105 n-Butylamine, N,N-bis(trimethylsilyl)  1.51 1.21 
106 Silane, trimethyl(2-methyl-2,4-cyclopentadien-1-yl)- 1.51 1.44 
107 Cyclododecene, 1-methyl- 1.50 0.15 
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108 2-Hexene, 4-ethyl-2,3-dimethyl- 1.50 0.24 
109 1,3-Oxathiane, 2-methyl-2-(1-methylethyl)- 1.50 2.10 
110 3-t-Pentylcyclopentanone 1.50 1.29 
111 Ethanol, 2-(methylamino)- 1.50 1.35 
112 2-Piperidinecarboxylic acid, trimethylsilyl ester 1.50 0.35 
113 L-Proline, 1-(trimethylsilyl)-, trimethylsilyl ester 1.50 0.14 
114 Silanamine, N-methoxy-1,1,1-trimethyl-N-(trimethylsilyl)- 1.49 1.13 
115 Silanol, trimethyl-, phosphate (3:1) 1.49 0.55 
116 Benzene, 1-ethyl-3-methyl- 1.49 2.17 
117 N,O-Bis-(trimethylsilyl)-2-pyrrolidone carboxylic acid 1.49 0.16 
118 1-Dimethyl(butyl)silyloxyoctane 1.49 0.67 
119 
Silanamine, 1,1,1-trimethyl-N-(1-methyl-2-phenylethyl)-N-
(trimethylsilyl)-, (ñ)- 1.49 2.03 
120 
Disiloxane, 1,1,3,3-tetramethyl-1,3-bis[3-
(oxiranylmethoxy)propyl]- 1.49 1.96 
121 Cyclohexene, 1-methyl-4-(1-methylethyl)- 1.48 1.18 
122 
9,12,15-Octadecatrienoic acid, 2-[(trimethylsilyl)oxy]-1-
[[(trimethylsilyl)oxy]methyl]ethyl ester, (Z,Z,Z)- 1.48 9.53 
123 3-Heptanol, 2-methyl-5-nitro-, (R*,R*)- 1.48 1.46 
124 Mercaptoacetic acid, bis(trimethylsilyl)- 1.48 1.67 
125 
Phosphoric acid, 2-(trimethylsiloxy)-1-
[(trimethylsiloxy)methyl]ethyl bis(trimethylsilyl) ester 1.47 1.28 
126 Silanamine, N,N'-methanetetraylbis[1,1,1-trimethyl- 1.47 1.31 
127 Benzene, 1-ethyl-2-methyl- 1.47 1.20 
128 1,3-Oxathiane, 2-methyl-2-(1-methylethyl)- 1.47 1.36 
129 1,5-Cyclooctadiene, 3-(1-methyl-2-propenyl)- 1.47 3.14 
130 1-(2-(2-Hydroxyethoxy)ethyl)piperazine 1.47 
Undetected in 
non-responders 
131 Silane, trimethyl(1-methylethoxy)- 1.47 1.21 
132 MDEA 1.47 3.18 
133 Glycine, N-acetyl-, trimethylsilyl ester 1.47 
Undetected in 
non-responders 
134 4-Trimethylsilyloxy-4-phenylbut-1-ene 1.47 2.76 
135 Butanoic acid, trimethylsilyl ester 1.46 1.22 
136 L-Tyrosine, N,O-bis(trimethylsilyl)-, trimethylsilyl ester 1.46 
Undetected in 
non-responders 
137 1-Penten-3-one, 1,5-diphenyl- 1.46 1.16 
138 




139 L-Proline, 1-(trimethylsilyl)-, trimethylsilyl ester 1.46 0.42 
140 3-Penten-1-ol, 2,2,4-trimethyl- 1.45 0.26 
141 Ethanedioic acid, bis(trimethylsilyl) ester 1.45 2.32 
142 Arachidonic acid, trimethylsilyl ester 1.45 1.77 
143 Analyte 1121 1.45 
Undetected in 
non-responders 




145 1-Butanamine 1.45 
Undetected in 
non-responders 




2,3-Dihydrooxazole-3,4-dicarboxylic acid, 2á-t-butyl-5-methyl-, 
dimethyl ester 1.45 
Undetected in 
non-responders 
148 Pentasiloxane, dodecamethyl- 1.45 1.15 
149 4-Allyl-1,6-heptadiene-4-ol 1.45 5.50 
150 4-(Trimethylsilyoxy)-3-penten-2-one 1.45 1.37 
151 Disiloxane, hexamethyl- 1.44 1.61 
152 2-Piperidinecarboxylic acid, tert-butyldimethylsilyl ester, (DL)- 1.44 
Undetected in 
non-responders 
153 Arachidonic acid, trimethylsilyl ester 1.44 1.22 
154 2-Monopalmitin trimethylsilyl ether 1.44 1.16 
155 2-(2-Benzyldecahydroisoquinolin-3-yl)ethanol 1.44 0.35 
156 Trimethylsilyl ether of glycerol 1.43 1.15 
157 Analyte 874 1.43 3.76 
158 
2-Imino-6-mercapto-4,4-dimethyl-1,2,3,4-tetrahydro-pyridine-
3,5-dicarbonitrile 1.43 12.50 
159 Dithioerythritol, O,O',S,S'-tetrakis(trimethylsilyl)- 1.42 0.27 
160 
Xylo-hexos-5-ulose, 2,3,4,6-tetrakis-O-(trimethylsilyl)-, bis(O-
methyloxime) 1.42 13.11 
161 
Cyclopentene-3-carboxylic acid, 1-(trimethylsilyl)oxy-, methyl 
ester 1.41 0.02 
162 Cyclotrisiloxane, hexamethyl- 1.41 1.22 





[(trimethylsilyl)oxy]ethyl]-, [S-(R*,R*)]- 1.41 1.28 
165 Cycloheptylamine 1.41 
Undetected in 
non-responders 
166 Urea, N,N'-bis(trimethylsilyl)- 1.40 2.84 
167 7-Azabicyclo[4.1.0]heptane, 2-methyl- 1.40 1.14 
168 Z,Z,Z-4,6,9-Nonadecatriene 1.40 1.64 
169 Palmitaldehyde, dibutyl acetal 1.40 1.41 
170 Acetamide, 2,2,2-trifluoro-N-methyl- 1.40 1.23 
171 
Propanamide, N-[4-(4-chlorophenyl)-2-thiazolyl]-3-(1-
piperidyl)- 1.39 0.41 
172 4-Dimethylsilyloxypentadecane 1.39 1.76 
173 1H-Imidazol-2-amine 1.39 
Undetected in 
non-responders 
174 Pentadecanoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester 1.39 1.68 
175 2-Propenoic acid, 2-(dimethylamino)ethyl ester 1.39 7.81 
176 Mannose, 6-deoxy-2,3,4,5-tetrakis-O-(trimethylsilyl)-, L- 1.39 1.96 
177 
Ethanone, 1-[4-(1,1-dimethylethyl)-2,6-dimethyl-3,5-
dinitrophenyl]- 1.38 1.71 
178 Trimethylsilyl ether of glycerol 1.38 1.20 
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179 Benzo[1,2-b:3,4-b']bis[1]benzothiophene 1.38 0.08 
180 Hexadecanoic acid, 2,3-bis[(trimethylsilyl)oxy]propyl ester 1.38 1.17 
181 n-Butylamine, N,N-bis(trimethylsilyl)  1.37 1.11 
182 1,3-Bis(2-trimethylsiloxyethylthio)propane 1.37 1.24 
183 Glycine, N-formyl-, trimethylsilyl ester 1.37 0.08 
184 Acetic acid, bis[(trimethylsilyl)oxyl]-, trimethylsilyl ester 1.37 3.63 
185 2-Ethyl-1-Pentamethyldisilyloxyhexane 1.37 1.44 
186 4-Pyridinecarboxamide 1.37 0.11 
187 Heptasiloxane, hexadecamethyl- 1.37 1.56 
188 Analyte 846 1.37 2.93 
189 L-Norvaline, N-(trimethylsilyl)-, trimethylsilyl ester 1.37 1.32 
190 1,2-Bis(trimethylsiloxy)ethane 1.37 1.14 
191 
9-Octadecenoic acid, 2-[(trimethylsilyl)oxy]-1-
[[(trimethylsilyl)oxy]methyl]ethyl ester 1.36 1.31 
192 Thiazole-5-carboxylic acid, 2-tert-butylthio-4-methyl- 1.36 0.69 
193 Cyclohexanone, 2-octyl- 1.36 1.54 
194 Bis-1,2-propanediol phosphate, tris(trimethylsilyl)- deriv. 1.36 1.96 
195 Nonane, 2,6-dimethyl- 1.36 0.29 
196 Eicosane 1.36 0.28 
197 Silanamine, N-(2,2-dimethylpropylidene)-1,1,1-trimethyl- 1.35 0.51 
198 Propanedioic acid, bis(trimethylsilyl) ester 1.35 1.28 
199 Methylmalonic monoamide, O,O'-bis(trimethylsilyl)-  1.35 1.16 
200 Trimethylsilyl ether of glycerol 1.35 1.34 
201 N,O,O-Tris(trimethylsilyl)-L-threonine 1.35 2.68 
202 2-Ethyl-1,3-bis(trimethylsilyloxy)propane 1.34 0.41 
203 1-Pentanol, 2-ethyl- 1.34 1.86 
204 
Phosphoric acid, bis(trimethylsilyl) 2,3-
bis[(trimethylsilyl)oxy]propyl ester 1.34 1.75 
205 N,O-Bis-(trimethylsilyl)leucine 1.34 0.84 
206 2-(1-Methyl-1,2,3,4-tetrahydro-isoquinolin-1-yl)-butan-2-ol 1.34 1.20 
207 Acetic acid, (methoxyimino)-, trimethylsilyl ester 1.33 1.32 
208 2-Aminocyanoacetamide 1.33 1.45 
209 n-Butylamine, N,N-bis(trimethylsilyl)  1.32 0.52 
210 4-Pentenoic acid, trimethylsilyl ester 1.32 1.14 
211 Cyclohexane, 1,2-diethyl-3-methyl- 1.32 2.26 
212 1H-Indene, 1-hexadecyl-2,3-dihydro- 1.32 1.88 
213 Acetic acid, (m-methoxyphenyl)-, trimethylsilyl ester 1.32 0.69 
214 Acetamide, N-methyl-N-(trimethylsilyl)- 1.32 1.12 
215 4-Nonene, 2,3,3-trimethyl-, (Z)- 1.32 1.90 
216 N-Methylphenylethanolamine, bis(trimethylsilyl)- 1.31 0.32 
217 Trimethylamine, compd. with borane (1:1) 1.31 1.83 
218 Arachidonic acid, trimethylsilyl ester 1.31 1.21 
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219 Glucopyranose, 1,2,3,4,6-pentakis-O-(trimethylsilyl)-, D- 1.30 5.33 
220 
Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(2-
methylpropyl)- 1.30 0.58 
221 Silicic acid, diethyl bis(trimethylsilyl) ester 1.30 1.18 
222 Aminomalonic acid, tris(trimethylsilyl)- 1.30 1.16 
223 
17-Methoxy-4-methyl-d-homo-18-norandrosta-4,8,13,15,17-
pentaen-3-one 1.30 1.10 
224 Gulonic acid, 2,3,5,6-tetrakis-O-(trimethylsilyl)-, lactone 1.30 0.76 
225 Glyoxylic oxime acid, bis(trimethylsilyl)- 1.29 1.16 
226 Butanoic acid, 4-[bis(trimethylsilyl)amino]-, trimethylsilyl ester 1.29 0.72 
227 Analyte 516 1.29 1.48 
228 Cyclohexanone, 4R-acetamido-2trans,3cis-dimethoxy- 1.29 0.55 
229 1,1-Dimethyl-1,2,3,4-tetrahydroisoquinoline 1.29 1.11 
230 L-Proline, 5-oxo-1-(trimethylsilyl)-, trimethylsilyl ester 1.29 5.49 
231 Mannose, 6-deoxy-2,3,4,5-tetrakis-O-(trimethylsilyl)-, L- 1.29 1.88 
232 1-Monooleoylglycerol trimethylsilyl ether 1.28 1.24 
233 Octanoic acid, trimethylsilyl ester 1.28 5.16 
234 Heptasiloxane, hexadecamethyl- 1.28 2.65 
235 Analyte 869 1.28 0.53 
236 Ethanedioic acid, bis(trimethylsilyl) ester 1.28 1.17 
237 11-Eicosenoic acid, trimethylsilyl ester 1.27 0.14 
238 
D-Glucopyranose, 2-(acetylamino)-2-deoxy-1,3,4,6-tetrakis-O-
(trimethylsilyl)- 1.27 1.49 
239 1H-Imidazol-2-amine 1.27 5.62 
240 1,2-Bis(trimethylsiloxy)ethane 1.27 0.44 
241 Butanoic acid, 2-methyl-, trimethylsilyl ester 1.27 0.46 
242 Acetamide, 2,2,2-trifluoro-N-methyl- 1.27 1.23 
243 
l-Galactopyranose, 6-deoxy-1,2-bis-O-(trimethylsilyl)-, cyclic 
methylboronate 1.27 3.25 
244 L-Methionine, ethyl ester 1.27 1.30 
245 Ribitol, 1,2,3,4,5-pentakis-O-(trimethylsilyl)- 1.26 2.69 
246 Arachidonic acid, trimethylsilyl ester 1.26 1.31 
247 Sulfur dioxide 1.26 7.55 
248 Ethanamine, N-ethyl- 1.26 1.34 
249 Analyte 679 1.26 0.41 
250 Bis(trimethylsilyl)alanine, methyl ester 1.26 2.74 
251 L-Proline, 5-oxo-1-(trimethylsilyl)-, trimethylsilyl ester 1.25 1.19 
252 2-Butenoic acid, 2-methyl-, trimethylsilyl ester, (E)- 1.25 0.23 
253 2-Pentene, 2,4,4-trimethyl- 1.25 1.32 
254 L-Serine, N,O-bis(trimethylsilyl)-, trimethylsilyl ester 1.25 0.46 
255 Acetamide, 2,2,2-trifluoro-N-methyl-N-(trimethylsilyl)- 1.25 0.83 
256 L-Aspartic acid, N-(trimethylsilyl)-, bis(trimethylsilyl) ester 1.25 0.56 
257 Propanoic acid, 2-oxo-3-(trimethylsilyl)-, trimethylsilyl ester 1.25 1.15 
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258 1-Ethyl(dimethyl)silyloxydecane 1.25 0.61 
259 N,N-Diethyl-1,1,1-trimethylsilylamine 1.24 1.34 
260 1,5-Di(trimethylsilyl)pentane 1.24 2.07 
261 Ethyl phosphoric acid, di-TMS derivative 1.24 0.60 
262 1,2-Bis(trimethylsiloxy)ethane 1.24 1.16 
263 Silane, trimethyl(3-phenoxypropoxy)- 1.24 1.20 
264 3-(2-Hydroxyethyl)imidazole-2-thione 1.23 0.74 
265 5-Hepten-3-one, 2,2-dimethyl-7-trimethylsilyl- 1.23 1.25 
266 
9-Octadecenoic acid, 2-[(trimethylsilyl)oxy]-1-
[[(trimethylsilyl)oxy]methyl]ethyl ester 1.23 4.16 
267 N,O-Bis(dimethyl-t-butylsilyl)-l-isoleucine 1.22 1.74 
268 Phosphoric acid, 2-isothiocyanatoethyl bis(trimethylsilyl) ester 1.22 0.83 
269 Tridecanoic acid, methyl ester 1.22 1.20 
270 1-Monooleoylglycerol trimethylsilyl ether 1.22 0.48 
271 1,2-Benzenedicarboxylic acid, diisooctyl ester 1.21 0.79 
272 tert-Butyldimethylsilanol 1.21 0.55 
273 Analyte 894 1.21 3.30 
274 Ethylbis(trimethylsilyl)amine 1.21 0.55 
275 Dodecyl acrylate 1.21 1.64 
276 Disiloxane, hexamethyl- 1.21 1.71 
277 Furan, tetrahydro- 1.21 3.14 
278 Myo-Inositol, 1,2,3,4,5,6-hexakis-O-(trimethylsilyl)- 1.21 1.63 
279 Triethylenediamine 1.20 
Undetected in 
non-responders 
280 (Z)-Bis-1,2-(trimethylsilyloxy)ethylene 1.20 1.14 
281 2-Pentamethyldisilanyloxybutane 1.20 1.85 
282 Glycine, N-(1-oxo-2-butenyl)-, trimethylsilyl ester 1.20 1.27 
283 Sulfide, allyl methyl 1.20 1.38 
284 6-Dimethyl(trimethylsilyl)silyloxytetradecane 1.20 1.50 
285 Ethylbis(trimethylsilyl)amine 1.20 0.68 
286 (Z)-Hex-2-ene, 5-methyl- 1.20 0.54 
287 Ethylbis(trimethylsilyl)amine 1.20 1.11 
288 2(3H)-Thiophenone, dihydro-3-[(trimethylsilyl)amino]- 1.20 0.71 
289 2-Octyn-1-ol, 7-[(tetrahydro-2H-pyran-2-yl)oxy]- 1.19 1.53 
290 N-Acetylmethionine, bis(trimethylsilyl)- 1.19 0.55 
291 Thiophene-2-carboxamide, N-(2-furfuryl)- 1.19 2.25 
292 Phosphonic acid, ethyl-, bis(trimethylsilyl) ester 1.19 0.58 
293 2-Deoxy-galactopyranose, tetrakis(trimethylsilyl) 1.19 3.88 
294 Octanamide, N-(2-hydroxyethyl)- 1.18 1.30 
295 
Benzenepropanoic acid, à,4-bis[(trimethylsilyl)oxy]-, 
trimethylsilyl ester 1.18 1.16 
296 Cyclotetrasiloxane, octamethyl- 1.18 3.30 
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297 d-Erythrotetrofuranose, tris-O-(trimethylsilyl)- 1.18 2.49 
298 Urea, N,N'-bis(trimethylsilyl)- 1.18 0.50 
299 Ribitol, 1,2,3,4,5-pentakis-O-(trimethylsilyl)- 1.18 1.79 
300 
Propanoic acid, 3-[bis(trimethylsilyl)amino]-2-methyl-, 
trimethylsilyl ester 1.18 1.08 
301 (Z)-Bis-1,2-(trimethylsilyloxy)ethylene 1.18 1.53 
302 
Silanamine, 1,1,1-trimethyl-N-(trimethylsilyl)-N-[2-
[(trimethylsilyl)oxy]ethyl]- 1.17 1.43 
303 2-Piperidinecarboxylic acid, tert-butyldimethylsilyl ester, (DL)- 1.17 1.13 
304 
Propanoic acid, 2-methyl-3-oxo-3-[[2-oxo-2-
[(trimethylsilyl)oxy]ethyl](trimethylsilyl)amino]- 1.17 0.35 
305 Octadecanoic acid, trimethylsilyl ester 1.17 66.96 
306 1,4-Butanediamine, N,N,N',N'-tetrakis(trimethylsilyl)- 1.17 0.60 
307 N,O-Bis-(trimethylsilyl)valine 1.17 1.17 
308 2,5-Furandicarboxylic acid, bis(trimethylsilyl) ester 1.17 4.62 
309 1H-Indene, 1-hexadecyl-2,3-dihydro- 1.16 2.70 
310 Benzoic acid, 2-[(trimethylsilyl)amino]-, trimethylsilyl ester 1.16 0.44 
311 
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-amino-
3,3-dimethyl-7-oxo-, [2S-(2à,5à,6á)]- 1.16 1.08 
312 Glycine, trimethylsilyl ester 1.16 1.22 
313 4-Dimethylsilyloxypentadecane 1.16 0.74 
314 Phosphoric acid, 2-isothiocyanatoethyl bis(trimethylsilyl) ester 1.16 0.52 
315 3-Heptene, 2,2,3,5,6-pentamethyl- 1.16 3.32 
316 
Silanamine, N,1,1,1-tetramethyl-N-[1-methyl-2-phenyl-2-
[(trimethylsilyl)oxy]ethyl]-, [S-(R*,R*)]- 1.15 1.25 
317 Ketone, methyl 2,2,3-trimethylcyclopentyl 1.15 1.49 
318 
Phosphoric acid, 2-(trimethylsiloxy)-1-
[(trimethylsiloxy)methyl]ethyl bis(trimethylsilyl) ester 1.15 0.23 
319 2-Butene-1,4-diol 1.15 
Undetected in 
responders 
320 Analyte 832 1.15 1.73 
321 2-Propanone, 1,1-diethoxy- 1.15 2.73 
322 Cyclotetrasiloxane, octamethyl- 1.15 4.60 
323 Acetamide, 2,2,2-trifluoro-N-(trimethylsilyl)- 1.14 1.69 
324 N,N-Dimethyl-2-cyclohexyloxyethylamine 1.14 2.27 
325 4-Cyano-4-hydroxy-1,2.5-trimethylpiperidine 1.14 1.44 
326 Acetone-D6 1.14 1.96 
327 3-Heptene, 2,2,3,5,6-pentamethyl- 1.14 1.71 
328 N,N-Diisopropyltrimethylsilylamine 1.14 1.72 
329 Dodecyl acrylate 1.14 1.61 
330 9,12-Octadecadienoic acid (Z,Z)-, trimethylsilyl ester 1.13 0.62 
331 L-Glutamic acid, diethyl ester 1.13 30.04 
332 Trimethylsilyl ether of glycerol 1.13 1.17 
333 Methanesulfinic acid, trimethylsilyl ester 1.13 1.49 
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334 Gulonic acid, 2,3,5,6-tetrakis-O-(trimethylsilyl)-, lactone 1.13 1.81 
335 Disiloxane, hexamethyl- 1.13 0.63 
336 Analyte 1026 1.13 
Undetected in 
responders 
337 9,12-Octadecadienoic acid, methyl ester, (E,E)- 1.13 
Undetected in 
responders 
338 L-Aspartic acid, N-(trimethylsilyl)-, bis(trimethylsilyl) ester 1.13 0.61 
339 Butanoic acid, 4-[bis(trimethylsilyl)amino]-, trimethylsilyl ester 1.13 0.70 
340 Silane, (2-ethoxyethoxy)trimethyl- 1.13 
Undetected in 
responders 
341 Nonanoic acid, trimethylsilyl ester 1.13 1.23 
342 Mannonic acid, 2,3,5,6-tetrakis-O-(trimethylsilyl)-, lactone 1.13 1.33 
343 9,12-Octadecadienoic acid (Z,Z)-, trimethylsilyl ester 1.13 1.68 
344 
D-Erythro-Pentofuranose, 2-deoxy-1,3-bis-O-(trimethylsilyl)-, 
bis(trimethylsilyl) phosphate 1.12 0.28 
345 Acetic acid, [(trimethylsilyl)oxy]-, trimethylsilyl ester 1.12 1.47 
346 Benzenesulfonamide, 4-(dimethylamino)-N,N-dimethyl- 1.12 0.84 
347 Butanedioic acid, methyl-, bis(tert-butyldimethylsilyl) ester 1.12 0.77 
348 Propanoic acid, 3-(methylthio)-, pentyl ester 1.12 1.66 
349 2-Dimethyl(trimethylsilylmethyl)silyloxytetradecane 1.12 2.03 
350 Arachidonic acid, trimethylsilyl ester 1.12 1.24 
351 2,4-Thiazolidinedione 1.11 2.22 





tetramethyl- 1.11 81.10 
354 Propanoic acid, 3-[(trimethylsilyl)oxy]-, trimethylsilyl ester 1.11 1.87 
355 Gluconic acid, ç-lactone, 5-methoximine, tri(trimethylsilyl)- 1.11 0.55 
356 Butanoic acid, 4-[bis(trimethylsilyl)amino]-, trimethylsilyl ester 1.11 0.47 
357 L-Serine, N,O-bis(trimethylsilyl)-, trimethylsilyl ester 1.11 0.79 
358 Mannose, 6-deoxy-2,3,4,5-tetrakis-O-(trimethylsilyl)-, L- 1.11 3.35 
359 Acetamide, 2-(1-pyrrolidinyl)-N-(2-methyl-4-quinolinyl)- 1.11 0.16 
360 1-(2-(2-Hydroxyethoxy)ethyl)piperazine 1.11 0.35 
361 Guaicol-á-d-glucopyranoside, pentakis(O-trimethylsilyl)- 1.11 3.55 
362 Arachidonic acid, trimethylsilyl ester 1.11 
Undetected in 
responders 
363 Xylonic acid, 2,3,5-tris-O-(trimethylsilyl)-, ç-lactone, D- 1.11 4.73 
364 L-Proline, ethyl ester 1.10 1.25 
365 N,N-Diethyl-1,1,1-trimethylsilylamine 1.10 1.25 
366 1,2-Cyclopentanediol, 3-methyl- 1.10 1.64 
367 Glyoxylic acid, di-TMS 1.10 1.07 
368 
Heptadecanoic acid, glycerine-(1)-monoester, bis-O-
trimethylsilyl- 1.10 1.29 
369 Dodecanoic acid, trimethylsilyl ester 1.09 0.75 
370 L-Proline, ethyl ester 1.09 1.36 
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371 2-Butanamine, N-methyl- 1.09 3.82 
372 Picolinic acid, trimethylsilyl ester 1.09 2.30 
373 1,2-Propanediol-1-phosphate, tris(trimethylsilyl)- 1.09 0.55 
374 3-Hexene, 2,2-dimethyl-, (Z)- 1.09 0.52 
375 Propane, 2-isocyanato-2-methyl- 1.09 0.36 
376 Ethylbis(trimethylsilyl)amine 1.09 1.09 
377 3H-Pyrazol-3-one, 2,4-dihydro-2,5-dimethyl- 1.09 0.51 
378 Sulfurous acid, cyclohexylmethyl isohexyl ester 1.09 1.09 
379 à-Tocopherol (vitamin E), trimethysilyl derivative 1.09 7.88 
380 Cyclohexane, 3-ethyl-5-methyl-1-propyl- 1.09 0.26 
381 Glycine, N-(1-oxo-2-butenyl)-, trimethylsilyl ester 1.09 1.09 
382 Propanoic acid, 3-mercapto-, dodecyl ester 1.09 1.95 
383 2-Pentamethyldisilyloxypropane 1.09 1.73 
384 Phosphoric acid, 2-isothiocyanatoethyl bis(trimethylsilyl) ester 1.08 0.79 
385 Arabinofuranose, 1,2,3,5-tetrakis-O-(trimethylsilyl)- 1.08 0.37 
386 3à-(Trimethylsiloxy)cholest-5-ene 1.08 1.26 
387 Mercaptoacetic acid, bis(trimethylsilyl)- 1.08 0.49 
388 Hexadecanoic acid, 4-[(trimethylsilyl)oxy]butyl ester 1.08 0.47 
389 Oleic acid, trimethylsilyl ester 1.08 0.28 
390 Silanamine, N,N'-methanetetraylbis[1,1,1-trimethyl- 1.08 1.67 
391 2-Butenoic acid, tert-butyldimethylsilyl ester 1.08 0.90 
392 1,4-Bis[(trimethylsilyl)ethynyl]benzene 1.08 1.39 
393 Propanoic acid, 2-oxo-3-(trimethylsilyl)-, trimethylsilyl ester 1.08 0.65 
394 2-Hexanamine 1.07 2.74 
395 1,4-Benzenedicarboxylic acid, bis(trimethylsilyl) ester 1.07 5.81 
396 D-Erythro-Pentofuranose, 2-deoxy-1,3,5-tris-O-(trimethylsilyl)- 1.07 0.58 
397 Indane 1.07 1.11 
398 Hexadecanoic acid, trimethylsilyl ester 1.07 1.14 
399 Cadaverine, N,N,N',N'-tetrakis(trimethylsilyl) 1.06 6.98 
400 Silane, [(1-methoxy-1,3-propanediyl)bis(oxy)]bis[trimethyl- 1.06 1.16 
401 Disiloxane, 1,3-bis(chloromethyl)-1,1,3,3-tetramethyl- 1.06 1.29 
402 dl-à-Methylglutamic acid 1.06 0.65 
403 Azelaic acid, bis(trimethylsilyl) ester 1.06 2.10 
404 Heptasiloxane, hexadecamethyl- 1.06 1.52 
405 Heptasiloxane, hexadecamethyl- 1.06 1.50 
406 Ethanimidic acid, N-(trimethylsilyl)-, trimethylsilyl ester 1.05 1.14 
407 Pyrazine, 2,5-bis(trimethylsilyloxy)- 1.05 0.44 
408 Butanedioic acid, bis(trimethylsilyl) ester 1.05 0.91 
409 Glycine, N-(trimethylsilyl)-, trimethylsilyl ester 1.05 1.61 
410 2-Ethylhexanoic acid, trimethylsilyl ester 1.05 0.75 
411 Silane, [(1,1-dimethyl-2-propynyl)oxy]trimethyl- 1.05 1.25 
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412 Hexadecanamide, N-(2-trimethylsilyloxyethyl)- 1.05 2.18 
413 4-(3-Chloro-propyl)-piperazine-1-carbaldehyde 1.05 5.69 
414 Uridine, 5-chloro-2'-desoxytris-O-(trimethylsilyl)- 1.05 1.53 
415 N,O-Bis(trimethylsilyl)-L-phenylalanine 1.05 0.59 
416 Propanoic acid, 3-mercapto-, dodecyl ester 1.05 1.71 
417 N,O,O-Tris(trimethylsilyl)-L-threonine 1.05 1.91 
418 Dodecanoic acid, 2,3-bis(acetyloxy)propyl ester 1.05 1.99 
419 
2,4(1H,3H)-Pyrimidinedione, dihydro-1,3-dimethyl-5-
[(trimethylsilyl)oxy]- 1.04 0.65 
420 Acetic acid, [(trimethylsilyl)oxy]-, trimethylsilyl ester 1.04 1.34 
421 Lyxose, tetra-(trimethylsilyl)-ether 1.04 1.67 
422 Glycine, N-(trimethylsilyl)-, trimethylsilyl ester 1.04 2.23 
423 2,4,4-Trimethyl-1-hexene 1.04 1.15 
424 Malic acid, tris(trimethylsilyl) ester 1.04 4.31 
425 Glucopyranose, pentakis-O-trimethylsilyl- 1.04 2.67 
426 
Phosphoric acid, bis(trimethylsilyl) 2,3-
bis[(trimethylsilyl)oxy]propyl ester 1.04 1.62 
427 1-Hexanamine, 2-ethyl-N-(2-ethylhexyl)-N-methyl- 1.03 
Undetected in 
non-responders 




[bis(trimethylsilyl) phosphate] 1.03 0.43 
430 D-Xylose, tetrakis(trimethylsilyl)- 1.03 1.08 
431 Acetamide, 2,2,2-trifluoro-N-methyl-N-(trimethylsilyl)- 1.03 1.11 
432 Glucopyranose, pentakis-O-trimethylsilyl- 1.03 1.68 
433 1,2-Benzenedicarboxylic acid, bis(2-methylpropyl) ester 1.03 1.10 
434 Ethanedioic acid, bis(trimethylsilyl) ester 1.03 1.28 
435 Phosphoric acid, 2-isothiocyanatoethyl bis(trimethylsilyl) ester 1.03 0.45 
436 Pyrimidine, 2,4-bis[(trimethylsilyl)oxy]- 1.03 0.87 
437 Trimethylsilyloxycyclopentane 1.03 0.95 
438 Phosphoric acid, bis(trimethylsilyl)monomethyl ester 1.03 0.52 
439 Ethanedioic acid, bis(trimethylsilyl) ester 1.02 1.54 
440 Pyrimidine, 5-methyl-2,4-bis[(trimethylsilyl)oxy]- 1.02 0.76 
441 Propanedioic acid, bis(trimethylsilyl) ester 1.02 1.92 
442 Disiloxane, hexamethyl- 1.02 0.62 
443 
Propanoic acid, 3-[bis(trimethylsilyl)amino]-2-methyl-, 
trimethylsilyl ester 1.02 1.69 
444 Sulfide, allyl methyl 1.02 1.53 
445 1,5-Di(trimethylsilyl)pentane 1.02 2.95 
446 Acetophenone, 4'-(trimethylsiloxy)- 1.02 0.55 
447 Cyclopentanecarboxamide, N-(4-fluorophenyl)- 1.01 0.29 
448 
Galactose, 2-(acetylamino)-2-deoxy-3,4,5,6-tetrakis-O-
(trimethylsilyl)- 1.01 0.90 
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449 Ethylbis(trimethylsilyl)amine 1.01 2204.13 
450 Silane, trimethyl(3-methylbutyl)- 1.01 0.60 
451 2-Keto-d-gluconic acid, pentakis(O-trimethylsilyl)- 1.01 0.22 
452 Heptacosane 1.01 1.16 
453 n-Butylamine, N,N-bis(trimethylsilyl)  1.01 0.51 
454 Analyte 905 1.01 4.65 
455 
á-D-Xylofuranose, 1,2-bis-O-(trimethylsilyl)-, cyclic 
methylboronate 1.00 1.30 
456 
D-Arabino-Hexopyranose, 2-deoxy-1,3,4-tris-O-
(trimethylsilyl)-, bis(trimethylsilyl) phosphate 1.00 0.79 




Supplementary Table 6 Primers for PCR and gene sequencing  

















































5’- TTTGCTCCAAACTGACCAA -3’ 
Reverse: 























KRAS: Ensembl assession number ENSG00000133703 
BRAF: Ensembl assession number ENSG00000157764 
PI3K: Ensembl assession number ENSG00000121879 




Supplementary Table 7 Clinicopathological characteristics of 45 mCRC 
patients 




     Mean 59 
   Range 30-83 
Sex  
     Male 29 64.4 
   Female 16 35.6 
Ethnicity  
     Chinese 34 75.6 
   Malay 7 15.6 
   Indian 4 8.9 
Tumor site  
     Ascending colon 1 2.2 
   Hepatic flexure 1 2.2 
   Sigmoid colon 21 46.7 
   Rectosigmoid 6 13.3 
   Rectum 16 35.6 
Tumor differentiation 
     Moderate 39 86.7 






Supplementary Table 8 Frequencies of KRAS, BRAF and PI3K mutations in different mCRC populations 
Study 
a
 Population N 
b
 KRAS  BRAF PI3K 











of mutation  





of mutation  





[90% CI, 21.8–44.9%]  
Codons 439, 459, 
600 and 601 
0% (0/45) Codons 542, 545, 
1043 and 1047   
2.2% (1/45) 
Pang et al [154] Singapore  8 Codons 12, 13 and 
61 
37.5% (3/8) in 
cytological specimens; 
50% (4/8) in tumor 
d
 
Analysis was conducted only on 
KRAS wild type cases 
-  




113 Codons 12 and 13 30.1% (34/113) Codon 600 9.7% 
(11/113)  
-  
Frattini et al [216] Switzerland  27 Codons 12 and 13 37.0% (10/27) -  -  




111 Codons 12, 13 and 
61 




Lievre et al [218] France  30 Codons 12 and 13 43% (13/30)  Exons 11 and 15 0% (0/30) 
 




Gao et al [147] China 59 Codons 12 and 13 18.6% (11 /59) Codon 600 8.5% (5/59) -  
Li et al [148]  China 190 Codons 12 and 13 31.1% (59/190) -  -  
Mao et al [149] China 57-
61 




Codons 542, 545 
and 1047 
8.2% (5/61)  
Kato et al [150] Japan  28 Codons 12 and 13 25.0% (7/28) -  Codons 542, 545, 
1043 and 1047   
14.3% 
(4/28) 
Kimura et al [151] Japan  61 Codons 12 and 13 34.4% (21/61) -  -  
Ito et al [152] Japan  242 Codons 12 and 13  43.8% (106/242) 
 
Analysis was conducted only on 
KRAS wild type cases 
Analysis was conducted only on 
KRAS wild type cases 
Nakanishi et al 
[153] 
Japan  34 Codons 12 and 13 50.0% (17/34) Codon 600 8.8% (3/34) -  
a Studies involved unselected patients (i.e. no biased inclusion criteria e.g. chemotherapy-refractory patients or exclusion criteria e.g.  history of neoplasm).  
b Sample size of mCRC patients  
c Only data derived from direct sequencing was presented to eliminate technical variation that may obscure population differences.  
d All mutations were observed in either codon 12 or 13.  
e Authors noted that KRAS & BRAF were not mutually exclusive. 
